トップ›研究者一覧›宮本弘志

研究者を探す

研究者にアプローチする
更新情報を通知する

宮本弘志

徳島大学

プロフィール
教育活動
研究活動
社会活動
リサーチマップ・
Jグローバル
KAKEN
注目研究

研究者総覧で最新データを確認する

2024年11月22日更新

職名: 准教授
電話: 研究者総覧に該当データはありませんでした。
電子メール: 研究者総覧に該当データはありませんでした。
学歴: 1995/3: 徳島大学医学部医学科卒業
学位: 博士(医学) (徳島大学) (2006年7月)
職歴・経歴: 〜: 徳島大学助手, 大学院ヘルスバイオサイエンス研究部 (-2007.3.)
2007/4: 徳島大学助教, 病院 (-2010.3.)
2010/9: 徳島大学医員, 病院 (-2010.9.)
2010/10: 徳島大学特任助教, 病院 (-2011.3.)
2011/4: 徳島大学助教, 病院 (-2013.7.)
2013/8: 徳島大学講師, 病院 (-2021.12.)
2022/1: 徳島大学准教授, 大学院医歯薬学研究部

専門分野・研究分野: ライフサイエンス (Life sciences) [消化器内科学 (Gastroenterology)]

研究者総覧で最新データを確認する

2024年11月22日更新

専門分野・研究分野: ライフサイエンス (Life sciences) [消化器内科学 (Gastroenterology)]
担当経験のある授業科目: 消化器コース (学部)
指導経験: 研究者総覧に該当データはありませんでした。

研究者総覧で最新データを確認する

2024年11月22日更新

専門分野・研究分野: ライフサイエンス (Life sciences) [消化器内科学 (Gastroenterology)]

研究テーマ: 研究者総覧に該当データはありませんでした。

著書

木村雅子, 宮本弘志, 高山哲治 :
2) 抗体 7 パニツムマブ(ベクティビックス®),
医薬ジャーナル社, 2015年11月. Hiroshi Miyamoto :
Mechanical Circulatory Support: Principles and Applications.,
McGrawHill Companies, Inc., Columbus, Sep. 2011. Hiroshi Miyamoto and Nose Yukihiko :
The early dialysate delivery systems in Japan,
World Scientific Pub Co Inc, 2011. Y Nose, T Motomura and Hiroshi Miyamoto :
History of Mechanical Circulatory Support,
The McGrawHill Companies, Inc, 2011.

論文

Tetsu Tomonari, Joji Tani, Yasushi Sato, Hironori Tanaka, Aasahiro Morishita, Koichi Okamoto, Yutaka Kawano, Masahiro Sogabe, Hiroshi Miyamoto and Tetsuji Takayama :
Initial treatment efficacy and safety of durvalumab plus tremelimumab combination therapy in unresectable hepatocellular carcinoma in clinical practice.,
JGH Open, Vol.8, No.10, e70033, 2024.

(出版サイトへのリンク): ● Publication site (DOI): 10.1002/jgh3.70033.
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 39371045; ● Search Scopus @ Elsevier (PMID): 39371045; ● Search Scopus @ Elsevier (DOI): 10.1002/jgh3.70033.

(DOI: 10.1002/jgh3.70033., PubMed: 39371045) Kazuyoshi Noda, Yasushi Sato, Yasuyuki Okada, Kensei Nishida, Yutaka Kawano, Toshihito Tanahashi, Masahiro Bando, Koichi Okamoto, Masanori Takehara, Masahiro Sogabe, Hiroshi Miyamoto, Kei Daizumoto, Hiro-omi Kanayama and Tetsuji Takayama :
Exosomal miR-199a-3p Secreted From Cancer-Associated Adipocytes Promotes Pancreatic Cancer Progression.,
Cancer Medicine, Vol.13, No.20, e70265, 2024.

(出版サイトへのリンク): ● Publication site (DOI): 10.1002/cam4.70265.
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 39431622; ● Search Scopus @ Elsevier (PMID): 39431622; ● Search Scopus @ Elsevier (DOI): 10.1002/cam4.70265.

(DOI: 10.1002/cam4.70265., PubMed: 39431622) Masahiro Sogabe, Toshiya Okahisa, Miwako Kagawa, Motoko Sei, Hiroyuki Ueda, reiko yokoyama, Kaizo Kagemoto, Hironori Tanaka, Yoshifumi Kida, Fumika Nakamura, Tetsu Tomonari, Koichi Okamoto, Yutaka Kawano, Hiroshi Miyamoto, Yasushi Sato, Masahiko Nakasono and Tetsuji Takayama :
Association of metabolic dysfunction-associated steatotic liver disease with erosive esophagitis development: a longitudinal observational study.,
Journal of Gastroenterology and Hepatology, Vol.39, No.6, 1107-1114, 2024.

(要約): Although erosive esophagitis (EE) is associated with fatty liver and metabolic dysregulation, the association between EE and metabolic dysfunction-associated steatotic liver disease (MASLD) remains unclear. Thus, this study aimed to investigate the longitudinal association between MASLD and EE. We included 1578 patients without EE at baseline who underwent more than two health checkups over 2 years. Generalized estimation equations were used to analyze associations between MASLD and EE according to repeated measures at baseline and most recent stages. EE development rates in men and women were 14.5% and 7.2%, respectively. After adjusting for lifestyle habits, the odds ratios of MASLD for EE development in men and women were 1.907 (95% confidence interval [CI]: 1.289-2.832, P < 0.005) and 1.483 (95% CI: 0.783-2.811, P = 0.227), respectively. In the subgroup analysis, after adjusting for lifestyle habits, among men and women aged 50 years with more than three MASLD components, the odds ratios for EE development were 2.408 (95% CI: 1.505-3.855, P < 0.001) and 2.148 (95% CI: 1.093-4.221, P < 0.05), respectively. After adjusting for various factors, the significant risk factors for EE development were different between men and women. The influence of MASLD and other factors on EE development differed by sex and age. Particularly, patients aged 50 years with MASLD and with an increased number of MASLD components should be considered at increased risk for EE.
(出版サイトへのリンク): ● Publication site (DOI): 10.1111/jgh.16530
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38419514; ● Search Scopus @ Elsevier (PMID): 38419514; ● Search Scopus @ Elsevier (DOI): 10.1111/jgh.16530

(DOI: 10.1111/jgh.16530, PubMed: 38419514) Masahiro Sogabe, Toshiya Okahisa, Miwako Kagawa, Motoko Sei, Hiroyuki Ueda, reiko yokoyama, Kaizo Kagemoto, Hironori Tanaka, Yoshifumi Kida, Fumika Nakamura, Tetsu Tomonari, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Masahiko Nakasono and Tetsuji Takayama :
Association of variabilities in body mass index and waist circumference with newly achieved remission of metabolic dysfunction-associated fatty liver disease.,
Diabetes & Metabolic Syndrome, Vol.18, No.5, 103036, 2024.

(要約): Although body weight reduction is recommended to ameliorate nonalcoholic fatty liver disease, the effects of body mass index (BMI) and waist circumference (WC) variability on newly achieved remission of metabolic dysfunction-associated fatty liver disease (MAFLD) remain unclear. We aimed to investigate the longitudinal association between BMI and WC variabilities and newly achieved MAFLD remission in both sexes. Among 26,952 patients, 1823 with MAFLD diagnosed by ultrasonography and with >2 health checkups over >2 years from April 2014 to March 2021 were included in this observational cohort study. A generalized estimation equation model analyzed the association between BMI and WC and newly achieved MAFLD remission according to repeated measures at baseline and the most recent stage. Rates of MAFLD remission in male and female patients were 7.4 % and 6.0 %, respectively. Regarding decreased BMI variability, newly achieved MAFLD remission prevalence among the subgroups differed significantly between sexes (p < 0.001). In male patients, a decrease in BMI variability of ≥1.5 kg/m and WC variability of ≥4.2 cm had adjusted odds ratios (ORs) of 5.215 and 2.820, respectively, for newly achieved MAFLD remission. Among female patients, regular exercise and breakfast consumption were accelerating factors for newly achieved MAFLD remission. Non-invasive liver fibrosis scores significantly differed between MAFLD and newly achieved MAFLD remission, including in the subgroups (p < 0.01 and p < 0.001, respectively). Reducing BMI and WC variabilities in male patients and improving lifestyle habits in female patients may accelerate MAFLD remission.
(キーワード): Humans / Male / Female / Body Mass Index / Middle Aged / Non-alcoholic Fatty Liver Disease / Waist Circumference / Adult / Remission Induction / Follow-Up Studies / Prognosis / Metabolic Diseases
(出版サイトへのリンク): ● Publication site (DOI): 10.1016/j.dsx.2024.103036
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38754333; ● Search Scopus @ Elsevier (PMID): 38754333; ● Search Scopus @ Elsevier (DOI): 10.1016/j.dsx.2024.103036

(DOI: 10.1016/j.dsx.2024.103036, PubMed: 38754333) Masahiro Sogabe, Toshiya Okahisa, Miwako Kagawa, Motoko Sei, Kaizo Kagemoto, Hironori Tanaka, Yoshifumi Kida, Fumika Nakamura, Tetsu Tomonari, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Masahiko Nakasono and Tetsuji Takayama :
Association of metabolic dysfunction-associated fatty liver disease with gallstone development: A longitudinal study.,
Journal of Gastroenterology and Hepatology, Vol.39, No.4, 754-761, 2024.

(要約): The influence of metabolic dysfunction-associated fatty liver disease on gallstone development remains unclear. We aimed to investigate the longitudinal association between metabolic dysfunction-associated fatty liver disease and gallstone development in both men and women. This observational cohort study included 5398 patients without gallstones who underwent > 2 health check-ups between April 1, 2014, and March 31, 2020. A generalized estimation equation model was used to analyze the association between metabolic dysfunction-associated fatty liver disease and gallstone development according to repeated measures at baseline and most recent stage. After adjustment, the odds ratios of metabolic dysfunction-associated fatty liver disease for gallstone development in men and women were 3.019 (95% confidence interval [CI]: 1.901-4.794) and 2.201 (95% CI: 1.321-3.667), respectively. Among patients aged 50 years, the odds ratio for gallstone development was significantly enhanced with increasing metabolic dysfunction-associated fatty liver disease component numbers in both sexes; however, no significance was observed in those aged < 50 years. Other significant risk factors for gallstone development were age (odds ratio: 1.093, 95% CI: 1.060-1.126) and waist circumference (odds ratio: 1.048, 95% CI: 1.018-1.079) in men and age (odds ratio: 1.035, 95% CI: 1.003-1.067) and current smoking (odd ratio: 5.465, 95% CI: 1.881-15.88) in women. Although the risk factors for gallstone development differed between sexes, metabolic dysfunction-associated fatty liver disease was common. Paying attention to an increase in the number of metabolic dysfunction-associated fatty liver disease components in patients aged 50 years is important for gallstone prevention.
(出版サイトへのリンク): ● Publication site (DOI): 10.1111/jgh.16483
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38212880; ● Search Scopus @ Elsevier (PMID): 38212880; ● Search Scopus @ Elsevier (DOI): 10.1111/jgh.16483

(DOI: 10.1111/jgh.16483, PubMed: 38212880) Ryo Shinomiya, Yasushi Sato, Takanori Yoshimoto, Tomoyuki Kawaguchi, Akihiro Hirao, Koichi Okamoto, Yutaka Kawano, Masahiro Sogabe, Hiroshi Miyamoto and Tetsuji Takayama :
A case of treatmentresistant advanced gastric cancer with FGFR2gene alteration successfully treated with pemigatinib.,
International Cancer Conference Journal, Vol.13, 240-244, 2024.

(出版サイトへのリンク): ● Publication site (DOI): 10.1007/s13691-024-00669-3
(文献検索サイトへのリンク): ● Search Scopus @ Elsevier (DOI): 10.1007/s13691-024-00669-3

(DOI: 10.1007/s13691-024-00669-3) Akinari Kasai, Jinsei Miyoshi, Yasushi Sato, Koichi Okamoto, Hiroshi Miyamoto, Takashi Kawanaka, Chisato Tonoiso, Masafumi Harada, Masakazu Goto, Takahiro Yoshida, Akihiro Haga and Tetsuji Takayama :
A novel CT-based radiomics model for predicting response and prognosis of chemoradiotherapy in esophageal squamous cell carcinoma.,
Scientific Reports, Vol.14, No.1, 2039, 2024.

(要約): No clinically relevant biomarker has been identified for predicting the response of esophageal squamous cell carcinoma (ESCC) to chemoradiotherapy (CRT). Herein, we established a CT-based radiomics model with artificial intelligence (AI) to predict the response and prognosis of CRT in ESCC. A total of 44 ESCC patients (stage I-IV) were enrolled in this study; training (n = 27) and validation (n = 17) cohorts. First, we extracted a total of 476 radiomics features from three-dimensional CT images of cancer lesions in training cohort, selected 110 features associated with the CRT response by ROC analysis (AUC ≥ 0.7) and identified 12 independent features, excluding correlated features by Pearson's correlation analysis (r ≥ 0.7). Based on the 12 features, we constructed 5 prediction models of different machine learning algorithms (Random Forest (RF), Ridge Regression, Naive Bayes, Support Vector Machine, and Artificial Neural Network models). Among those, the RF model showed the highest AUC in the training cohort (0.99 [95%CI 0.86-1.00]) as well as in the validation cohort (0.92 [95%CI 0.71-0.99]) to predict the CRT response. Additionally, Kaplan-Meyer analysis of the validation cohort and all the patient data showed significantly longer progression-free and overall survival in the high-prediction score group compared with the low-prediction score group in the RF model. Univariate and multivariate analyses revealed that the radiomics prediction score and lymph node metastasis were independent prognostic biomarkers for CRT of ESCC. In conclusion, we have developed a CT-based radiomics model using AI, which may have the potential to predict the CRT response as well as the prognosis for ESCC patients with non-invasiveness and cost-effectiveness.
(キーワード): Humans / Esophageal Squamous Cell Carcinoma / Artificial Intelligence / Bayes Theorem / Esophageal Neoplasms / Radiomics / Prognosis / Chemoradiotherapy / Tomography, X-Ray Computed
(徳島大学機関リポジトリ): ● Metadata: 119113
(出版サイトへのリンク): ● Publication site (DOI): 10.1038/s41598-024-52418-4
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38263395; ● Search Scopus @ Elsevier (PMID): 38263395; ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-024-52418-4

(徳島大学機関リポジトリ: 119113, DOI: 10.1038/s41598-024-52418-4, PubMed: 38263395) Tetsu Tomonari, Joji Tani, Yasushi Sato, Hironori Tanaka, Takahiro Tanaka, Tatsuya Taniguchi, Yutaka Kawano, Asahiro Morishita, Koichi Okamoto, Masahiro Sogabe, Hiroshi Miyamoto, Tsutomu Masaki and Tetsuji Takayama :
Clinical Features and Outcomes of Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma.,
Cancers, Vol.15, No.21, 5221, 2023.

(要約): <jats:p>This retrospective multicenter study analyzed 244 patients with unresectable hepatocellular carcinoma treated with lenvatinib (LEN) and atezolizumab + bevacizumab (Atezo + Bev) to examine the characteristics, treatment courses, and prognoses. The cases of patients who could achieve HCC downstaging from Barcelona Clinic Liver Cancer (BCLC) stage B or C to A or zero indicated the need for conversion therapy. The patients' prognoses with and without conversion therapy were compared. Of the 244 patients, 12 (4.9%) underwent conversion therapy, six out of 131 (4.6%) were treated with LEN, and six out of 113 (5.3%) were treated with Atezo + Bev. Eleven patients (91.7%) with a modified albumin bilirubin (mALBI) grade 1 or 2a and BCLC-B stage showed significantly higher rates of transition during conversion therapy (p < 0.05). The patients undergoing conversion therapy had a significantly longer median overall survival rate than those receiving chemotherapy alone (1208 [1064–NA] vs. 569 [466–704] days, p < 0.01). A comparison of the patients who achieved a partial response with and without conversion was evaluated using propensity score matching to reduce the confounding factors, showing a significant survival benefit in the conversion group (1208 [1064–NA] vs. 665 days, p < 0.01). Among the patients with u-HCC who were treated with LEN and Atezo + Bev, those with mALBI 1 + 2a and BCLC-B were likely to achieve conversion therapy with downstaging.</jats:p>
(出版サイトへのリンク): ● Publication site (DOI): 10.3390/cancers15215221
(文献検索サイトへのリンク): ● CiNii @ 国立情報学研究所 (CRID): 1360580235903920000; ● Summary page in Scopus @ Elsevier: 2-s2.0-85176601973

(DOI: 10.3390/cancers15215221, CiNii: 1360580235903920000, Elsevier: Scopus) Reiko Yokoyama, Yasushi Sato, Fumika Nakamura, Kaizo Kagemoto, Yasuhiro Mitsui, Koichi Okamoto, Yutaka Kawano, Masahiro Sogabe, Hiroshi Miyamoto and Tetsuji Takayama :
Efficacy of immune checkpoint inhibitors in patients with anorectal melanoma in association with immune-related adverse events: a case series.,
Clinical Journal of Gastroenterology, Vol.Online ahead of print., 2023.

(要約): Anorectal melanoma (AM) is a rare subtype of mucosal melanoma with a poor prognosis. Given its rarity compared to its cutaneous counterpart, the benefits and side effects of immune checkpoint inhibitor (ICI) therapy and the relationship between side effects and prognosis remain unclear. Herein, we describe the clinical presentation of five patients with AM treated with ICI as well as their relationship to the treatment course and the development of immune-related adverse events (irAEs). Three patients received sequential or concurrent administrations of nivolumab and ipilimumab, one received nivolumab alone, and one received ipilimumab alone. The response rate (RR) and disease control rate (DCR) were 40% and 80%, respectively. Pituitary and hepatic dysfunctions were the most common irAEs observed (40% each), followed by thyroid, diarrhea, and renal dysfunctions (20% each). The RR was 67% in patients with irAEs while no response was observed in patients without irAEs. DCR was 100% and 50% in patients with and without irAEs, respectively. Overall survival was 34 months in irAE and 8.75 months in non-irAE cases, with a longer survival trend in irAE cases. ICI therapy was effective and well-tolerated by AM patients, with potentially better outcomes for those who experienced irAEs compared to those who did not.
(出版サイトへのリンク): ● Publication site (DOI): 10.1007/s12328-023-01849-z
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37632658; ● Summary page in Scopus @ Elsevier: 2-s2.0-85169147432

(DOI: 10.1007/s12328-023-01849-z, PubMed: 37632658, Elsevier: Scopus) Taku Takahashi, Yasushi Sato, Takanori Kashihara, Yoshihiro Miyata, Yasuteru Fujino, Yasuhiro Mitsui, Koichi Okamoto, Hiroshi Miyamoto, Yasuhiko Nishioka and Tetsuji Takayama :
Nintedanib-Induced Gastric Antral Vascular Ectasia in Patients with Idiopathic Pulmonary Fibrosis.,
ACG Case Reports Journal, Vol.10, e01107, 2023.

(出版サイトへのリンク): ● Publication site (DOI): 10.14309/crj.0000000000001107
(文献検索サイトへのリンク): ● Search Scopus @ Elsevier (DOI): 10.14309/crj.0000000000001107

(DOI: 10.14309/crj.0000000000001107) Yasushi Sato, Koichi Okamoto, Yutaka Kawano, Akinari kasai, Tomoyuki Kawaguchi, Tamotsu Sagawa, Masahiro Sogabe, Hiroshi Miyamoto and Tetsuji Takayama :
Novel Biomarkers of Gastric Cancer: Current Research and Future Perspectives.,
Journal of Clinical Medicine, Vol.12, 4646, 2023.

(出版サイトへのリンク): ● Publication site (DOI): 10.3390/jcm12144646
(文献検索サイトへのリンク): ● Summary page in Scopus @ Elsevier: 2-s2.0-85166316472

(DOI: 10.3390/jcm12144646, Elsevier: Scopus) Tamotsu Sagawa, Yasushi Sato, Hiroyuki Nagashimia, Kohichi Takada, Mamoru Takahashi, Masahiro Hiarakawa, Kyoko Hamaguchi, Fumito Tamura, Koshi Fujikawa, Koichi Okamoto, Yutaka Kawano, Masahiro Sogabe, Hiroshi Miyamoto and Tetsuji Takayama :
Hilar/mediastinal and cutaneous drug-induced sarcoidosis-like reaction associated with immune checkpoint inhibitors in metastatic colorectal cancer: a case report.,
Frontiers in Immunology, Vol.14, 1203621, 2023.

(要約): Immune checkpoint inhibitors (ICIs) are the standard treatment for metastatic colorectal cancer (mCRC) with high microsatellite instability (MSI-H). Among immune-related adverse events (irAEs), drug-induced sarcoidosis-like reactions (DISR) are often difficult to differentiate from cancer progression. This is a case of a woman in her mid-60s, with mCRC (RAS wild/BRAF mutant/MSI-H) and abdominal lymph node metastasis, treated with four courses of ipilimumab + nivolumab every 3 weeks, followed by nivolumab every 2 weeks as third-line treatment. After treatment, the original lymph node metastases shrank, but hilar/mediastinal lymph nodes appeared. Endoscopic ultrasound-guided fine-needle aspiration of these lymph nodes revealed multiple epithelioid granulomas without necrosis, indicating a sarcoidosis-like reaction. Fluorodeoxyglucose-positron emission tomography scan showed abnormal subcutaneous accumulation in bilateral forearms and bilateral knee joints. Biopsy of the cutaneous lesions was also performed, which revealed epithelioid granulomas. As the patient had no symptoms in other organs, no specific therapeutic intervention was administered. After the discontinuation of immunotherapy, the sarcoidosis-like reaction regressed without cancer relapse. Clinicians should be aware of the possibility of DISR as an irAE during the ICI treatment of mCRC. In suspected cases of DISR following ICI therapy, it is important to differentiate between cancer progression and DISR through histological diagnosis for the subsequent strategy, as radiological and serological findings are not definitive.
(キーワード): Humans / Female / Nivolumab / Immune Checkpoint Inhibitors / Neoplasm Recurrence, Local / Sarcoidosis / Colonic Neoplasms / Rectal Neoplasms / Granuloma / Lymphatic Metastasis
(出版サイトへのリンク): ● Publication site (DOI): 10.3389/fimmu.2023.1203621
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37492584; ● Summary page in Scopus @ Elsevier: 2-s2.0-85165588753

(DOI: 10.3389/fimmu.2023.1203621, PubMed: 37492584, Elsevier: Scopus) Tamotsu Sagawa, Yasushi Sato, Masahiro Hirakawa, Kyoko Hamguchi, Fumito Tamura, Hiroyuki Nagashima, Koshi Fujikawa, Koichi Okamoto, Yutaka Kawano, Masahiro Sogabe, Hiroshi Miyamoto and Tetsuji Takayama :
Case Report: Longitudinal monitoring of clonal evolution by circulating tumor DNA for resistance to anti-EGFR antibody in a case of metastatic colorectal cancer.,
Frontiers in Oncology, Vol.13, 1203296, 2023.

(要約): Treatment with anti-EGFR antibody has been shown to prolong survival in patients with RAS wild-type metastatic colorectal cancer (mCRC). However, even patients who initially respond to anti-EGFR antibody therapy, almost without exception, develop resistance to the therapy and then fail to respond. Secondary mutations in the mitogen-activated protein (MAPK) signaling pathway (mainly in NRAS and BRAF) have been implicated in anti-EGFR resistance. However, the process by which resistant clones develop during therapy has not been elucidated, and considerable intrapatient and interpatient heterogeneity exists. Circulating tumor DNA (ctDNA) testing has recently allowed the noninvasive detection of heterogeneous molecular alterations that underlie the evolution of resistance to anti-EGFR. In this report, we describe our observation of genomic alterations in and in a patient with acquired resistance to anti-EGFR antibody drugs by tracking clonal evolution using serial ctDNA anaylsis. A 54-year-old woman was initially diagnosed with sigmoid colon cancer with multiple liver metastases. After receiving first-line mFOLFOX + cetuximab, second-line FOLFIRI + ramucirumab, third-line trifluridine/tipiracil + bevacizumab, fourth-line regorafenib, and fifth-line CAPOX + bevacizumab, she was rechallenged with CPT-11 + cetuximab. The best response to anti-EGFR rechallenge therapy was a partial response. in the ctDNA was assessed during treatment. The status changed from wild type to mutant type, back to wild type, and again to mutant type ( codon 61) during the course of treatment. In this report, tracking of ctDNA allowed us to describe clonal evolution in a case in which we observed genomic alterations in and in a patient who acquired resistance to anti-EGFR antibody drugs during treatment. It is reasonable to consider repeat molecular interrogation during progression in patients with mCRC by using ctDNA analysis, which could help to identify patients who may benefit from a rechallenge strategy.
(出版サイトへのリンク): ● Publication site (DOI): 10.3389/fonc.2023.1203296
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37434969; ● Summary page in Scopus @ Elsevier: 2-s2.0-85164679900

(DOI: 10.3389/fonc.2023.1203296, PubMed: 37434969, Elsevier: Scopus) Masahiro Sogabe, Toshiya Okahisa, Miwako Kagawa, Hiroyuki Ueda, Kaizo Kagemoto, Hironori Tanaka, Yoshifumi Kida, Tetsu Tomonari, Tatsuya Taniguchi, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Masahiko Nakasono and Tetsuji Takayama :
Influence of alcohol on newly developed metabolic dysfunction-associated fatty liver disease in both sexes: A longitudinal study.,
Clinical Nutrition, Vol.42, No.5, 810-816, 2023.

(要約): The influence of changes in alcohol consumption on newly developed metabolic dysfunction-associated fatty liver disease (MAFLD) is unclear. We investigated the influence of alcohol consumption on newly developed MAFLD in both sexes. This observational cohort study included 4071 patients who underwent more than two health check-ups between 2015 and 2020 over an interval of more than a year. Generalised estimating equations were used for analyses. At baseline, the rates of drinking and MAFLD between men and women were 72.5% versus 41.7% and 42.2% versus 22.1%, respectively. At the most recent stage, the rates of an increase in alcohol consumption for men and women were 13.3% and 8.7%, respectively, and 311/1192 (26.1%) men and 155/1566 (9.9%) women had newly developed MAFLD. The odds ratio (OR) for drinking in patients with newly developed MAFLD was 0.863 (men) (95% confidence interval [CI], 0.676-1.102, p = 0.237) and 1.041 (women) (95% CI, 0.753-1.439, p = 0.808); the OR for women who drank 140-279.9 g/week was 2.135 (95% CI, 1.158-3.939, p < 0.05) and that for all drinking categories among women was >1. Several non-invasive fibrosis scores were significantly associated with the quantity of alcohol consumption in patients with newly developed MAFLD (p < 0.005). Alcohol consumption had no significant protective effect against newly developed MAFLD in both sexes, regardless of quantity. Conversely, alcohol consumption ≥140 g/week was a risk factor for newly developed MAFLD in women. The development of liver fibrosis with increased alcohol intake should be considered in patients with MAFLD.
(徳島大学機関リポジトリ): ● Metadata: 118599
(出版サイトへのリンク): ● Publication site (DOI): 10.1016/j.clnu.2023.03.020
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37043935; ● Search Scopus @ Elsevier (PMID): 37043935; ● Search Scopus @ Elsevier (DOI): 10.1016/j.clnu.2023.03.020

(徳島大学機関リポジトリ: 118599, DOI: 10.1016/j.clnu.2023.03.020, PubMed: 37043935) Tetsu Tomonari, Hironori Tanaka, Takahiro Tanaka, Tatsuya Taniguchi, Masahiro Sogabe, Yutaka Kawano, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato and Tetsuji Takayama :
A case of complete response with rechallenge-lenvatinib plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma refractory to multiple molecular-targeted agent treatments.,
Clinical Journal of Gastroenterology, Vol.16, No.3, 438-443, 2023.

(要約): The efficacy of lenvatinib (LEN) plus transcatheter arterial chemoembolization (LEN-TACE) has been reported, but its effect on unresectable hepatocellular carcinoma (HCC) refractory to LEN therapy has not been demonstrated. We report a case of HCC refractory to multiple molecular-targeted agents (MTA) treatments, including LEN, that was successfully treated with LEN-TACE. A 59-year-old man was referred to our department with multiple HCCs and a background of hepatitis B virus infection. TACE was the initial treatment. However, he was determined to be TACE-refractory, and multitargeted therapy was initiated. LEN was started at 12 mg/day but resulted in progressive disease (PD) after 13 months of the administration. The response to second-line sorafenib was PD after 2 months. Third-line therapy with atezolizumab + bevacizumab was stopped after one course because of an immune-related adverse event (i.e., dermatitis). The response to fourth-line regorafenib was PD at 2 months, and the response to fifth-line cabozantinib was PD after 6 months. The efficacy of LEN-TACE was recently reported; therefore, we decided to attempt LEN-TACE therapy as a salvage line. After obtaining the patient's consent to repeat LEN and TACE, treatment was initiated. The tumor markers levels markedly reduced after LEN-TACE therapy. After three additional TACE treatments with continued LEN administration, the tumor marker levels normalized, and complete response was determined based on RECIST guidelines. LEN-TACE therapy may effectively treat unresectable advanced HCC in the LEN-rechallenge setting and may be a treatment option as a last-line therapeutic option.
(出版サイトへのリンク): ● Publication site (DOI): 10.1007/s12328-023-01777-y
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36856957; ● Search Scopus @ Elsevier (PMID): 36856957; ● Search Scopus @ Elsevier (DOI): 10.1007/s12328-023-01777-y

(DOI: 10.1007/s12328-023-01777-y, PubMed: 36856957) Yoshifumi Kida, Toshiya Okahisa, Yasushi Sato, Masahiro Bando, Shota Fujimoto, ma beibei, Tadahiko Nakagawa, Tomoyuki Kawaguchi, Fumika Nakamura, Koichi Okamoto, Hiroshi Miyamoto, Masahiro Sogabe, Koichi Tsuneyama and Tetsuji Takayama :
Urokinase-type plasminogen activator blockade ameliorates experimental colitis in mice.,
Scientific Reports, Vol.13, No.1, 2899, 2023.

(要約): Although several angiogenesis-related factors are reportedly involved in the pathogenesis of ulcerative colitis (UC), the mechanisms by which they contribute to disease are unclear. We first examined the expression of angiogenesis-related factors in inflamed colorectal tissue of UC patients using antibody array, and identified the 5 factors with highest expression, which included matrix metalloproteinase-8, urokinase-type plasminogen activator (uPA), angiostatin/plasminogen, hepatocyte growth factor and endoglin. Subsequent real-time PCR experiments using additional colorectal tissues revealed that uPA mRNA levels were significantly higher in inflamed tissues than in non-inflamed tissues, and significantly correlated with the severity of UC. Mirror section immunohistochemistry revealed that uPA was expressed in the neutrophils of inflamed colorectal tissues. We administered dextran sulfate sodium (DSS) in drinking water to uPA knockout (uPA) mice, and found that the disease activity index in uPA mice was marginally lower and the histological score in uPA mice was significantly lower than those in wild-type mice, suggesting the importance of uPA in colitis. When an uPA-selective inhibitor, UK122, was administered to DSS-treated C57BL6J mice, the disease activity index and histological score in those mice were significantly lower compared with control mice. Multiple cytokine/chemokine assay using colorectal tissues from uPA and UK122-treated mice revealed significantly lowered level of RANTES. In conclusion, uPA was highly expressed in neutrophils of the inflamed mucosa of UC patients, and the expression level correlated with the severity of UC. Genetic uPA deletion or pharmacological uPA blockade significantly ameliorated colitis in mice, concomitant with downregulation of RANTES.
(キーワード): Animals / Mice / Urokinase-Type Plasminogen Activator / Colitis / Colitis, Ulcerative / Serine Proteases / Colorectal Neoplasms
(徳島大学機関リポジトリ): ● Metadata: 118522
(出版サイトへのリンク): ● Publication site (DOI): 10.1038/s41598-023-29824-1
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36806262; ● Search Scopus @ Elsevier (PMID): 36806262; ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-023-29824-1

(徳島大学機関リポジトリ: 118522, DOI: 10.1038/s41598-023-29824-1, PubMed: 36806262) Tetsu Tomonari, Joji Tani, Chikara Ogawa, Akihiro Deguchi, Tomonori Senoh, Akio Moriya, Hiroshi Shibata, Hiroshi Fukuno, Hironori Tanaka, Takahiro Tanaka, Tatsuya Taniguchi, Masahiro Sogabe, Yutaka Kawano, Akihiro Morishita, Koichi Takaguchi, Hiroshi Miyamoto, Yasushi Sato, Tsutomu Masaki and Tetsuji Takayama :
Multicenter retrospective study of Initial treatment outcome and feasibility of initiating dose reduction of cabozantinib in unresectable hepatocellular carcinoma.,
Hepatology Research, Vol.53, No.2, 172-178, 2023.

(要約): Cabozantinib (CAB), a multiple kinase inhibitor, has been approved for use in patients with previously treated unresectable hepatocellular carcinoma (uHCC). However, real-world clinical data are lacking, particularly clinical data regarding dose modifications of CAB. We analyzed the clinical outcomes of CAB in uHCC and compared treatment outcomes between the full- and reduced-dose groups. This multicenter, observational study included patients with uHCC who were treated with CAB from March 2021 to April 2022. Patient characteristics, efficacy, and safety were compared between the full- and reduced-dose groups. Twenty-six patients from eight institutes were analyzed. Cabozantinib was administered as a third-line or later treatment in 25 (96.2%) patients and postimmunotherapy in 21 (80.5%) patients. There were 15 patients in the full-dose group (60 mg CAB) and 11 in the reduced-dose group (40 or 20 mg CAB). The objective response rate (ORR) and disease control rate (DCR) were not significantly different between the two groups. The ORR was 6.7% for the full-dose group and 9.1% for the reduced-dose group, and the DCR was 53.4% and 81.8%, respectively. Progression-free survival analysis showed no significant differences between the two groups. The incidence of decreased appetite, fatigue, and diarrhea, and the rate of discontinuation and dose reduction, was significantly higher in the full-dose group. Our study suggests that the efficacy and safety of CAB in real-world clinical practice are comparable to those of the phase III trial (CELESTIAL), and that dose reduction of CAB may be a safer treatment option.
(出版サイトへのリンク): ● Publication site (DOI): 10.1111/hepr.13845
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36214071; ● Search Scopus @ Elsevier (PMID): 36214071; ● Search Scopus @ Elsevier (DOI): 10.1111/hepr.13845

(DOI: 10.1111/hepr.13845, PubMed: 36214071) Tetsu Tomonari, Joji Tani, Yasushi Sato, Hironori Tanaka, Takahiro Tanaka, Tatsuya Taniguchi, Akihiro Morishita, Koichi Okamoto, Masahiro Sogabe, Hiroshi Miyamoto, Naoki Muguruma, Tsutomu Masaki and Tetsuji Takayama :
Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve.,
Cancer Medicine, Vol.12, No.3, 2646-2657, 2023.

(要約): We analyzed the association between the modified albumin-bilirubin (mALBI) grade and therapeutic efficacy of atezolizumab plus bevacizumab (Atezo+Bev) for the treatment of unresectable hepatocellular carcinoma (u-HCC). In this retrospective observational study, we included 71 u-HCC patients treated with Atezo+Bev between September 2020 and September 2021. Patients were grouped corresponding to the mALBI grade at the start of treatment (mALBI 1+2a or mALBI 2b+3) and analyzed for therapeutic effect and the transition rate to secondary treatment. According to the Response Evaluation Criteria in Solid Tumors, the overall response rate was significantly higher for the mALBI 1+2a group, than for the mALBI 2b+3 group, with 26.2% and 3.4%, respectively. The progression-free survival (PFS) was significantly longer in the mALBI 1+2a group (10.5 months) than in the mALBI 2b+3 group (3.0 months). In the multivariate analysis, an mALBI of 1+2a was found to be an independent factor of PFS. The rate of second-line treatment with multi-targeted agents was also significantly higher in the mALBI 1+2a group. In real-world practice, Atezo+Bev treatment might have higher therapeutic efficacy in u-HCC patients with mALBI 1+2a.
(徳島大学機関リポジトリ): ● Metadata: 117987
(出版サイトへのリンク): ● Publication site (DOI): 10.1002/cam4.5145
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35964253; ● Search Scopus @ Elsevier (PMID): 35964253; ● Search Scopus @ Elsevier (DOI): 10.1002/cam4.5145

(徳島大学機関リポジトリ: 117987, DOI: 10.1002/cam4.5145, PubMed: 35964253) Yasushi Sato, Yasuyuki Okada, Yasuteru Fujino, Tomoyuki Kawaguchi, Yoshifumi Kida, Yasuhiro Mitsui, Hironori Tanaka, Tetsu Tomonari, Shinji Kitamura, Koichi Okamoto, Yutaka Kawano, Hiroshi Miyamoto, Masahiro Sogabe and Tetsuji Takayama :
Clinical Outcomes of Comprehensive Genomic Profiling Tests for Gastrointestinal Cancers: Experience from Tokushima University Hospital.,
The Journal of Medical Investigation : JMI, Vol.70, No.1.2, 154-159, 2023.

(要約): In Japan, cancer genome profiling (CGP) for cancer patients without standard treatment has been covered by public insurance since June 2019. This study analyzed data of 122 patients with gastrointestinal tumors who underwent CGP to clarify cancer genome medicine's current status and possible problems at the Tokushima University Hospital. The major types of cancer included pancreatic (n=30), colorectal (n=25), biliary tract (n=15), gastric (n=11), and hepatocellular carcinoma (n=8). CGP tests included F1CDx in 70 patients (57%), F1LCDx in 36 (30%), TSO500 in 14 (11%), and NCC Oncopanel in 2 (2%). Actionable gene alterations were identified in 72 patients (59%), but only 5 patients (4%) were treated for pancreatic (n=1), colorectal (n=3), and small bowel cancers (n=1). The main reasons for not receiving genotype-matched therapy included the lack of appropriate drugs or clinical trials that matched the actionable gene alterations (n=40) and the inability to participate in clinical trials (n=10). There is still not a sufficient number of patients receiving genotype-matched treatment for gastrointestinal cancers. To promote cancer genome medicine in regional areas, attempts to improve access to genotype-matched therapies are required, as well as to promote the development of new molecular-targeted drugs and clinical trials for these drugs. J. Med. Invest. 70 : 154-159, February, 2023.
(キーワード): Humans / Gastrointestinal Neoplasms / Neoplasms / Colorectal Neoplasms / Genomics / Hospitals / Japan
(徳島大学機関リポジトリ): ● Metadata: 118346
(出版サイトへのリンク): ● Publication site (DOI): 10.2152/jmi.70.154
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37164713; ● Search Scopus @ Elsevier (PMID): 37164713; ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.70.154

(徳島大学機関リポジトリ: 118346, DOI: 10.2152/jmi.70.154, PubMed: 37164713) Megumi Yamasaki, Yasushi Sato, Koichi Okamoto, Akira Fukuya, Tomoyuki Kawaguchi, Kazuyoshi Noda, Kaizo Kagemoto, Yasuhiro Mitsui, Hiroshi Miyamoto and Tetsuji Takayama :
Two cases of anal squamous cell carcinoma achieving complete response after docetaxel + cisplatin + S1 (DCS) induction chemotherapy followed by chemoradiation.,
Clinical Journal of Gastroenterology, Vol.16, No.2, 180-186, 2022.

(要約): Anal squamous cell carcinoma (ASCC) is an uncommon tumor. However, its incidence is increasing worldwide. Surgical resection of locally advanced cases requires permanent anal prosthesis. Thus, chemoradiotherapy (CRT) is preferred as the first-line treatment; however, high local recurrence rate remains an issue. Here, we describe two cases of locally advanced ASCC treated with docetaxel + cisplatin + S-1 (DCS) followed by CRT with S-1 that showed complete response. The two patients, aged 69 and 65 years, were diagnosed with ASCC (cStage IIIB) at our hospital. Due to extensive lymph node metastases, the patients were treated with triple induction chemotherapy (DCS) followed by CRT with S-1. Positron emission tomography/computed tomography performed six months after starting the treatment showed disappearance of tumors, indicating a complete response. The patients continued to receive S-1 for one year and achieved relapse-free long-term survival since the completion of treatment. Therefore, induction chemotherapy with DCS, prior to CRT with S-1 may benefit patients with locally advanced ASCC.
(出版サイトへのリンク): ● Publication site (DOI): 10.1007/s12328-022-01736-z
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36409453; ● Search Scopus @ Elsevier (PMID): 36409453; ● Search Scopus @ Elsevier (DOI): 10.1007/s12328-022-01736-z

(DOI: 10.1007/s12328-022-01736-z, PubMed: 36409453) Masahiro Sogabe, Toshiya Okahisa, Miwako Kagawa, Hiroyuki Ueda, Kaizo Kagemoto, Hironori Tanaka, Yoshifumi Kida, Tetsu Tomonari, Tatsuya Taniguchi, Hiroshi Miyamoto, Yasushi Sato, Masahiko Nakasono and Tetsuji Takayama :
Influence of Alcohol Consumption on the Development of Erosive Esophagitis in Both Sexes: A Longitudinal Study.,
Nutrients, Vol.14, No.22, 4760, 2022.

(要約): The influence of changes in alcohol consumption on erosive esophagitis (EE) development in both sexes is unclear. This observational study investigated sex differences in the influence of alcohol consumption on EE development, and included 2582 patients without EE at baseline from 13,448 patients who underwent >2 health check-ups over >1 year. The rates of non-drinkers who started drinking, and drinkers who abstained from drinking, who increased, and who decreased their weekly alcohol consumption were 7.2%, 9.7%, 14.7%, and 24.1% and 7.3%, 17.8%, 12.8%, and 39.0% in men and women, respectively. In the final cohort, 211/1405 (15.0%) men and 79/1177 (6.7%) women newly developed EE. The odds ratio (OR) for drinking in EE development was 1.252 (95% confidence interval (CI), 0.907-1.726) among men and 1.078 (95% CI, 0.666-1.747) among women. Among men aged <50 years, the OR for drinking ≥70 g/week in EE development was 2.825 (95% CI, 1.427-5.592), whereas among women, the OR for drinking ≥140 g/week in EE development was 3.248 (95% CI, 1.646-6.410). Among participants aged <50 years, the OR for daily drinking in EE development was 2.692 (95% CI, 1.298-5.586) among men and 4.030 (95% CI, 1.404-11.57) among women. The influence of alcohol consumption on EE development differed between the sexes. We recommend no alcohol consumption for individuals aged <50 years to avoid EE development. Daily drinkers should be assessed for EE development.
(キーワード): Humans / Male / Female / Longitudinal Studies / Alcohol Drinking / Esophagitis / Sexual Behavior / Cohort Studies / Peptic Ulcer
(徳島大学機関リポジトリ): ● Metadata: 118071
(出版サイトへのリンク): ● Publication site (DOI): 10.3390/nu14224760
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36432447; ● Search Scopus @ Elsevier (PMID): 36432447; ● Search Scopus @ Elsevier (DOI): 10.3390/nu14224760

(徳島大学機関リポジトリ: 118071, DOI: 10.3390/nu14224760, PubMed: 36432447) 和田浩典, 藤野泰輝, 影本開三, 喜田慶史, 岡田泰行, 三井康裕, 岡本耕一, 佐藤康史, 坂東良美, 宮本弘志, 高山哲治 :
がん遺伝子パネル検査を契機にHER2陽性が判明しTrastuzumab投与により長期生存が得られた進行胃癌の1例.,
日本消化器病学会雑誌, Vol.119, No.10, 937-945, 2022年.

(要約): Intratumoral HER2 heterogeneity is a well-described gastric cancer feature and may explain many false-negative results related to this oncogene. An 81-year-old man was diagnosed at our hospital with stage IV gastric cancer with multiple lymph node metastases. Immunohistochemistry (IHC) analysis indicated that the primary tumor was HER2-negative. After a chemotherapy course, we submitted a pretreatment biopsy specimen for comprehensive cancer genome profiling (CGP) to determine the last-line therapy. This revealed HER2 amplification. The specimen was reevaluated using fluorescence in situ hybridization and IHC with deeper-cut specimens, which confirmed that the tumor was indeed HER2-positive. Therefore, the patient was treated with chemotherapy plus trastuzumab, which elicited tumor shrinkage and conferred long-term survival. Our current data underscore the CGP importance, which can provide more accurate tumor profilings and inform subsequent treatment decisions.
(キーワード): がん遺伝子パネル検査 / Trastuzumab / HER2陽性胃癌
(出版サイトへのリンク): ● Publication site (DOI): 10.11405/nisshoshi.119.937
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36216544; ● CiNii @ 国立情報学研究所 (CRID): 1390293710918867840; ● Search Scopus @ Elsevier (PMID): 36216544; ● Search Scopus @ Elsevier (DOI): 10.11405/nisshoshi.119.937

(DOI: 10.11405/nisshoshi.119.937, PubMed: 36216544, CiNii: 1390293710918867840) Masahiro Sogabe, Toshiya Okahisa, Takeshi Kurihara, Miwako Kagawa, Hiroyuki Ueda, Tomoyuki Kawaguchi, Akira Fukuya, Kaizoh Kagemoto, Hironori Tanaka, Yoshifumi Kida, Tetsu Tomonari, Tatsuya Taniguchi, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Masahiko Nakasono and Tetsuji Takayama :
Comparison of the role of alcohol consumption and qualitative abdominal fat on NAFLD and MAFLD in males and females.,
Scientific Reports, Vol.12, No.1, 16048, 2022.

(要約): The clinical difference between nonalcoholic fatty liver disease (NAFLD) and metabolic-associated fatty liver disease (MAFLD) between the two sexes is unclear. This study aimed to determine the influences of alcohol consumption and qualitative abdominal fat between male and female patients with NAFLD and MAFLD. This cross-sectional study examined 11,766 participants who underwent health check-ups comparing lifestyle habits, biochemical features, and noninvasive liver fibrosis scores, between non-MAFLD and MAFLD groups. Furthermore, differences in alcohol consumption and qualitative abdominal fat were examined between male and female patients with NAFLD and MAFLD. The prevalence of metabolic dysregulation, ratio of visceral fat area to subcutaneous fat area, and noninvasive liver fibrosis scores were significantly higher in male patients with MAFLD than in those with NAFLD (p < 0.05), but these were not significantly different in female patients. Among male patients with an alcohol consumption of > 70 g/week, several noninvasive liver fibrosis scores were significantly higher in the MAFLD group than in the NAFLD group (all p < 0.05). The influences of alcohol consumption and qualitative abdominal fat on NAFLD and MAFLD were different between sexes. The development of liver fibrosis should be considered in male patients with MAFLD who exceed mild drinking.
(キーワード): Alcohol Drinking / Cross-Sectional Studies / Female / Humans / Intra-Abdominal Fat / Liver Cirrhosis / Male / Non-alcoholic Fatty Liver Disease
(徳島大学機関リポジトリ): ● Metadata: 117853
(出版サイトへのリンク): ● Publication site (DOI): 10.1038/s41598-022-20124-8
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36163355; ● Search Scopus @ Elsevier (PMID): 36163355; ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-022-20124-8

(徳島大学機関リポジトリ: 117853, DOI: 10.1038/s41598-022-20124-8, PubMed: 36163355) Hironori Wada, Yasushi Sato, Shota Fujimoto, Koichi Okamoto, Masahiro Bando, Tomoyuki Kawaguchi, Hiroshi Miyamoto, Naoki Muguruma, Katsuhisa Horimoto, Yui Matsuzawa, Michihiro Mutoh and Tetsuji Takayama :
Resveratrol inhibits development of colorectal adenoma via suppression of LEF1; comprehensive analysis with connectivity map.,
Cancer Science, Vol.113, No.12, 4374-4384, 2022.

(要約): Although many chemopreventive studies on colorectal tumors have been reported, no effective and safe preventive agent is currently available. We searched for candidate preventive compounds against colorectal tumor comprehensively from United States Food and Drug Administration (FDA)-approved compounds by using connectivity map (CMAP) analysis coupled with in vitro screening with colorectal adenoma (CRA) patient-derived organoids (PDOs). We generated CRA-specific gene signatures based on the DNA microarray analysis of CRA and normal epithelial specimens, applied them to CMAP analysis with 1309 FDA-approved compounds, and identified 121 candidate compounds that should cancel the gene signatures. We narrowed them down to 15 compounds, and evaluated their inhibitory effects on the growth of CRA-PDOs in vitro. We finally identified resveratrol, one of the polyphenolic phytochemicals, as a compound showing the strongest inhibitory effect on the growth of CRA-PDOs compared with normal epithelial PDOs. When resveratrol was administered to Apc mice at 15 or 30 mg/kg, the number of polyps (adenomas) was significantly reduced in both groups compared with control mice. Similarly, the number of polyps (adenomas) was significantly reduced in azoxymethane-injected rats treated with 10 or 100 mg/resveratrol compared with control rats. Microarray analysis of adenomas from resveratrol-treated rats revealed the highest change (downregulation) in expression of LEF1, a key molecule in the Wnt signaling pathway. Treatment with resveratrol significantly downregulated the Wnt-target gene (MYC) in CRA-PDOs. Our data demonstrated that resveratrol can be the most effective compound for chemoprevention of colorectal tumors, the efficacy of which is mediated through suppression of LEF1 expression in the Wnt signaling pathway.
(キーワード): Mice / Rats / Animals / Resveratrol / Adenoma / Colorectal Neoplasms / Wnt Signaling Pathway / Chemoprevention / Lymphoid Enhancer-Binding Factor 1
(徳島大学機関リポジトリ): ● Metadata: 117988
(出版サイトへのリンク): ● Publication site (DOI): 10.1111/cas.15576
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36082704; ● Search Scopus @ Elsevier (PMID): 36082704; ● Search Scopus @ Elsevier (DOI): 10.1111/cas.15576

(徳島大学機関リポジトリ: 117988, DOI: 10.1111/cas.15576, PubMed: 36082704) Beibei Ma, Hiroyuki Ueda, Koichi Okamoto, Masahiro Bando, Shota Fujimoto, Yasuyuki Okada, Tomoyuki Kawaguchi, Hironori Wada, Hiroshi Miyamoto, Mitsuo Shimada, Yasushi Sato and Tetsuji Takayama :
TIMP1 promotes cell proliferation and invasion capability of right-sided colon cancers via the FAK/Akt signaling pathway.,
Cancer Science, Vol.113, No.12, 4244-4257, 2022.

(要約): Although right-sided colorectal cancer (CRC) shows a worse prognosis than left-sided CRC, the underlying mechanism remains unclear. We established patient-derived organoids (PDOs) from left- and right-sided CRCs and directly compared cell proliferation and invasion capability between them. We then analyzed the expression of numerous genes in signal transduction pathways to clarify the mechanism of the differential prognosis. Cell proliferation activity and invasion capability in right-sided cancer PDOs were significantly higher than in left-sided cancer PDOs and normal PDOs, as revealed by Cell Titer Glo and transwell assays, respectively. We then used quantitative RT-PCR to compare 184 genes in 30 pathways among right-sided and left-sided cancer and normal PDOs and found that the TIMP1 mRNA level was highest in right-sided PDOs. TIMP1 protein levels were upregulated in right-sided PDOs compared with normal PDOs but was downregulated in left-sided PDOs. TIMP1 knockdown with shRNA significantly decreased cell proliferation activity and invasion capability in right-sided PDOs but not in left-sided PDOs. Moreover, TIMP1 knockdown significantly decreased pFAK and pAkt expression levels in right-sided PDOs but not in left-sided PDOs. A database analysis of The Cancer Genome Atlas revealed that TIMP1 expression in right-sided CRCs was significantly higher than in left-sided CRCs. Kaplan-Meier survival analysis showed significantly shorter overall survival in high-TIMP1 patients versus low-TIMP1 patients with right-sided CRCs but not left-sided CRCs. Our data suggest that TIMP1 is overexpressed in right-sided CRCs and promotes cell proliferation and invasion capability through the TIMP1/FAK/Akt pathway, leading to a poor prognosis. The TIMP1/FAK/Akt pathway can be a target for therapeutic agents in right-sided CRCs.
(キーワード): Humans / Prognosis / Signal Transduction / Colorectal Neoplasms / Colonic Neoplasms / Cell Proliferation / Tissue Inhibitor of Metalloproteinase-1
(徳島大学機関リポジトリ): ● Metadata: 117615
(出版サイトへのリンク): ● Publication site (DOI): 10.1111/cas.15567
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36073574; ● Search Scopus @ Elsevier (PMID): 36073574; ● Search Scopus @ Elsevier (DOI): 10.1111/cas.15567

(徳島大学機関リポジトリ: 117615, DOI: 10.1111/cas.15567, PubMed: 36073574) Fumika Nakamura, Yasushi Sato, Koichi Okamoto, Yasuteru Fujino, Yasuhiro Mitsui, kaizo kagemoto, Tomoyuki Kawaguchi, Hiroshi Miyamoto, Naoki Muguruma, Tomoko Sonoda, Koichi Tsuneyama and Tetsuji Takayama :
Colorectal carcinoma occurring via the adenoma-carcinoma pathway in patients with serrated polyposis syndrome.,
Journal of Gastroenterology, Vol.57, No.4, 286-299, 2022.

(要約): Although serrated polyposis syndrome (SPS) is associated with an increased colorectal cancer (CRC) risk, the carcinogenic mechanisms remain unknown. We investigated clinicopathological characteristics and genetic abnormalities in colorectal polyps and CRC to elucidate carcinogenic mechanisms in SPS. We retrospectively analyzed clinicopathological features of colorectal polyps in 44 SPS patients, and examined mutations of genes including APC, RAS, BRAF, and TP53, and microsatellite instability (MSI) in CRC tissues. Of the 44 patients, 25 (56%) fulfilled WHO criterion 1, 11 (25%) fulfilled criterion 2, and 8 (18%) fulfilled both. A total of 956 polyps were observed; 642 (67%) hyperplastic polyps (HP), 204 (21%) sessile serrated lesions (SSL), 10 (1%) traditional serrated adenoma (TSA), and 100 (11%) adenomas. The median numbers of polyps (/patient) were 10.5 (IQR 2.75-23) HPs, 4.0 (2.0-6.0) SSLs, 0 (0-0) TSA, and 1 (0-3.3) adenoma. SSL and HP located preferentially in the proximal and distal colon, respectively. Twenty-two CRCs were found in 18 patients. Based on the histological coexistence of SSL/TSA, BRAF mutation and MSI, 5 CRCs (26%) were classified as serrated-neoplasia pathway. Conversely, based on the coexistence of adenoma, APC/RAS and TP53 mutations, 11 CRCs (58%) were classified as adenoma-carcinoma pathway. The remaining three were unclassifiable. Most CRCs through adenoma-carcinoma pathway were located in the left-side colorectum and patients bearing those met criterion 2, characterized by many HP and advanced adenomas. Adenoma was a significant risk factor for CRC. Our results suggest that more than half of the CRCs, particularly those in the left-side colorectum, developed through the adenoma-carcinoma pathway in SPS patients. Adenoma was a risk factor for CRCs, suggesting its importance in colorectal carcinogenesis.
(キーワード): Adenoma / Carcinoma / Colonic Polyps / Colorectal Neoplasms / Humans / Intestinal Polyposis / Microsatellite Instability / Mutation / Proto-Oncogene Proteins B-raf / Retrospective Studies
(徳島大学機関リポジトリ): ● Metadata: 117614
(出版サイトへのリンク): ● Publication site (DOI): 10.1007/s00535-022-01858-8
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35194694; ● Search Scopus @ Elsevier (PMID): 35194694; ● Search Scopus @ Elsevier (DOI): 10.1007/s00535-022-01858-8

(徳島大学機関リポジトリ: 117614, DOI: 10.1007/s00535-022-01858-8, PubMed: 35194694) Noriaki Murayama, Koichi Okamoto, Tadahiko Nakagawa, Jinsei Miyoshi, Kensei Nishida, Tomoyuki Kawaguchi, kaizo kagemoto, Shinji Kitamura, Beibei Ma, Hiroshi Miyamoto, Naoki Muguruma, Mitsuyasu Yano, Koichi Tsuneyama, Takahiro Fujimori, Yasushi Sato and Tetsuji Takayama :
miR-144-3p/miR-451a promotes lymphovascular invasion through repression of PTEN/p19 in rectal neuroendocrine tumors.,
Journal of Gastroenterology and Hepatology, Vol.37, No.5, 919-927, 2022.

(要約): Although rectal neuroendocrine tumor (NET-G1) have potential metastatic capability, even among small tumors, no predictive biomarker for invasion and metastasis has been reported. We analyzed microRNA (miRNA) expression profiles in rectal NET-G1 tissues with and without lymphovascular invasion (LVI). Moreover, we then investigated their target genes to clarify the mechanism of invasion/metastasis in NET-G1. miRNA array analysis was performed using seven rectal NET-G1 tissues with LVI and seven without LVI. miRNA expression was confirmed by quantitative real-time PCR. A NET cell line H727 was transfected with miRNA mimic or target gene small interfering RNA, and migration and invasion assays were performed. The expression levels of miR-144-3p and miR-451a were significantly higher in NET-G1 with LVI versus without LVI, as determined by miRNA array analysis and RT-qPCR. A significant correlation was observed between miR-144-3p and miR-451a expression levels, strongly suggesting miR144/451 cluster overexpression in NET-G1 with LVI. Bioinformatic analysis of target genes revealed that miR-144-3p and miR-451a directly interact with PTEN and p19 mRNA, respectively. Immunohistochemistry revealed significantly lower expression of PTEN and p19 in NET-G1 tissues with LVI than in those without LVI. The miR-144-3p and miR-451a mimic significantly increased cell migration/invasion capability, respectively. Knockdown of PTEN and p19 induced significant augmentation of cell invasion and migration capability, respectively. Our data suggest that overexpression of miR-144/miR-451 cluster promotes LVI via repression of PTEN and p19 in rectal NET-G1 cells. miR-144/451 cluster may be a novel biomarker for predicting invasion/metastasis in rectal NET-G1.
(キーワード): Biomarkers / Cell Line, Tumor / Cell Movement / Cell Proliferation / Gene Expression Regulation, Neoplastic / Humans / MicroRNAs / Neuroendocrine Tumors / PTEN Phosphohydrolase / Rectal Neoplasms
(徳島大学機関リポジトリ): ● Metadata: 117699
(出版サイトへのリンク): ● Publication site (DOI): 10.1111/jgh.15833
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35332577; ● Search Scopus @ Elsevier (PMID): 35332577; ● Search Scopus @ Elsevier (DOI): 10.1111/jgh.15833

(徳島大学機関リポジトリ: 117699, DOI: 10.1111/jgh.15833, PubMed: 35332577) Kumiko Tanaka, Yasushi Sato, Hideki Ishikawa, Naoki Muguruma, Satoshi Teramae, Yoji Takeuchi, Yasuhiro Mitsui, Koichi Okamoto, Hiroshi Miyamoto, Yoshimi Bando, Tomoko Sonoda, Naoki Omiya, Michihiro Mutoh and Tetsuji Takayama :
Small Intestinal Involvement and Genotype-Phenotype Correlation in Familial Adenomatous Polyposis.,
Techniques and Innovations in Gastrointestinal Endoscopy, Vol.24, No.1, 26-34, 2022.

(徳島大学機関リポジトリ): ● Metadata: 116979
(出版サイトへのリンク): ● Publication site (DOI): 10.1016/j.tige.2021.10.001
(文献検索サイトへのリンク): ● CiNii @ 国立情報学研究所 (CRID): 1360861291391377024; ● Summary page in Scopus @ Elsevier: 2-s2.0-85119353922

(徳島大学機関リポジトリ: 116979, DOI: 10.1016/j.tige.2021.10.001, CiNii: 1360861291391377024, Elsevier: Scopus) Yasushi Sato, Koichi Okamoto, Hiroshi Miyamoto and Tetsuji Takayama :
Chemotherapy in older adults with gastrointestinal cancer:Current practices and future directions in Japan.,
The Journal of Medical Investigation : JMI, Vol.69, No.1.2, 25-30, 2022.

(要約): Chemotherapy for cancer has significantly improved owing to the increasing number of effective chemotherapeutic agents and supportive care. Recently, the number of older cancer patients has rapidly increased owing to the aging of the global population. However, in most cases, it is difficult to treat those using similar dosages or schedules as that of younger patients because older patients generally have unfavorable factors, such as decreased performance status and physical and cognitive conditions, thus increasing the incidence of complications and side effects. Chemotherapy for gastrointestinal cancers has made significant progress in recent years with the introduction of molecular-targeted agents and immunotherapy. However, clinical trials showed limited evidence regarding the efficacy of chemotherapy in older cancer patients, accounting for half of all patients, making it difficult to develop a well-established treatment strategy. This review aimed to evaluate the current state of chemotherapy for gastrointestinal cancer in older adults. Furthermore, the limitations and future perspectives were discussed. J. Med. Invest. 69 : 25-30, February, 2022.
(キーワード): Aged / Antineoplastic Agents / Antineoplastic Combined Chemotherapy Protocols / Gastrointestinal Neoplasms / Humans / Japan
(徳島大学機関リポジトリ): ● Metadata: 117006
(出版サイトへのリンク): ● Publication site (DOI): 10.2152/jmi.69.25
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35466142; ● CiNii @ 国立情報学研究所 (CRID): 1390291932640865024; ● Summary page in Scopus @ Elsevier: 2-s2.0-85128802446

(徳島大学機関リポジトリ: 117006, DOI: 10.2152/jmi.69.25, PubMed: 35466142, CiNii: 1390291932640865024, Elsevier: Scopus) Tetsu Tomonari, Yasushi Sato, Hironori Tanaka, Takeshi Mitsuhashi, Akihiro Hirao, Takahiro Tanaka, Tatsuya Taniguchi, Koichi Okamoto, Masahiro Sogabe, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama :
Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma.,
JGH Open, Vol.5, No.11, 1275-1283, 2021.

(徳島大学機関リポジトリ): ● Metadata: 116741
(出版サイトへのリンク): ● Publication site (DOI): 10.1002/jgh3.12663
(文献検索サイトへのリンク): ● Search Scopus @ Elsevier (DOI): 10.1002/jgh3.12663

(徳島大学機関リポジトリ: 116741, DOI: 10.1002/jgh3.12663) Masanori Takehara, Hiroshi Miyamoto, Yasuteru Fujino, Tetsu Tomonari, Tatsuya Taniguchi, Shinji Kitamura, Koichi Okamoto, Masahiro Sogabe, Yasushi Sato, Naoki Muguruma, Yoshimi Bando and Tetsuji Takayama :
Long-Term Survival due to Chemotherapy including Paclitaxel in a Patient with Metastatic Primary Splenic Angiosarcoma.,
Case Reports in Gastroenterology, Vol.15, No.3, 910-918, 2021.

(要約): A primary splenic angiosarcoma is a rare type of soft tissue sarcoma and is associated with an extremely poor prognosis. In this study, we describe the case of a patient who was diagnosed with metastatic primary splenic angiosarcoma and survived for about 2 years. A 62-year-old female was referred to us for the treatment of splenic angiosarcoma with disseminated intravascular coagulation (DIC) and multiple liver and bone metastases. Paclitaxel therapy resulted in recovery from DIC and enabled her to continue sequential treatment through to sixth-line chemotherapy. We reviewed all splenic angiosarcoma case reports which were described as stage IV to date and compared with our case. From these data, we found that the median overall survival was 105 days, and the prognosis of splenic angiosarcoma of stage IV was worse than conventional case series. Splenectomy was performed in more patients than chemotherapy as a treatment. Moreover, various chemotherapeutic regimens were used. These data suggest that administering chemotherapy including paclitaxel to patients with splenic angiosarcoma might improve their prognosis.
(徳島大学機関リポジトリ): ● Metadata: 116721
(出版サイトへのリンク): ● Publication site (DOI): 10.1159/000519211
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34720843; ● Summary page in Scopus @ Elsevier: 2-s2.0-85117511057

(徳島大学機関リポジトリ: 116721, DOI: 10.1159/000519211, PubMed: 34720843, Elsevier: Scopus) Akihiro Hirao, Yasushi Sato, Hironori Tanaka, Kensei Nishida, Tetsu Tomonari, Misato Hirata, Masahiro Bando, Yoshifumi Kida, Takahiro Tanaka, Tomoyuki Kawaguchi, Hironori Wada, Tatsuya Taniguchi, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma, Toshihito Tanahashi and Tetsuji Takayama :
MiR-125b-5p is Involved in Sorafenib Resistance through Ataxin-1-Mediated Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma.,
Cancers, Vol.13, No.19, 4917, 2021.

(要約): The mechanism of resistance to sorafenib in hepatocellular carcinoma (HCC) remains unclear. We analyzed miRNA expression profiles in sorafenib-resistant HCC cell lines (PLC/PRF5-R1/R2) and parental cell lines (PLC/PRF5) to identify the miRNAs responsible for resistance. Drug sensitivity, migration/invasion capabilities, and epithelial-mesenchymal transition (EMT) properties were analyzed by biochemical methods. The clinical relevance of the target genes to survival in HCC patients were assessed using a public database. Four miRNAs were significantly upregulated in PLC/PRF5-R1/-R2 compared with PLC/PRF5. Among them, miR-125b-5p mimic-transfected PLC/PRF5 cells (PLC/PRF5-miR125b) and showed a significantly higher IC50 for sorafenib compared with controls, while the other miRNA mimics did not. PLC/PRF5-miR125b showed lower E-cadherin and higher Snail and vimentin expression-findings similar to those for PLC/PRF5-R2-which suggests the induction of EMT in those cells. PLC/PRF5-miR125b exhibited significantly higher migration and invasion capabilities and induced sorafenib resistance in an in vivo mouse model. Bioinformatic analysis revealed ataxin-1 as a target gene of miR-125b-5p. PLC/PRF5 cells transfected with ataxin-1 siRNA showed a significantly higher IC50, higher migration/invasion capability, higher cancer stem cell population, and an EMT phenotype. Median overall survival in the low-ataxin-1 patient group was significantly shorter than in the high-ataxin-1 group. In conclusion, miR-125b-5p suppressed ataxin-1 and consequently induced Snail-mediated EMT and stemness, leading to a poor prognosis in HCC patients.
(徳島大学機関リポジトリ): ● Metadata: 116647
(出版サイトへのリンク): ● Publication site (DOI): 10.3390/cancers13194917
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34638401; ● Search Scopus @ Elsevier (PMID): 34638401; ● Search Scopus @ Elsevier (DOI): 10.3390/cancers13194917

(徳島大学機関リポジトリ: 116647, DOI: 10.3390/cancers13194917, PubMed: 34638401) Shinji Kitamura, Naoki Muguruma, Koichi Okamoto, Kaizo Kagemoto, Yoshifumi Kida, Yasuhiro Mitsui, Hiroyuki Ueda, Tomoyuki Kawaguchi, Hiroshi Miyamoto, Yasushi Sato, Rika Aoki, Joji Shunto, Yoshimi Bando and Tetsuji Takayama :
Clinicopathological characteristics of early gastric cancer associated with autoimmune gastritis.,
JGH Open, Vol.5, No.10, 1210-1215, 2021.

(徳島大学機関リポジトリ): ● Metadata: 116931
(出版サイトへのリンク): ● Publication site (DOI): 10.1002/jgh3.12656
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34622010; ● Summary page in Scopus @ Elsevier: 2-s2.0-85114915216

(徳島大学機関リポジトリ: 116931, DOI: 10.1002/jgh3.12656, PubMed: 34622010, Elsevier: Scopus) Masahiro Sogabe, Toshiya Okahisa, Takeshi Kurihara, Miwako Kagawa, Kaizoh Kagemoto, Yoshifumi Kida, Tetsu Tomonari, Tatsuya Taniguchi, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Masahiko Nakasono and Tetsuji Takayama :
Differences in Several Factors in the Development of Erosive Esophagitis Among Patients at Various Stages of Metabolic Syndrome: A Cross-Sectional Study.,
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy, Vol.14, 1589-1600, 2021.

(徳島大学機関リポジトリ): ● Metadata: 116294
(出版サイトへのリンク): ● Publication site (DOI): 10.2147/DMSO.S298326
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33883913; ● Summary page in Scopus @ Elsevier: 2-s2.0-85104815967

(徳島大学機関リポジトリ: 116294, DOI: 10.2147/DMSO.S298326, PubMed: 33883913, Elsevier: Scopus) Tetsu Tomonari, Yasushi Sato, Joji Tani, Akira Hirose, Chikara Ogawa, Akihiro Morishita, Hironori Tanaka, Takahiro Tanaka, Tatsuya Taniguchi, Koichi Okamoto, Masahiro Sogabe, Hiroshi Miyamoto, Naoki Muguruma, Kazushige Uchida, Tsutomu Masaki and Tetsuji Takayama :
Comparison of therapeutic outcomes of Sorafenib and Lenvatinib as primary treatments for hepatocellular carcinoma with a focus on molecular-targeted agent sequential therapy: A propensity score-matched analysis.,
Hepatology Research, Vol.51, No.4, 472-481, 2021.

(要約): The optimal choice between sorafenib (SOR) or lenvatinib (LEN) as the first-line treatment for unresectable hepatocellular carcinoma (u-HCC) remains debatable. Using propensity score matching, this study compares the outcomes of SOR and LEN in the molecular-targeted agent (MTA) sequential treatment of u-HCC patients. This retrospective, multicenter, observational study recruited 137 u-HCC patients who underwent primary treatment with LEN (n = 52) or SOR (n = 85) between June 2017 and June 2020 after regorafenib was approved as the secondary treatment for u-HCC. Propensity score matching was used to reduce confounding, resulting in the selection of 104 patients (n = 52 for the SOR and LEN cohorts). The median overall survival was 21.8 months for LEN and 20.4 months for SOR. LEN exhibited significantly greater therapeutic efficacy as compared to SOR (objective response rate: 3.8% [SOR] vs. 42.3% [LEN], P <0.01; progression-free survival: 10 months [LEN] vs. 5.1 months [SOR], P <0.01). No significant intergroup differences were noted in the rate of transition to secondary MTA treatments (SOR: 58.7%; LEN: 48.4%), adverse events (SOR: 86%; LEN: 95%), and maintenance of the Child-Pugh (CP) score during treatment. Compared to non-MTA treatments, secondary MTA treatment achieved a greater improvement in survival ( 4.3 months vs. 2.8 months, P=0.0047). Multivariate analysis demonstrated that the CP score (P <0.01) and alpha-fetoprotein level (P <0.01) were independent prognostic factors. Both SOR and LEN treatments showed a clinically comparable therapeutic efficacy as the first-line treatments for u-HCC patients in an MTA sequential therapy.
(出版サイトへのリンク): ● Publication site (DOI): 10.1111/hepr.13597
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33238074; ● Search Scopus @ Elsevier (PMID): 33238074; ● Search Scopus @ Elsevier (DOI): 10.1111/hepr.13597

(DOI: 10.1111/hepr.13597, PubMed: 33238074) Hironori Tanaka, Yoshihito Saijyo, Tetsu Tomonari, Takahiro Tanaka, Tatsuya Taniguchi, Shusuke Yagi, Koichi Okamoto, Hiroshi Miyamoto, Masahiro Sogabe, Yasushi Sato, Naoki Muguruma, Koichi Tsuneyama, Masataka Sata and Tetsuji Takayama :
An Adult Case of Congenital Extrahepatic Portosystemic Shunt Successfully Treated with Balloon-occluded Retrograde Transvenous Obliteration,
Internal Medicine, Vol.60, No.12, 1839-1845, 2021.

(要約): A 42-year-old woman visited our hospital due to syncope. Contrast-enhanced CT revealed portosystemic shunt, portal vein hypoplasia, and multiple liver nodules. The histological examination of a liver biopsy specimen exhibited portal vein hypoplasia and revealed that the liver tumor was positive for glutamine synthetase. The patient was therefore diagnosed with congenital extrahepatic portosystemic shunt type II, and with focal nodular hyperplasia (FNH)-like nodules. She had the complication of severe portopulmonary hypertension and underwent complete shunt closure by balloon-occluded retrograde transvenous obliteration (B-RTO). The intrahepatic portal vein was well developed at 1 year after B-RTO, and multiple liver nodules completely regressed. Her pulmonary hypertension also improved.
(徳島大学機関リポジトリ): ● Metadata: 116336
(出版サイトへのリンク): ● Publication site (DOI): 10.2169/internalmedicine.5914-20
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33456037; ● Search Scopus @ Elsevier (PMID): 33456037; ● Search Scopus @ Elsevier (DOI): 10.2169/internalmedicine.5914-20

(徳島大学機関リポジトリ: 116336, DOI: 10.2169/internalmedicine.5914-20, PubMed: 33456037) Sayo Takahashi, Koichi Okamoto, Toshihito Tanahashi, Shota Fujimoto, Tadahiko Nakagawa, Masahiro Bando, beibei ma, Tomoyuki Kawaguchi, Yasuteru Fujino, Yasuhiro Mitsui, Shinji Kitamura, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma, Yoshimi Bando, Toshiro Sato, Takahiro Fujimori and Tetsuji Takayama :
S100P expression via DNA hypomethylation promotes cell growth in the sessile serrated adenoma/polyp-cancer sequence.,
Digestion, Vol.102, No.5, 789-802, 2021.

(要約): Sessile serrated adenomas/polyps (SSA/Ps) are a putative precursor lesion of colon cancer. Although the relevance of DNA hypermethylation in the SSA/P-cancer sequence is well documented, the role of DNA hypomethylation is unknown. We investigated the biological relevance of DNA hypomethylation in the SSA/P-cancer sequence by using 3-dimensional organoids of SSA/P. We first analyzed hypomethylated genes using datasets from our previous DNA methylation array analysis on 7 SSA/P and 2 cancer in SSA/P specimens. Expression levels of hypomethylated genes in SSA/P specimens were determined by RT-PCR and immunohistochemistry. We established 3-dimensional SSA/P organoids and performed knockdown experiments using a lentiviral shRNA vector. DNA hypomethylation at CpG sites of the gene was quantitated by MassARRAY analysis. The mean number of hypomethylated genes in SSA/P and cancer in SSA/P was 41.6 ± 27.5 and 214 ± 19.8, respectively, showing a stepwise increment in hypomethylation during the SSA/P-cancer sequence. S100P, S100α2, PKP3, and MUC2 were most commonly hypomethylated in SSA/P specimens. The mRNA and protein expression levels of S100P, S100α2, and MUC2 were significantly elevated in SSA/P compared with normal colon tissues, as revealed by RT-PCR and immunohistochemistry, respectively. Among these, mRNA and protein levels were highest for S100P. Knockdown of the S100P gene using a lentiviral shRNA vector in 3-dimensional SSA/P organoids inhibited cell growth by >50% (p < 0.01). The mean diameter of SSA/P organoids with S100P gene knockdown was significantly smaller compared with control organoids. MassARRAY analysis of DNA hypomethylation in the S100P gene revealed significant hypomethylation at specific CpG sites in intron 1, exon 1, and the 5'-flanking promoter region. These results suggest that DNA hypomethylation, including S100P hypomethylation, is supposedly associated with the SSA/P-cancer sequence. S100P overexpression via DNA hypomethylation plays an important role in promoting cell growth in the SSA/P-cancer sequence.
(徳島大学機関リポジトリ): ● Metadata: 115966
(出版サイトへのリンク): ● Publication site (DOI): 10.1159/000512575
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33395688; ● Summary page in Scopus @ Elsevier: 2-s2.0-85099095900

(徳島大学機関リポジトリ: 115966, DOI: 10.1159/000512575, PubMed: 33395688, Elsevier: Scopus) Tomoyuki Kawaguchi, Koichi Okamoto, Shota Fujimoto, Masahiro Bando, Hironori Wada, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma, Katsuhisa Horiimoito and Tetsuji Takayama :
Lansoprazole Inhibits the Development of Sessile Serrated Lesions by Inducing G1 Arrest via Skp2/p27 Signaling Pathway.,
Journal of Gastroenterology, Vol.59, No.1, 11-23, 2021.

(要約): Although the serrated-neoplasia pathway reportedly accounts for 15-30% of colorectal cancer (CRC), no studies on chemoprevention of sessile serrated lesions (SSLs) have been reported. We searched for effective compounds comprehensively from a large series of compounds by employing Connectivity Map (CMAP) analysis of SSL-specific gene expression profiles coupled with in vitro screening using SSL patient-derived organoids (PDOs), and validated their efficacy using a xenograft mouse model of SSL. We generated SSL-specific gene signatures based on DNA microarray data, and applied them to CMAP analysis with 1309 FDA-approved compounds to select candidate compounds. We evaluated their inhibitory effects on SSL-PDOs using a cell viability assay. SSL-PDOs were orthotopically transplanted into NOG mice for in vivo evaluation. The signal transduction pathway was evaluated by gene expression profile and protein expression analysis. We identified 221 compounds by employing CMAP analysis of SSL-specific signatures, which should cancel the gene signatures, and narrowed them down to 17 compounds. Cell viability assay using SSL-PDOs identified lansoprazole as having the lowest IC50 value (47 µM) among 17 compounds. When SSL-PDO was orthotopically transplanted into murine intestinal tract, the tumor grew gradually. Administration of lansoprazole to mice inhibited the growth of SSL xenograft whereas the tumor in control mice treated with vehicle alone grew gradually over time. The Ki67 index in xenograft lesions from the lansoprazole group was significantly lower compared with the control group. Cell cycle analysis of SSL-PDOs treated with lansoprazole exhibited a significant increase in G1 phase cell population. Microarray and protein analysis revealed that lansoprazole downregulated Skp2 expression and upregulated p27 expression in SSL-PDOs. Our data strongly suggest that lansoprazole is the most effective chemopreventive agent against SSL, and that lansoprazole induces G1 cell cycle arrest by downregulating Skp2 and upregulating p27 in SSL cells.
(徳島大学機関リポジトリ): ● Metadata: 119258
(出版サイトへのリンク): ● Publication site (DOI): 10.1007/s00535-023-02052-0
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37989907; ● Search Scopus @ Elsevier (PMID): 37989907; ● Search Scopus @ Elsevier (DOI): 10.1007/s00535-023-02052-0

(徳島大学機関リポジトリ: 119258, DOI: 10.1007/s00535-023-02052-0, PubMed: 37989907) Tamotsu Sagawa, Yasushi Sato, Masahiro Hirakawa, Kyoko Hamaguchi, Akira Fukuya, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma, Koshi Fujikawa, Yasuo Takahashi and Tetsuji Takayama :
Clinical impact of primary tumour location, early tumour shrinkage, and depth of response in the treatment of metastatic colorectal cancer with first-line chemotherapy plus cetuximab or bevacizumab.,
Scientific Reports, Vol.10, No.1, 19815, 2020.

(要約): The primary tumour location is an important prognostic factor for previously untreated metastatic colorectal cancer (mCRC). However, the predictive efficacies of primary tumour location, early tumour shrinkage (ETS), and depth of response (DpR) on mCRC treatment has not been fully evaluated. This study aimed to investigate the predictive efficacies of these traits in mCRC patients treated with first-line 5-fluorouracil-based chemotherapy plus biologic agents, namely, cetuximab and bevacizumab. This was a retrospective analysis of the medical records of 110 patients with pathology-documented unresectable mCRC. Patients with left-sided mCRC receiving any first-line regimen showed better overall survival (OS) than those with right-sided mCRC [33.3 vs 16.3 months; hazard ratio (HR) 0.44; 95% confidence interval (CI) 0.27-0.74; p < 0.001]. In patients with left-sided tumours, treatment with chemotherapy plus cetuximab yielded longer OS than chemotherapy plus bevacizumab (50.6 vs 27.8 months, HR 0.55; 95% CI 0.32-0.97; p = 0.0378). mCRC patients with ETS and high DpR showed better OS than those lacking ETS and with low DpR (33.5 vs 19.6 months, HR 0.50, 95% CI 0.32-0.79, p = 0.023 and 38.3 vs 19.0 months, HR 0.43, 95% CI 0.28-0.68, p < 0.001, respectively). Moreover, ETS and/or high DpR achieved in patients with right-sided mCRC receiving chemotherapy plus cetuximab were associated with significantly better OS than in those lacking ETS and with low DpR (34.3 vs 10.4 months, HR 0.19, 95% CI 0.04-0.94, p = 0.025 and 34.3 vs 10.4 months, HR 0.19, 95% CI 0.04-0.94, p = 0.0257, respectively). Taken together, our study demonstrates that primary tumour location is not only a well-known prognostic factor but also a relevant predictive factor in patients with mCRC receiving chemotherapy plus cetuximab. Additionally, both ETS and DpR could predict treatment outcomes and also potentially guide cetuximab treatment even in right-sided mCRCs.
(徳島大学機関リポジトリ): ● Metadata: 115620
(出版サイトへのリンク): ● Publication site (DOI): 10.1038/s41598-020-76756-1
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33188279; ● Summary page in Scopus @ Elsevier: 2-s2.0-85095953611

(徳島大学機関リポジトリ: 115620, DOI: 10.1038/s41598-020-76756-1, PubMed: 33188279, Elsevier: Scopus) Jun Okazaki, Toshihito Tanahashi, Yasushi Sato, Jinsei Miyoshi, Tadahiko Nakagawa, Tetsuo Kimura, Hiroshi Miyamoto, Yasuteru Fujino, Fumika Nakamura, Masanori Takehara, beibei ma, Masahiro Bando, Shinji Kitamura, Koichi Okamoto, Naoki Muguruma, Masahiro Sogabe and Tetsuji Takayama :
MicroRNA-296-5p Promotes Cell Invasion and Drug Resistance by Targeting Bcl2-Related Ovarian Killer, Leading to a Poor Prognosis in Pancreatic Cancer.,
Digestion, Vol.101, No.6, 794-806, 2020.

(要約): Pancreatic ductal adenocarcinoma (PDAC) is characterized by aggressive invasion, early metastasis, and resistance to chemotherapy, leading to a poor prognosis. To clarify the molecular mechanism of these malignant characteristics, we performed a genome-wide microRNA (miRNA) array analysis utilizing micro-cancer tissues from patients with unresectable PDAC (stage IV), obtained by endoscopic ultrasound-fine needle aspiration (EUS-FNA). The expression profiles of 2,042 miRNAs were determined using micro-cancer tissues from 13 patients with unresectable PDAC obtained by EUS-FNA. The relationship between individual miRNA levels and overall survival (OS) was analyzed. Possible target genes for miRNAs were bioinformatically analyzed using the online database miRDB. Pancreatic cancer cell lines PANC-1, MIA PaCa-2, and PK-8 were transfected with miRNA mimic or small interfering RNA, and cell invasion, epithelial-mesenchymal transition (EMT), and apoptosis markers were examined. miRNA and mRNA expressions were examined by quantitative polymerase chain reaction. Of 2,042 miRNAs, the 10 that exhibited the lowest correlation coefficient (p 0.005) between miRNA expression level and OS among the patients were identified. The miRDB and expression analysis in cancer cell lines for the 10 miRNAs identified miR-296-5p and miR-1207-5p as biomarkers predictive of shorter survival (p < 0.0005). Bioinformative target gene analysis and transfection experiments with miRNA mimics showed that Bcl2-related ovarian killer (BOK), a pro-apoptotic gene, is a target for miR296-5p in pancreatic cancer cells; transfection of miR-296-5p mimic into PANC-1, MIA PaCa-2, and PK-8 cells resulted in significant suppression of BOK mRNA and protein expression. These transfectants showed significantly higher invasion capability compared with control cells, and knock down of BOK in pancreatic cancer cells similarly enhanced invasion capability. Transfectants of miR-296-5p mimic also exhibited aberrant expression of EMT markers, including vimentin and N-cadherin. Moreover, these transfectants showed a significantly lower apoptosis rate in response to 5-fluorouracil and gemcitabine with a decrease of BOK expression, suggesting a role of miR-296-5p in drug resistance. These results suggest that miR-296-5p is a useful biomarker for a poor prognosis in patients with PDAC, and that the miR-296-5p/BOK signaling axis plays an important role in cell invasion, drug resistance, and EMT in PDACs.
(徳島大学機関リポジトリ): ● Metadata: 114153
(出版サイトへのリンク): ● Publication site (DOI): 10.1159/000503225
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31563901; ● Summary page in Scopus @ Elsevier: 2-s2.0-85072925180

(徳島大学機関リポジトリ: 114153, DOI: 10.1159/000503225, PubMed: 31563901, Elsevier: Scopus) Tetsu Tomonari, Yasushi Sato, Hironori Tanaka, Takahiro Tanaka, Tatsuya Taniguchi, Masahiro Sogabe, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma, Yu Saitou, Satoru Imura, Yoshimi Bando, Mitsuo Shimada and Tetsuji Takayama :
Conversion therapy for unresectable hepatocellular carcinoma after lenvatinib Three case reports.,
Medicine, Vol.99, No.42, e22782, 2020.

(要約): Lenvatinib (LEN) is a novel potent multi-tyrosine kinase inhibitor, approved as first-line treatment for unresectable hepatocellular carcinoma (HCC). Considering its high objective response rate, LEN therapy could be expected to achieve downstaging of tumors and lead to conversion therapy with hepatectomy or ablation. However, the feasibility of conversion therapy after LEN treatment in unresectable HCC remains largely unknown. Here, we reported 3 cases of unresectable HCC: case 1, a 69-year-old man diagnosed with ruptured HCC; case 2, a 72-year-old woman with nonalcoholic steatohepatitis-based HCC; and case 3, a 73-year-old man with a history of alcoholic cirrhosis-based HCC. In all cases, cirrhosis was classified as Child-Pugh 5 and modified albumin-bilirubin grade 1 or 2a. HCC was diagnosed as Barcelona Clinic Liver Cancer (BCLC) stage B. In all cases, LEN was initiated after conventional-transcatheter arterial embolization enforcement, while maintaining liver function. In all cases, the main tumor size decreased after 6 months of LEN treatment and no satellite nodes were detected, indicating downstaging of HCC to BCLC stage A. Subsequently, conversion hepatectomy or ablation was performed. After successful conversion therapy, the general condition of the patients was good, without tumor recurrence during the observation period (median 10 months). This study demonstrated that LEN enables downstaging of HCC and thus represents a bridge to successful surgery or ablation therapy. In particular, LEN treatment may facilitate the possibility for conversion therapy of initially unresectable HCC, while maintaining the hepatic functional reserve.
(キーワード): Ablation Techniques / Aged / Biomarkers / Carcinoma, Hepatocellular / Female / Hepatectomy / Humans / Liver Neoplasms / Male / Phenylurea Compounds / Protein Kinase Inhibitors / Quinolines / alpha-Fetoproteins
(徳島大学機関リポジトリ): ● Metadata: 116240
(出版サイトへのリンク): ● Publication site (DOI): 10.1097/MD.0000000000022782
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33080748; ● Search Scopus @ Elsevier (PMID): 33080748; ● Search Scopus @ Elsevier (DOI): 10.1097/MD.0000000000022782

(徳島大学機関リポジトリ: 116240, DOI: 10.1097/MD.0000000000022782, PubMed: 33080748) 藤井祥平, 中村文香, 佐藤康史, 岸和弘, 吉田守美子, 三井康裕, 藤野泰輝, 北村晋志, 岡本耕一, 宮本弘志, 六車直樹, 高山哲治 :
胃癌における免疫チェックポイント阻害薬の効果と免疫関連副作用(irAE) との関連性についての検討,
四国医学雑誌, Vol.76, No.3-4, 173-178, 2020年.

(要約): Recently, immune checkpoint inhibitors(ICI)have been approved for use in advanced gastric cancer(AGC)based on the positive results of ATTRACTION‐2 trial in Japan. There has been accumulating evidence that the development of immune-related adverse events(irAE)may be associated with a response to ICI therapy, particularly in lung cancer, although little is known about these correlations in gastrointestinal cancer. To investigate the efficacy and irAE of ICI treatment and their correlation in AGC, we retrospectively examined 29 patients with AGC who received nivolumab therapy in our departments. Among them, 15 patients(52%)developed irAEs including 4 patients(14%)for grade 3 irAEs ; liver dysfunction(n＝2), type 1 diabetes mellitus(n＝2) and adrenal insufficiency(n＝1). The median overall survival was12．0months in the irAE group and 3．25 months in the non-irAE group(p＝0．164), which suggested the relationship between the effects and irAEs in ICI treatment of AGC. Further research is required to understand the implications of irAE characteristics on ICI response in GCA patients.
(キーワード): Immune-checkpoint inhibitors / Gastric cancer / Immune-related adverse events / Nivolumab
(文献検索サイトへのリンク): ● CiNii @ 国立情報学研究所 (CRID): 1050004953486029824

(CiNii: 1050004953486029824) Tetsu Tomonari, Yasushi Sato, Hironori Tanaka, Takahiro Tanaka, Tatsuya Taniguchi, Masahiro Sogabe, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama :
Sorafenib as second-line treatment option after failure of lenvatinib in patients with unresectable hepatocellular carcinoma,
JGH Open, Vol.4, No.6, 1135-1139, 2020.

(要約): Abstract Background and Aim Currently, there is no molecular-targeted agent that has demonstrated evidence of efficacy in patients with unresectable hepatocellular carcinoma (u-HCC) who have developed resistance to treatment with lenvatinib (LEN). In this real-world study, we aimed to investigate the therapeutic effect and safety of sorafenib (SOR) in patients with u-HCC after progression on treatment with LEN. Methods (Patients) and Results A total of 13 patients with u-HCC (12 males and 1 female), who were treated with SOR after progression on LEN, were enrolled in this retrospective study. Therapeutic efficacy was evaluated via contrast-enhanced computerized tomography at 8 weeks after the initiation of SOR therapy according to modified response evaluation criteria in solid tumors (mRECIST) and RECIST. According to mRECIST, the objective response rate (ORR) and disease control rate (DCR) were 15.3
(徳島大学機関リポジトリ): ● Metadata: 115923
(出版サイトへのリンク): ● Publication site (DOI): 10.1002/jgh3.12408
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33319048; ● Summary page in Scopus @ Elsevier: 2-s2.0-85089378719

(徳島大学機関リポジトリ: 115923, DOI: 10.1002/jgh3.12408, PubMed: 33319048, Elsevier: Scopus) Masanori Takehara, Yasushi Sato, Tetsuo Kimura, Kazuyoshi Noda, Hiroshi Miyamoto, Yasuteru Fujino, Jinsei Miyoshi, Fumika Nakamura, Hironori Wada, Yoshimi Bando, Tetsuya Ikemoto, Mitsuo Shimada, Naoki Muguruma and Tetsuji Takayama :
Cancer-associated Adipocytes Promote Pancreatic Cancer Progression Through SAA1 Expression,
Cancer Science, Vol.111, No.8, 2883-2894, 2020.

(要約): Although pancreatic cancer often invades into peripancreatic adipose tissue, little is known about the cancer-adipocyte interaction. We first investigated the ability of adipocytes to de-differentiate to cancer-associated adipocytes (CAAs) by co-culturing with pancreatic cancer cells. We then examined the effects of CAA-conditioned media (CAA-CM) on the malignant characteristics of cancer cells, the mechanism underlying those effects, and their clinical relevance in pancreatic cancer. When 3T3-L1 adipocytes were co-cultured with pancreatic cancer cells (PANC-1) using Transwell system, adipocytes lost their lipid droplets and morphologically changed to fibroblast-like cells (CAA). Adipocyte-specific marker mRNA levels significantly decreased but those of fibroblast-specific markers appeared, characteristic findings of CAA, as revealed by real-time PCR. When PANC-1 cells were cultured with CAA-CM, significantly higher migration/invasion capability, chemoresistance, and epithelial-mesenchymal transition (EMT) properties were observed compared with control cells. To investigate the mechanism underlying these effects, we performed microarray analysis of PANC-1 cells cultured with CAA-CM, and found 78.5-fold higher expression of SAA1 compared with control cells. When SAA1 gene in PANC-1 cells was knocked down with SAA1 siRNA, migration/invasion capability, chemoresistance, and EMT properties were significantly attenuated compared with control cells. Immunohistochemical analysis on human pancreatic cancer tissues revealed positive SAA1 expression in 46/61 (75.4%). Overall survival in the SAA1-positive group was significantly shorter than in the SAA1-negative group (p=0.013). In conclusion, we demonstrated that pancreatic cancer cells induced de-differentiation in adipocytes toward CAA, and CAA promoted malignant characteristics of pancreatic cancer via SAA1 expression, suggesting that SAA1 is a novel therapeutic target in pancreatic cancer.
(徳島大学機関リポジトリ): ● Metadata: 115328
(出版サイトへのリンク): ● Publication site (DOI): 10.1111/cas.14527
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32535957; ● Summary page in Scopus @ Elsevier: 2-s2.0-85087562532

(徳島大学機関リポジトリ: 115328, DOI: 10.1111/cas.14527, PubMed: 32535957, Elsevier: Scopus) Hironori Tanaka, Koichi Okamoto, Yasushi Sato, Takahiro Tanaka, Tetsu Tomonari, Fumika Nakamura, Yasuteru Fujino, Yasuhiro Mitsui, Hiroshi Miyamoto, Naoki Muguruma, Akinori Morita, Hitoshi Ikushima and Tetsuji Takayama :
Synergistic anti-tumor activity of miriplatin and radiation through PUMA-mediated apoptosis in hepatocellular carcinoma.,
Journal of Gastroenterology, Vol.55, No.11, 1072-1086, 2020.

(要約): The prognosis for patients with unresectable advanced hepatocellular carcinoma (HCC) is poor. Miriplatin is a hydrophobic platinum compound that has a long retention time in lesions after transarterial chemoembolization (TACE). We investigated anti-tumor activity of miriplatin combined with irradiation on HCC cells, and its underlying mechanism of apoptosis. We also analyzed the effectiveness of miriplatin-TACE and radiotherapy for locally advanced HCC. Human HCC cell lines HepG2 and HuH-7 were treated with DPC (active form of miriplatin) and radiation, and synergy was evaluated using a combination index (CI). Apoptosis-related proteins and cell cycles were analyzed by western blotting and flowcytometry. We retrospectively analyzed treatment outcomes in 10 unresectable HCC patients with vascular/bile duct invasion treated with miriplatin-TACE and radiotherapy. DPC or X-ray irradiation decreased cell viability dose-dependently. DPC plus irradiation decreased cell viability synergistically in both cell lines (CI < 1, respectively). Cleaved PARP expression was induced much more strongly by DPC plus irradiation than by each treatment alone. Expression of p53 up-regulated modulator of apoptosis (PUMA) was significantly induced by the combination, and knockdown of PUMA with siRNA significantly decreased apoptosis in both cell lines. DPC plus irradiation caused sub-G1, G2/M, and S phase cell arrest in those cells. The combination of miriplatin-TACE and radiotherapy showed a high response rate for patients with locally advanced HCC despite small number of patients. Miriplatin plus irradiation had synergistic anti-tumor activity on HCC cells through PUMA-mediated apoptosis and cell cycle arrest. This combination may possibly be effective in treating locally advanced HCC.
(徳島大学機関リポジトリ): ● Metadata: 115325
(出版サイトへのリンク): ● Publication site (DOI): 10.1007/s00535-020-01705-8
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32666201; ● Summary page in Scopus @ Elsevier: 2-s2.0-85087895196

(徳島大学機関リポジトリ: 115325, DOI: 10.1007/s00535-020-01705-8, PubMed: 32666201, Elsevier: Scopus) Tetsu Tomonari, Yasushi Sato, Hironori Tanaka, Takahiro Tanaka, Yasuteru Fujino, Yasuhiro Mitsui, Akihiro Hirao, Tatsuya Taniguchi, Koichi Okamoto, Masahiro Sogabe, Hiroshi Miyamoto, Naoki Muguruma, Harumi Kagiwada, Masashi Kitazawa, Kazuhiro Fukui, Ktsuhisa Horimoto and Tetsuji Takayama :
Potential use of lenvatinib for patients with unresectable hepatocellular carcinoma including after treatment with sorafenib: Real-world evidence and in vitro assessment via protein phosphorylation array.,
Oncotarget, Vol.11, No.26, 2531-2542, 2020.

(要約): The efficacy and safety of lenvatinib (LEN) as a second/third-line treatment for unresectable hepatocellular carcinoma (HCC) after sorafenib (SOR) therapy remains unknown. We evaluated the outcomes of second/third-line LEN treatment, investigated the sensitivity of a SOR-resistant HCC cell line (PLC/PRF5-R2) to LEN, and assessed their signal transduction pathways by protein array analysis. We retrospectively enrolled 57 patients with unresectable HCC. Fifty-three radiologically evaluated patients comprised 34 molecular-targeted agent (MTA)-naive (first-line), nine intolerant to SOR (second-line), and 10 resistant to regorafenib (third-line). The objective response rates (ORRs) were 61.8% in first-line, 33.3% in second-line, and 20.0% in third-line groups. The overall survival (OS) in the first-line was significantly longer than that in the third-line group ( < 0.05). Patients with better liver functional reserves (child score, ALBI grade) exhibited higher ORR and longer OS. The IC of LEN against PLC/PRF5-R2 was significantly higher than that against PLC/PRF5. LEN significantly inhibited more LEN-related signal transduction pathways in PLC/PRF5 than in PLC/PRF5-R2 cells. This suggests that LEN is active and safe as a second/third-line treatment for unresectable HCC. LEN seems more effective for patients with HCC with better hepatic reserve functions or before MTA-resistance is acquired because of the partial cross-resistance to SOR.
(徳島大学機関リポジトリ): ● Metadata: 116246
(出版サイトへのリンク): ● Publication site (DOI): 10.18632/oncotarget.27640
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32655838; ● Search Scopus @ Elsevier (PMID): 32655838; ● Search Scopus @ Elsevier (DOI): 10.18632/oncotarget.27640

(徳島大学機関リポジトリ: 116246, DOI: 10.18632/oncotarget.27640, PubMed: 32655838) Tadahiko Nakagawa, Yasushi Sato, Toshihito Tanahashi, Yasuhiro Mitsui, Yoshifumi Kida, Yasuteru Fujino, Misato Hirata, Shinji Kitamura, Hiroshi Miyamoto, Koichi Okamoto, Naoki Muguruma, Yoshimi Bando and Tetsuji Takayama :
JMJD2A sensitizes gastric cancer to chemotherapy by cooperating with CCDC8.,
Gastric Cancer, Vol.23, No.3, 426-436, 2020.

(要約): Jumonji domain-containing protein 2A (JMJD2A) of the JMJD2 family of histone lysine demethylases has been implicated in tumorigenesis. However, its expression and role in gastric cancer (GC) drug resistance remain unknown. Here, we investigated the role of JMJD2A in GC chemotherapeutic susceptibility and its clinical relevance in GC. We selected 12 relevant genes from previously identified gene signatures that can predict GC susceptibility to docetaxel, cisplatin, and S-1 (DCS) therapy. Each gene was knocked down using siRNA in GC cell lines, and cell viability assays were performed. JMJD2A expression in GC cell lines and tissues was assessed using qRT-PCR and immunohistochemistry, respectively. A JMJD2A downstream target related to drug susceptibility was examined using whole-gene expression array and immunoprecipitation. Among the 12 candidate genes, down-regulation of JMJD2A showed the maximum effect on GC susceptibility to anti-cancer drugs and increased the IC values for 5-FU, cisplatin, and docetaxel 15.3-, 2.7-, and 4.0-fold, respectively. JMJD2A was universally expressed in 12 GC cell lines, and its overexpression in GC tissue was positively correlated with tumor regression in 34 DCS-treated patients. A whole-gene expression array of JMJD2A-knockdown GC cells demonstrated a significant decrease in the expression of pro-apoptotic coiled-coil domain containing 8 (CCDC8), a downstream target of JMJD2A. Direct interaction between CCDC8 and JMJD2A was verified using immunoprecipitation. CCDC8 inhibition restored drug resistance to docetaxel, cisplatin, and S-1. Our results indicate that JMJD2A is a novel epigenetic factor affecting GC chemotherapeutic susceptibility, and JMJD2A/CCDC8 is a potential GC therapeutic target.
(出版サイトへのリンク): ● Publication site (DOI): 10.1007/s10120-019-01024-9
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31677131; ● Summary page in Scopus @ Elsevier: 2-s2.0-85074813194

(DOI: 10.1007/s10120-019-01024-9, PubMed: 31677131, Elsevier: Scopus) Masahiro Sogabe, Toshiya Okahisa, Akira Fukuya, Kaizoh Kagemoto, Yasuyuki Okada, Yuka Adachi, Takeshi Kurihara, Toru Nii, Satoshi Teramae, Hironori Tanaka, Tetsu Tomonari, Koichi Okamoto, Hiroshi Miyamoto, Masahiko Nakasono and Tetsuji Takayama :
Effects of audio and visual distraction on patients' vital signs and tolerance during esophagogastroduodenoscopy: a randomized controlled trial.,
BMC Gastroenterology, Vol.20, No.1, 122, 2020.

(要約): Esophagogastroduodenoscopy (EGD) provides an indispensable and unambiguous inspection allowing the discovery upper gastrointestinal lesions. However, many patients are anxious about undergoing EGD. Few studies have investigated the influence on patients' vital signs and tolerance during EGD using subjective and objective assessments. This study was a prospective randomized controlled study that investigated the influence of audio and visual distraction on EGD. We randomly divided 289 subjects who underwent EGD into 4 groups (control group, audio group, visual group, combination group) and examined their vital signs, heart rate variability (HRV), psychological items, and acceptance of distraction. Pulse rate (PR) at post-distraction and post-EGD in the 3 distraction groups were significantly lower than those of control group (p < 0.001 and p < 0.01, respectively). Blood pressure (BP) during and post-EGD was significantly higher than that at pre-EGD in control group (p < 0.05), but no significant elevation of BP was observed during the latter half of EGD and post-EGD in the 3 distraction groups. BP at post-distraction improved significantly compared to pre-distraction in the 3 distraction groups (p < 0.05). There was a significant difference in the low-frequency (LF) power/ high-frequency (HF) power at post-distraction and post-EGD among the 4 groups (p < 0.001 and p < 0.001, respectively). The LF power/HF power at post-distraction and post-EGD in the 3 distraction groups was significantly lower than that in control group (p < 0.05). Several items of profile of mood states (POMS) and the impression of EGD at post-distraction improved significantly compared to those at pre-distraction among the 3 distraction groups (p < 0.05). Visual analog scale (VAS) of willingness for the next use of distraction in the 3 distraction groups was excellent because VAS was more than 70. Distractions effectively improved psychological factors, vital signs and some of HRV at pre and post-EGD. Distractions may suppress BP elevation during the latter half of EGD and lead to stability of HRV on EGD. This prospective trial was registered in the University Hospital Medical Information Network (UMIN) Clinical Trials Registry as UMIN000029637. Registered on 20 October 2017.
(徳島大学機関リポジトリ): ● Metadata: 114760
(出版サイトへのリンク): ● Publication site (DOI): 10.1186/s12876-020-01274-3
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32316918; ● Search Scopus @ Elsevier (PMID): 32316918; ● Search Scopus @ Elsevier (DOI): 10.1186/s12876-020-01274-3

(徳島大学機関リポジトリ: 114760, DOI: 10.1186/s12876-020-01274-3, PubMed: 32316918) Yoshihiko Miyamoto, Naoki Muguruma, Shota Fujimoto, Yasuyuki Okada, Yoshifumi Kida, Fumika Nakamura, Kumiko Tanaka, Tadahiko Nakagawa, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato and Tetsuji Takayama :
Epidermal growth factor receptortargeted molecular imaging of colorectal tumors: Detection and treatment evaluation of tumors in animal models.,
Cancer Science, Vol.110, No.6, 1921-1930, 2019.

(要約): To overcome the problem of overlooking colorectal tumors, a new and highly sensitive modality of colonoscopy is needed. Moreover, it is also important to establish a new modality to evaluate viable tumor volume in primary lesions of colorectal cancer (CRC) during chemotherapy. Therefore, we carried out molecular imaging of colorectal tumors targeting epidermal growth factor receptor (EGFR), which is highly expressed on tumor cells, for evaluating chemotherapeutic efficacy and for endoscopic detection of colorectal adenomas. We first attempted to image five CRC cell lines with various levels of EGFR expression using an Alexa Fluor-labeled anti-EGFR monoclonal antibody (AF-EGFR-Ab). A strong fluorescence signal was observed in the cells depending on the level of EGFR expression. When nude mice xenografted with LIM1215 CRC cells, which highly express EGFR, were i.v. injected with AF-EGFR-Ab, a strong fluorescence signal appeared in the tumor with a high signal to noise ratio, peaking at 48 hours after injection and then gradually decreasing, as shown using an IVIS Spectrum system. When the xenografted mice were treated with 5-fluorouracil, fluorescence intensity in the tumor decreased in proportion to the viable tumor cell volume. Moreover, when the colorectum of azoxymethane-treated rats was observed using a thin fluorescent endoscope with AF-EGFR-Ab, all 10 small colorectal adenomas (3 mm) were detected with a clear fluorescence signal. These preliminary results of animal experiments suggest that EGFR-targeted fluorescent molecular imaging may be useful for quantitatively evaluating cell viability in CRC during chemotherapy, and also for detecting small adenomas using a fluorescent endoscope.
(キーワード): Animals / Antineoplastic Agents / Azoxymethane / Cell Line, Tumor / Cell Survival / Colorectal Neoplasms / ErbB Receptors / 女性 (female) / Fluorouracil / HT29 Cells / Humans / 男性 (male) / Mice, Inbred BALB C / Mice, Nude / Molecular Targeted Therapy / Rats, Inbred F344 / Xenograft Model Antitumor Assays
(徳島大学機関リポジトリ): ● Metadata: 113790
(出版サイトへのリンク): ● Publication site (DOI): 10.1111/cas.14020
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30973663; ● Summary page in Scopus @ Elsevier: 2-s2.0-85066789077

(徳島大学機関リポジトリ: 113790, DOI: 10.1111/cas.14020, PubMed: 30973663, Elsevier: Scopus) Chisato Tonoiso, Hitoshi Ikushima, Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani, Takaharu Kudoh, Takahiro Yoshida, Hiroshi Miyamoto, Masafumi Harada, Tetsuji Takayama and Akira Tangoku :
Clinical outcomes and prognostic factors of definitive radiotherapy for esophageal cancer,
The Journal of Medical Investigation : JMI, Vol.66, No.1, 2, 99-105, 2019.

(要約): Purpose To assess the treatment results of definitive radiotherapy for esophageal cancer at Tokushima University Hospital and clarify the prognostic factors. Methods Seventy consecutive patients with esophageal cancer who underwent definitive radiotherapy between May 2004 and March 2012 were included in the present study. Local control rate, overall survival rate, and radiation morbidity were examined and univariate and multivariate analyses were performed to investigate prognostic factors. Results The 5-yearoverall survival rates of stages I, II, III, and IVA were 81%, 71%, 0%, and 9%, respectively. Performance status, clinical stage, and neoadjuvant chemotherapy were significant prognostic factors. A past history of interstitial pneumonia was associated with severe radiation-induced lung injury. Conclusions Patients who underwent definitive chemoradiotherapy for esophageal cancer in stage I/II showed good prognosis. However, treatment results of the patients in stage III/IV were not satisfactory, and those who could not undergo surgery after neoadjuvant chemotherapy had the worst prognosis.J.Med.Invest.66:99-105, February, 2019.
(キーワード): esophageal cancer / radiotherapy / chemoradiotherapy
(徳島大学機関リポジトリ): ● Metadata: 113342
(出版サイトへのリンク): ● Publication site (DOI): 10.2152/jmi.66.99
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31064964; ● Summary page in Scopus @ Elsevier: 2-s2.0-85065782310

(徳島大学機関リポジトリ: 113342, DOI: 10.2152/jmi.66.99, PubMed: 31064964, Elsevier: Scopus) Hiroshi Miyamoto, Kumiko Tanaka, Fumika Nakamura, Takahiro Ikeda, Shinji Kitamura, Tetsuo Kimura, Koichi Okamoto, Masahiro Sogabe, Naoki Muguruma, Yoshimi Bando and Tetsuji Takayama :
Massive hemobilia following plastic stent removal in common bile duct cancer associated with primary sclerosing cholangitis (with video).,
Clinical Journal of Gastroenterology, Vol.12, No.1, 2019.

(要約): Hemobilia is defined as bleeding into the biliary tract. Herein, we report a very rare case of massive hemobilia following plastic stent (PS) removal in common bile duct (CBD) cancer. A 72-year-old man with primary sclerosing cholangitis had undergone repeated insertion of a PS into the CBD. Biliary tract biopsy was performed based on suspicion of combined CBD cancer. Biopsy revealed poorly differentiated adenocarcinoma of the CBD. One month after the biliary tract biopsy, he was admitted for acute cholangitis, and endoscopic retrograde cholangiography was performed for the exchange of the PS. When one of the two biliary PSs was removed, spurting bleeding from the major papilla began abruptly. The massive bleeding caused the patient to be in a pre-shock state. A retrieval balloon catheter was compressed against the papilla for hemostasis. Although he was treated conservatively, the patient developed a bloody discharge. Upper gastrointestinal endoscopy revealed that the pulsatile bleeding beside the PSs started immediately after the removal of the coagula. Emergent contrast-enhanced computed tomography showed right hepatic artery aneurysm across the CBD. Therefore, transarterial embolization was performed. The patient's post-therapeutic course was uneventful. He received chemotherapy, but died about a half year after hemobilia occurred.
(出版サイトへのリンク): ● Publication site (DOI): 10.1007/s12328-018-0888-7
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30056613; ● Summary page in Scopus @ Elsevier: 2-s2.0-85050721343

(DOI: 10.1007/s12328-018-0888-7, PubMed: 30056613, Elsevier: Scopus) Yasushi Sato, Tamotsu Sagawa, Hiroyuki Ohnuma, Masahiro Hiarakawa, Yasuo Takahashi, Kyoko Hamaguchi, Koshi Fujikawa, Takayuki Nobuoka, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma, Ichiro Takemasa and Tetsuji Takayama :
A dose-escalation study of docetaxel, oxaliplatin, and S-1 (DOS) as a first-line therapy for patients with unresectable metastatic gastric cancer.,
Cancer Chemotherapy and Pharmacology, Vol.83, No.1, 161-167, 2019.

(要約): The aim of this study was to determine the recommended dose (RD) for a docetaxel/oxaliplatin/S-1 (DOS) regimen in patients with unresectable gastric cancer and to preliminarily evaluate its efficacy. Previously untreated patients with histologically proven unresectable metastatic gastric cancer were enrolled (n = 16). Docetaxel and oxaliplatin were administered intravenously on day 8 and S-1 was administered orally twice a day on days 1-14. Each cycle was repeated every 3 weeks. Dose-limiting toxicities (DLTs) were evaluated during the first treatment cycle. Three dose escalations of DOS were employed in this study: level 1 (50/100/80 mg/m), level 2 (50/130/80 mg/m), and level 3 (60/130/80 mg/m). According to the 3 + 3 dose-escalating schedule, we determined that the RD and maximum tolerated dose for this regimen were level 1 and level 2, respectively. The DLTs were grade 3 diarrhea and febrile neutropenia. The overall response rate was 78% (7/9) for patients with measurable lesions and consisted of two complete responses and five partial responses. Five patients underwent conversion surgery. The median follow-up time was 19 months with median survival time and progression-free survival being 19.6 months and 7.6 months, respectively. The results from this study demonstrated the safety and tolerability of DOS in unresectable metastatic gastric cancer patients and revealed promising preliminary efficacy with a high conversion rate. A phase II trial of DOS regimen using the identified RD is ongoing.
(出版サイトへのリンク): ● Publication site (DOI): 10.1007/s00280-018-3719-0
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30406285; ● Search Scopus @ Elsevier (PMID): 30406285; ● Search Scopus @ Elsevier (DOI): 10.1007/s00280-018-3719-0

(DOI: 10.1007/s00280-018-3719-0, PubMed: 30406285) Kaizo Kagemoto, Koichi Okamoto, Tohshi Takaoka, Yasushi Sato, Shinji Kitamura, Tetsuo Kimura, Masahiro Sogabe, Hiroshi Miyamoto, Naoki Muguruma, Koichi Tsuneyama and Tetsuji Takayama :
Detection of aberrant crypt foci with image-enhanced endoscopy.,
Endoscopy International Open, Vol.6, No.8, E924-E933, 2018.

(要約): Conventional detection of aberrant crypt foci (ACF) with dye-spraying and magnifying observation is labor- and skill-intensive. We performed a prospective non-inferiority study to investigate the utility of image-enhanced endoscopy (IEE) for detection of ACF. Patients with a history of colorectal neoplasm were eligible. The number of ACF in the lower rectum was counted first using IEE magnification with narrow-band imaging (NBI) or blue-laser imaging (BLI), and subsequently using the methylene blue method. The primary endpoint was the ACF detection rate with IEE, i. e., the number of ACF detected with IEE relative to the number of ACF detected with methylene blue. The secondary endpoints were bowel preparation time, ACF detection time, and the detection rate with NBI or BLI. A total of 40 patients were enrolled (NBI 20 and BLI 20). The overall detection rate for ACF with IEE was 81.7 % (503/616; 95 %CI 78.8 - 84.6 %), meeting the primary endpoint. The detection rate for ACF with BLI (84.9 %, 258/304) was significantly higher than with NBI (78.5 %, 245/312; < 0.05). Both bowel preparation time and ACF detection time were significantly shorter with IEE versus the methylene blue method ( < 0.01, respectively). The detection rates for dysplastic and non-dysplastic ACF with IEE were 84.4 % (27/32) and 80.3 % (469/584), respectively. IEE is able to detect ACF during colonoscopy with sensitivity non-inferior to that of the conventional methylene blue method. IEE is simpler than the methylene blue method and is therefore a potentially useful new tool for ACF detection.
(徳島大学機関リポジトリ): ● Metadata: 112032
(出版サイトへのリンク): ● Publication site (DOI): 10.1055/a-0621-8794
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30123821; ● Search Scopus @ Elsevier (PMID): 30123821; ● Search Scopus @ Elsevier (DOI): 10.1055/a-0621-8794

(徳島大学機関リポジトリ: 112032, DOI: 10.1055/a-0621-8794, PubMed: 30123821) Shota Fujimoto, Naoki Muguruma, Koichi Okamoto, Takeshi Kurihara, Yasushi Sato, Yoshihiko Miyamoto, Shinji Kitamura, Hiroshi Miyamoto, Takahiro Taguchi, Koichi Tsuneyama and Tetsuji Takayama :
A Novel Theranostic Combination of Near-infrared Fluorescence Imaging and Laser Irradiation Targeting c-KIT for Gastrointestinal Stromal Tumors.,
Theranostics, Vol.8, No.9, 2313-2328, 2018.

(要約): It is difficult to distinguish gastrointestinal stromal tumors (GISTs) from other types of submucosal tumors under conventional gastrointestinal endoscopy. We aimed to detect GISTs by molecular fluorescence imaging using a near-infrared (NIR) photosensitizer (IR700)-conjugated anti-c-KIT antibody and to treat GISTs by photoimmunotherapy with NIR irradiation as a non-invasive theranostic procedure. We also investigated the therapeutic mechanisms. Human GIST cell lines GIST-T1 and GIST-882M were incubated with IR700-conjugated anti-c-KIT antibody, IR700-12A8, and observed by confocal laser microscopy. Mice with GIST-T1 xenografts or rats with orthotopic xenografts were injected with IR700-12A8 or AF488-conjugated antibody, and observed under IVIS or autofluorescence imaging (AFI) endoscopy. GIST cells were treated with IR700-12A8 and NIR light and vivo, and cell viability, histology and apoptosis were evaluated. Strong red fluorescence of IR700-12A8 was observed on the cell membrane of GIST cells and was gradually internalized into the cytoplasm. Tumor-specific accumulation of IR700-12A8 was observed in GIST-T1 xenografts in mice. Under AFI endoscopy, a strong fluorescence signal was observed in orthotopic GIST xenografts in rats through the normal mucosa covering the tumor. The percentage of dead cells significantly increased in a light-dose-dependent manner and both acute necrotic and late apoptotic cell death was observed with annexin/PI staining. Cleaved PARP expression was significantly increased after IR700-12A8-mediated NIR irradiation, which was almost completely reversed by NaN. All xenograft tumors (7/7) immediately regressed and 4/7 tumors completely disappeared after IR700-12A8-mediated NIR irradiation. Histologic assessment and TUNEL staining revealed apoptosis in the tumors. NIR fluorescence imaging using IR700-12A8 and subsequent NIR irradiation could be a very effective theranostic technology for GIST, the underlying mechanism of which appears to involve acute necrosis and supposedly late apoptosis induced by singlet oxygen.
(徳島大学機関リポジトリ): ● Metadata: 111436
(出版サイトへのリンク): ● Publication site (DOI): 10.7150/thno.22027
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29721082; ● Summary page in Scopus @ Elsevier: 2-s2.0-85044356978

(徳島大学機関リポジトリ: 111436, DOI: 10.7150/thno.22027, PubMed: 29721082, Elsevier: Scopus) Hiroyuki Ohnuma, Yasushi Sato, Masahiro Hirakawa, Shohei Kikuchi, Koji Miyanishi, Tamotsu Sagawa, Yasuo Takahashi, Takayuki Nobuoka, Koichi Okamoto, Hiroshi Miyamoto, Ichiro Takemasa, Tetsuji Takayama and Junji Kato :
Docetaxel, cisplatin and S-1 (DCS) combination chemotherapy for gastric cancer patients with peritoneal metastasis: a retrospective study.,
Cancer Chemotherapy and Pharmacology, Vol.81, No.3, 539-548, 2018.

(要約): ) and docetaxel (50-60 mg/m
(出版サイトへのリンク): ● Publication site (DOI): 10.1007/s00280-018-3523-x
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29383482; ● Search Scopus @ Elsevier (PMID): 29383482; ● Search Scopus @ Elsevier (DOI): 10.1007/s00280-018-3523-x

(DOI: 10.1007/s00280-018-3523-x, PubMed: 29383482) Daisaku Fujimoto, Naoki Muguruma, Koichi Okamoto, Yasuteru Fujino, Kaizoh Kagemoto, Yasuyuki Okada, Yoshifumi Takaoka, Yasuhiro Mitsui, Shinji Kitamura, Tetsuo Kimura, Hiroshi Miyamoto, Yoshimi Bando, Tomoko Sonoda and Tetsuji Takayama :
Linked color imaging enhances endoscopic detection of sessile serrated adenoma/polyps.,
Endoscopy International Open, Vol.6, No.3, E322-E334, 2017.

(要約): Although new image-enhanced endoscopy (IEE) technologies such as blue laser imaging (BLI), BLI-bright, and linked color imaging (LCI) have been developed, their utility for the detection of sessile serrated adenoma/polyps (SSA/Ps) is still unclear. This study aimed to evaluate the utility of BLI, BLI-bright, and LCI for SSA/P detection in still image examinations and in a prospective randomized controlled trial (RCT). A group of 6 expert and non-expert endoscopists read 200 endoscopic still images containing SSA/P lesions using white light image (WLI), BLI, BLI-bright, and LCI. Color differences were calculated using the color space method. A prospective RCT of tandem colonoscopy with WLI and LCI was performed. Patients with SSA/P and those with a history of SSA/P that had been endoscopically removed were enrolled and randomly allocated to WLI-LCI or LCI-WLI groups. Additional endoscopic detection rates for SSA/P were compared between the 2 groups. LCI showed the highest SSA/P detection rate among the 4 modes for both expert and non-expert endoscopists. The detection rate with LCI for the 6 expert endoscopists (mean 98.3 ± standard deviation 2.0 %) was significantly higher than that with WLI (86.7 ± 6.0 %, < 0.01). Likewise, the detection rate with LCI for the 6 non-expert endoscopists (92.3 ± 2.9 %) was significantly higher than that with WLI (72.7 ± 11.5 %, < 0.01). The color difference of SSA/P with LCI was the highest among the 4 modes, and was significantly higher than with WLI (median 15.9, (interquartile range 13.7 - 20.6) vs. 10.2, (7.6 - 14.2); < 0.0001). In the RCT, a total of 44 patients (WLI-LCI 22 vs. LCI-WLI 22) underwent colonoscopy. The additional detection rate for SSA/P in the second inspection in the WLI-LCI group (21.6 %, 8/37) was significantly higher than in the LCI-WLI group (3.2 %, 1/31; = 0.02). The small, flat, non-mucus and isochromatic SSA/Ps in the transverse colon were detected more frequently in the second inspection with LCI. LCI was the most sensitive mode for SSA/P detection among WLI, BLI, BLI-bright, and LCI in the still image examinations. Our RCT strongly suggests that LCI is superior to conventional WLI for SSA/P detection during colonoscopy. UMIN000017599.
(徳島大学機関リポジトリ): ● Metadata: 111442
(出版サイトへのリンク): ● Publication site (DOI): 10.1055/s-0043-124469
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29527554; ● Search Scopus @ Elsevier (PMID): 29527554; ● Search Scopus @ Elsevier (DOI): 10.1055/s-0043-124469

(徳島大学機関リポジトリ: 111442, DOI: 10.1055/s-0043-124469, PubMed: 29527554) Yasushi Sato, Masahiro Hirakawa, Hiroyuki Ohnuma, Minoru Takahashi, Tetsuro Okamoto, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma, Tomohisa Furuhata, Ichiro Takemasa, Junji Kato and Tetsuji Takayama :
A triplet combination with capecitabine/oxaliplatin/irinotecan (XELOXIRI) plus cetuximab as first-line therapy for patients with metastatic colorectal cancer: a dose escalation study.,
Cancer Chemotherapy and Pharmacology, Vol.80, No.6, 1133-1139, 2017.

(要約): The addition of cetuximab to triplet chemotherapy can increase treatment efficacy for patients with metastatic colorectal cancer (mCRC). We explored the dose-limiting toxicity and feasibility of a triweekly capecitabine, oxaliplatin, irinotecan, plus cetuximab (XELOXIRI plus cetuximab) regimen in patients with wild-type KRAS mCRC. Patients received oxaliplatin (100 mg/m, day 1), capecitabine (1700 mg/m per day from day 2 to 15), irinotecan (100, 120, and 150 mg/m for dose levels 1, 2, 3, respectively, on day 1), and cetuximab (400 mg/m, day 1 and, thereafter, 250 mg/m every week), repeated every 3 weeks. Dose-limiting toxicities (DLTs) were assessed in the first 2 treatment cycles to determine the maximum tolerated dose (MTD) and the recommended dose (RD). Twelve patients received a median of 7 cycles of therapy (range 2-10). The DLT was grade 4 neutropenia, observed in 1 of 6 patients at dose level 2. The MTD was not reached at dose level 3. Therefore, the RD of irinotecan was defined as 150 mg/m. Most common grade ≥ 3 toxicities were neutropenia (50%), diarrhea (17%), and febrile neutropenia (8%). The response rate was 83% (complete and partial response: 1 and 9 patient(s), respectively), including 4 conversion cases. The combination of XELOXIRI and cetuximab is feasible and has an acceptable toxicity profile; neutropenia was the DLT. The RD of irinotecan is 150 mg/m. The observed response rate was promising and warrants further investigation.
(キーワード): Adult / Aged / Antimetabolites, Antineoplastic / Antineoplastic Combined Chemotherapy Protocols / Camptothecin / Capecitabine / Cetuximab / Colorectal Neoplasms / Female / Humans / Male / Middle Aged / Neoplasm Metastasis / Organoplatinum Compounds
(出版サイトへのリンク): ● Publication site (DOI): 10.1007/s00280-017-3458-7
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29038850; ● Summary page in Scopus @ Elsevier: 2-s2.0-85031928685

(DOI: 10.1007/s00280-017-3458-7, PubMed: 29038850, Elsevier: Scopus) Yasuyuki Okada, Tetsuo Kimura, Tadahiko Nakagawa, Koichi Okamoto, Akira Fukuya, Takahiro Goji, Shota Fujimoto, Masahiro Sogabe, Hiroshi Miyamoto, Naoki Muguruma, Yasushi Tsuji, Toshiya Okahisa and Tetsuji Takayama :
EGFR Down-regulation After anti-EGFR Therapy Predicts the Anti-tumor Effect in Colorectal Cancer.,
Molecular Cancer Research : MCR, Vol.15, No.10, 1445-1454, 2017.

(要約): Anti-EGFR mAb is reported to induce EGFR internalization in colorectal cancer cells. However, the biological relevance of EGFR internalization with anti-EGFR mAb is unknown. Therefore, the relevance of EGFR downregulation with anti-EGFR mAb to antitumor activity in colorectal cancer cells was investigated. Quantification of EGFR on the cell surface before cetuximab treatment was assessed by flow cytometry, and its growth-inhibitory effects were measured by Trypan blue exclusion, in 10 wild-type colorectal cancer cell lines, but there was no significant correlation between EGFR number and its growth-inhibitory effect. However, a significant correlation existed between the percentage decrease in the number of EGFRs after cetuximab treatment and its growth-inhibitory effect in those cell lines. Treatment with TGFα, a ligand for EGFR, induced EGFR internalization in colorectal cancer cells, but most EGFRs subsequently recycled to the cell surface, consistent with previous studies. While cetuximab treatment induced EGFR internalization, most receptors subsequently translocated into the late endosome, leading to lysosomal degradation, as revealed by immunoblotting and double immunofluorescence. Cetuximab-sensitive colorectal cancer cells showed greater EGFR internalization, stronger cell growth inhibition, and more augmented apoptotic signals than nonsensitive cells. IHC for EGFR, performed using an EGFR pharmDx Kit (mouse anti-human EGFR mAb clone 2-18C9), in clinical specimens before and after anti-EGFR mAb therapy in 13 colorectal cancer patients showed a significant correlation between the response to anti-EGFR mAb and decreased staining after therapy. This report clearly demonstrates that anti-EGFR mAb facilitates internalization and subsequent degradation of EGFRs in lysosomes, which is an important determinant of the efficacy of anti-EGFR mAb treatment for colorectal cancer. .
(キーワード): Adult / Aged / Antineoplastic Agents, Immunological / Caco-2 Cells / Cell Line, Tumor / Cell Survival / Cetuximab / Colorectal Neoplasms / Down-Regulation / Endosomes / Female / HCT116 Cells / HT29 Cells / Humans / Male / Middle Aged / Proto-Oncogene Proteins B-raf / Receptor, Epidermal Growth Factor / Transforming Growth Factor alpha / ras Proteins
(徳島大学機関リポジトリ): ● Metadata: 110960
(出版サイトへのリンク): ● Publication site (DOI): 10.1158/1541-7786.MCR-16-0383
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28698359; ● Search Scopus @ Elsevier (PMID): 28698359; ● Search Scopus @ Elsevier (DOI): 10.1158/1541-7786.MCR-16-0383

(徳島大学機関リポジトリ: 110960, DOI: 10.1158/1541-7786.MCR-16-0383, PubMed: 28698359) Shinji Kitamura, Naoki Muguruma, Koichi Okamoto, Toshihito Tanahashi, Akira Fukuya, Kumiko Tanaka, Daisaku Fujimoto, Tetsuo Kimura, Hiroshi Miyamoto, Yoshimi Bando, Hisashi Takeuchi, Masako Shiba and Tetsuji Takayama :
Clinicopathological Assessment of Gastric Xanthomas as Potential Predictive Markers of Gastric Cancer.,
Digestion, Vol.96, No.4, 199-206, 2017.

(要約): Gastric xanthomas are frequently observed in the stomach as small yellowish plaques or nodules. A close relationship among Helicobacter pylori infection, atrophic gastritis, and xanthomas has been reported. We assessed the clinicopathological features of gastric cancer with or without xanthomas. A total of 91 patients who were diagnosed as having early gastric cancer were enrolled. We evaluated the gastritis status using scores for gastritis and atrophy, positivity of H. pylori infection, the prevalence rate of xanthomas, and the clinicopathological features of gastric cancer. Gastric xanthomas were observed in 72.5% of early gastric cancer cases. Scores for gastritis and atrophy were significantly higher in the xanthoma-positive group than those in the xanthoma-negative group. A higher prevalence of differentiated-type adenocarcinoma was found in the xanthoma-positive group. Among the cases with multiple gastric xanthomas, the prevalence of males was significantly higher than that of females. A high prevalence rate of gastric xanthomas in gastric cancer cases was shown. Xanthomas were highly associated with age, the severities of gastritis and atrophy, and differentiated-type adenocarcinoma. Regardless of the eradication of H. pylori, xanthomas may be useful predictive markers for the development of differentiated-type adenocarcinoma.
(出版サイトへのリンク): ● Publication site (DOI): 10.1159/000481346
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28965110; ● Summary page in Scopus @ Elsevier: 2-s2.0-85030724288

(DOI: 10.1159/000481346, PubMed: 28965110, Elsevier: Scopus) Masanori Takehara, Naoki Muguruma, Shinji Kitamura, Tetsuo Kimura, Koichi Okamoto, Hiroshi Miyamoto, Yoshimi Bando and Tetsuji Takayama :
Twin Rectal Tonsils Mimicking Carcinoid or Mucosa-Associated Lymphoid Tissue Lymphoma.,
Clinical Endoscopy, Vol.50, No.5, 500-503, 2017.

(要約): The rectal tonsil is a rare polypoid lesion exclusively found in the rectum and is considered a reactive proliferation of the lymphoid tissue. Although this lesion is benign, we recommend that it should be differentiated from carcinoid or polypoid type of mucosaassociated lymphoid tissue (MALT) lymphomas, based on gross findings. In this case report, we describe a case of rectal lesions with a unique appearance in a 41-year-old man. Colonoscopy revealed two 5-mm-sized nodules located opposite from each other on the left and right sides of the lower rectum. Endoscopic mucosal resection was conducted. Histopathologically, both lesions were mainly located in the submucosa and consisted of prominent lymphoid follicles with germinal centers of various sizes. No immunoreactivity of Bcl-2 was seen in the germinal centers. Immunohistochemical staining for kappa and lambda light chains revealed a polyclonal pattern. Therefore, these lesions were diagnosed as rectal tonsils.
(徳島大学機関リポジトリ): ● Metadata: 115063
(出版サイトへのリンク): ● Publication site (DOI): 10.5946/ce.2016.157
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28241409; ● Summary page in Scopus @ Elsevier: 2-s2.0-85030241581

(徳島大学機関リポジトリ: 115063, DOI: 10.5946/ce.2016.157, PubMed: 28241409, Elsevier: Scopus) Naoki Uemura, Shohei Kikuchi, Yasushi Sato, Hiroyuki Ohnuma, Koichi Okamoto, Hiroshi Miyamoto, Masahiro Hirakawa, Tamotsu Sagawa, Koshi Fujikawa, Yasuo Takahashi, Toshinori Okuda, Shinya Minami, Minoru Takahashi, Tetsuro Okamoto, Kohichi Takada, Koji Miyanisi, Tetsuji Takayama and Junji Kato :
A phase II study of modified docetaxel, cisplatin, and S-1 (mDCS) chemotherapy for unresectable advanced gastric cancer.,
Cancer Chemotherapy and Pharmacology, Vol.80, No.4, 707-713, 2017.

(要約): Forty-nine patients were enrolled from November 2011 to April 2014, and 43 were eligible. The overall RR was 79.1%, including two cases of a complete response (4.7%), and 32 cases of a partial response (74.4%). Nine cases had stable disease (20.9%) but none showed progressive disease. Of the 43 cases, 15 cases (34.9%) underwent curative conversion surgery. The median PFS was 350 days (95% CI 240-416 days) and median OS was 722 days (95% CI 411 days-not reached). Grade 3/4 neutropenia developed in 79.1%, and febrile neutropenia in 34.9%, of patients. Non-hematological grade 3/4 adverse events were anorexia (25.6%), nausea (4.7%), and diarrhea (9.3%).
(出版サイトへのリンク): ● Publication site (DOI): 10.1007/s00280-017-3404-8
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28849257; ● Search Scopus @ Elsevier (PMID): 28849257; ● Search Scopus @ Elsevier (DOI): 10.1007/s00280-017-3404-8

(DOI: 10.1007/s00280-017-3404-8, PubMed: 28849257) Naoki Muguruma, Koichi Okamoto, Tadahiko Nakagawa, Katsutaka Sannomiya, Shota Fujimoto, Yasuhiro Mitsui, Tetsuo Kimura, Hiroshi Miyamoto, Jun Higashijima, Mitsuo Shimada, Yoko Horino, Shinya Matsumoto, Kenjiro Hanaoka, Tetsuo Nagano, Makoto Shibutani and Tetsuji Takayama :
Molecular imaging of aberrant crypt foci in the human colon targeting glutathione S-transferase P1-1.,
Scientific Reports, Vol.7, No.1, 6536, 2017.

(要約): Aberrant crypt foci (ACF), the earliest precursor lesion of colorectal cancers (CRCs), are a good surrogate marker for CRC risk stratification and chemoprevention. However, the conventional ACF detection method with dye-spraying by magnifying colonoscopy is labor- and skill-intensive. We sought to identify rat and human ACF using a fluorescent imaging technique that targets a molecule specific for ACF. We found that glutathione S-transferase (GST) P1-1 was overexpressed in ACF tissues in a screening experiment. We then synthesized the fluorogenic probe, DNAT-Me, which is fluorescently quenched but is activated by GSTP1-1. A CRC cell line incubated with DNAT-Me showed strong fluorescence in the cytosol. Fluorescence intensities correlated significantly with GST activities in cancer cell lines. When we sprayed DNAT-Me onto colorectal mucosa excised from azoxymethane-treated rats and surgically resected from CRC patients, ACF with strong fluorescent signals were clearly observed. The ACF number determined by postoperative DNAT-Me imaging was almost identical to that determined by preoperative methylene blue staining. The signal-to-noise ratio for ACF in DNAT-Me images was significantly higher than that in methylene blue staining. Thus, we sensitively visualized ACF on rat and human colorectal mucosa by using a GST-activated fluorogenic probe without dye-spraying and magnifying colonoscopy.
(徳島大学機関リポジトリ): ● Metadata: 112373
(出版サイトへのリンク): ● Publication site (DOI): 10.1038/s41598-017-06857-x
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28747791; ● Search Scopus @ Elsevier (PMID): 28747791; ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-017-06857-x

(徳島大学機関リポジトリ: 112373, DOI: 10.1038/s41598-017-06857-x, PubMed: 28747791) Masahiro Sogabe, Toshiya Okahisa, Masahiko Nakasono, Hiroshi Fukuno, Yoshihiko Miyamoto, Yasuyuki Okada, Jun Okazaki, Jinsei Miyoshi, Tetsu Tomonari, Tatsuya Taniguchi, Takahiro Goji, Shinji Kitamura, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama :
The differing influence of several factors on the development of fatty liver with elevation of liver enzymes between genders with metabolic syndrome: A cross-sectional study.,
PLoS ONE, Vol.12, No.6, e0177925, 2017.

(要約): Nonalcoholic fatty liver disease (NAFLD) is known to be strongly associated with obesity, visceral fat, metabolic syndrome (MS), lifestyle, and lifestyle-related diseases in both males and females. However, the prevalence of NAFLD, MS, and clinical backgrounds is different between males and females. We conducted a cross-sectional study to examine the differing influence of lifestyle-related factors and visceral fat on fatty liver (FL) with elevation of liver enzymes between males and females with MS. We enrolled 42,134 persons who underwent a regular health check-up, and after excluding subjects who fulfilled excluding criteria, the remaining subjects were 2,110 persons with MS. We examined the differing influence of lifestyle-related factors and visceral fat on FL with elevation of alanine aminotransferase (ALT) (ALT elevation was defined as ALT level of ≥31 IU/l in the present study). The odds rations for FL with ALT elevation were as follows: WC, 1.83 (95% confidence interval (CI) 1.36-2.46); dyslipidemia, 1.89 (95% CI 1.34-2.68); hemoglobin A1c, 1.36 (95% CI 1.00-1.85); visceral fat type MS (V-type MS), 5.78 (95% CI 4.29-7.80); and light drinker, 0.56 (95% CI 0.41-0.78) in males with MS and BMI, 2.18 (95% CI 1.43-3.33); WC, 1.85 (95% CI 1.27-2.70); diastolic blood pressure, 1.69 (95% CI 1.16-2.45); triglyceride, 2.22 (95% CI 1.56-3.17); impaired glucose tolerance, 1.66 (95% CI 1.11-2.47); and V-type MS, 3.83 (95% CI 2.57-5.70) in females with MS. The prevalence of FL with ALT elevation and ALT was significantly higher in V-type MS than in the subcutaneous fat type MS in both males and females with MS (P < 0.001). Although V-type MS and WC is a common significant predictor of an increased prevalence of FL with ALT elevation in both males and females with MS, gender, lifestyle-related factors, and MS type in individuals with MS should be considered for the development of FL with ALT elevation.
(徳島大学機関リポジトリ): ● Metadata: 112319
(出版サイトへのリンク): ● Publication site (DOI): 10.1371/journal.pone.0177925
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28574988; ● Summary page in Scopus @ Elsevier: 2-s2.0-85020298128

(徳島大学機関リポジトリ: 112319, DOI: 10.1371/journal.pone.0177925, PubMed: 28574988, Elsevier: Scopus) Jun Okazaki, Naoki Muguruma, Shinji Kitamura, Tetsuo Kimura, Koichi Okamoto, Hiroshi Miyamoto, Kazuhiro Kishi, Yoshimi Bando, Takeshi Kondo, Itsuro Endo, Masahiro Abe and Tetsuji Takayama :
Paraneoplastic hypocalcemia developed in gastric cancer accompanied by osteoblastic metastasis,
Internal Medicine, Vol.56, No.11, 1345-1349, 2017.

(要約): Paraneoplastic syndromes are generally defined as clinical disorders associated with malignant diseases, and hypocalcemia associated with cancer is a rare condition. A woman in her 60s was referred to our hospital for the further examination of massive ascites due to carcinoma of unknown primary origin. She complained of numbness around her lips, and marked hypocalcemia of 5.0 mg/dL was noted. After two courses of chemotherapy, computed tomography showed a decrease in the ascites, and her serum calcium level increased. Although hypocalcemia is a very rare condition in patients with gastric cancer, serum calcium values should be evaluated when neurological symptoms are observed.
(キーワード): Adult / Aged / Female / Humans / Hypocalcemia / Middle Aged / Neoplasm Metastasis / Osteoblasts / Paraneoplastic Syndromes / Stomach Neoplasms / Tomography, X-Ray Computed / Treatment Outcome / Young Adult
(徳島大学機関リポジトリ): ● Metadata: 114393
(出版サイトへのリンク): ● Publication site (DOI): 10.2169/internalmedicine.56.8545
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28566596; ● Summary page in Scopus @ Elsevier: 2-s2.0-85020067897

(徳島大学機関リポジトリ: 114393, DOI: 10.2169/internalmedicine.56.8545, PubMed: 28566596, Elsevier: Scopus) Shinji Kitamura, Toshihito Tanahashi, Eriko Aoyagi, Tadahiko Nakagawa, Koichi Okamoto, Tetsuo Kimura, Hiroshi Miyamoto, Yasuhiro Mitsui, Kazuhito Rokutan, Naoki Muguruma and Tetsuji Takayama :
Response Predictors of S-1, Cisplatin, and Docetaxel Combination Chemotherapy for Metastatic Gastric Cancer: Microarray Analysis of Whole Human Genes.,
Oncology, Vol.93, No.2, 127-135, 2017.

(要約): The aim of this study was to identify biomarkers for predicting the efficacy of docetaxel, cisplatin, and S-1 (DCS) therapy for advanced gastric cancer using microarrays of biopsy specimens before chemotherapy. Nineteen samples were taken from 19 patients with unresectable metastatic gastric cancer who received DCS as a first-line therapy. Laser capture microdissection was performed, and total cellular RNA was extracted from each microdissected sample. Whole-gene expression was analyzed by microarray, and the difference in mRNA expression observed with the microarrays was confirmed by quantitative real-time PCR. Immunohistochemical staining was performed using clinical tissue sections obtained by endoscopic biopsy. Eleven patients were identified as early responders and 8 patients as nonresponders to DCS therapy. Twenty-nine genes showed significant differences in relative expression ratios between tumor and normal tissues. A classifier set of 29 genes had high accuracy (94.7%) for distinguishing gene expression between 11 early responders and 8 nonresponders. Decreasing the size of the classifier set to 4 genes (PDGFB, PCGF3, CISH, and ANXA5) increased the accuracy to 100%. Expression levels by real-time PCR for validation were well correlated with those 4 genes in microarrays. The genes identified may serve as efficient biomarkers for personalized cancer-targeted therapy.
(徳島大学機関リポジトリ): ● Metadata: 111015
(出版サイトへのリンク): ● Publication site (DOI): 10.1159/000464329
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28511180; ● Summary page in Scopus @ Elsevier: 2-s2.0-85019884830

(徳島大学機関リポジトリ: 111015, DOI: 10.1159/000464329, PubMed: 28511180, Elsevier: Scopus) Yasushi Sato, Hiroyuki Ohnuma, Takayuki Nobuoka, Masahiro Hirakawa, Tamotsu Sagawa, Koshi Fujikawa, Yasuo Takahashi, Shinya Minami, Shinichi Katsuki, Minoru Takahashi, Masahiro Maeda, Yutaka Okagawa, Naoki Uemura, Syouhei Kikuch, Koichi Okamoto, Hiroshi Miyamoto, Mitsuo Shimada, Ichiro Takemasa, Junji Kato and Tetsuji Takayama :
Conversion therapy for inoperable advanced gastric cancer patients by docetaxel, cisplatin, and S-1 (DCS) chemotherapy: a multi-institutional retrospective study.,
Gastric Cancer, Vol.20, No.3, 517-526, 2017.

(要約): Conversion therapy is an option for unresectable metastatic gastric cancer when distant metastases are controlled by chemotherapy; however, the feasibility and efficacy remain unclear. This study aimed to assess the feasibility and efficacy of conversion therapy in patients with initially unresectable gastric cancer treated with docetaxel, cisplatin, and S-1 (DCS) chemotherapy by evaluating clinical outcomes. One hundred unresectable metastatic gastric cancer patients, enrolled in three DCS chemotherapy clinical trials, were retrospectively evaluated. The patients received oral S-1 (40 mg/m2 b.i.d.) on days 1-14 and intravenous cisplatin (60 mg/m2) and docetaxel (50-60 mg/m2) on day 8 every 3 weeks. Conversion therapy was defined when the patients could undergo R0 resection post-DCS chemotherapy and were able to tolerate curative surgery. Conversion therapy was achieved in 33/100 patients, with no perioperative mortality. Twenty-eight of the 33 patients (84.8 %) achieved R0 resection, and 78.8 % were defined as histological chemotherapeutic responders. The median overall survival (OS) of patients who underwent conversion therapy was 47.8 months (95 % CI 28.0-88.5 months). Patients who underwent R0 resection had significantly longer OS than those who underwent R1 and R2 resections (P = 0.0002). Of the patients with primarily unresectable metastases, 10 % lived >5 years. Among patients who underwent conversion therapy, multivariate analysis showed that the pathological response was a significant independent predictor for OS. DCS safely induced a high conversion rate, with very high R0 and pathological response rates, and was associated with a good prognosis; these findings warrant further prospective investigations.
(キーワード): Administration, Oral / Adult / Aged / Antineoplastic Combined Chemotherapy Protocols / Cisplatin / Drug Combinations / Female / Humans / Male / Middle Aged / Oxonic Acid / Postoperative Care / Prognosis / Retrospective Studies / Stomach Neoplasms / Survival Analysis / Taxoids / Tegafur / Treatment Outcome
(出版サイトへのリンク): ● Publication site (DOI): 10.1007/s10120-016-0633-1
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27553665; ● Summary page in Scopus @ Elsevier: 2-s2.0-84983383466

(DOI: 10.1007/s10120-016-0633-1, PubMed: 27553665, Elsevier: Scopus) Koichi Okamoto, Naoki Muguruma, Kaizo Kagemoto, Yasuhiro Mitsui, Daisaku Fujimoto, Shinji Kitamura, Tetsuo Kimura, Masahiro Sogabe, Hiroshi Miyamoto and Tetsuji Takayama :
Efficacy of hybrid endoscopic submucosal dissection (ESD) as a rescue treatment in difficult colorectal ESD cases.,
Digestive Endoscopy, Vol.29, No.suppl.2, 45-52, 2017.

(要約): Endoscopic submucosal dissection (ESD), which provides a higher en bloc resection rate than conventional endoscopic mucosal resection (EMR), is considered to be a useful treatment option for large colorectal tumors. However, colorectal ESD is not widely used because of its technical difficulty, risk of complications and time required. To overcome these drawbacks, a simpler modified technique, ESD with snaring (hybrid ESD), has been developed. The aim of the present study was to retrospectively compare the safety and efficacy of hybrid ESD and conventional ESD for colorectal tumors. Between September 2008 and June 2016, ESD was carried out on 137 lesions and hybrid ESD on 27 lesions. All hybrid ESD cases were carried out as a rescue treatment in difficult ESD cases. We retrospectively investigated procedure time, and the rates of en bloc resection, perforation, bleeding, and local recurrence. In the hybrid ESD group, procedure time was shorter compared with the ESD group (108 ± 59.5 min vs 122 ± 72.2 min), but the en bloc resection rate was lower (66.7% vs 94.2%). However, there were no significant differences in procedure time, or in rates of en bloc resection, perforation and bleeding between the two groups. Local recurrence did not develop in any of our cases. Hybrid ESD as a rescue treatment in difficult ESD cases may be less effective for en bloc resection of large colorectal tumors. Indication for hybrid ESD may be limited to scheduled treatment from the outset and emergency cases with patients who present unstable vital signs during ESD.
(出版サイトへのリンク): ● Publication site (DOI): 10.1111/den.12863
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28425649; ● Search Scopus @ Elsevier (PMID): 28425649; ● Search Scopus @ Elsevier (DOI): 10.1111/den.12863

(DOI: 10.1111/den.12863, PubMed: 28425649) Tatsuya Taniguchi, Kazuhiro Kishi, Tadahiko Nakagawa, Hironori Tanaka, Takahiro Tanaka, Tetsu Tomonari, Koichi Okamoto, Masahiro Sogabe, Hiroshi Miyamoto, Toshiya Okahisa, Naoki Muguruma, Mayumi Kajimoto, Ikuko Sagawa and Tetsuji Takayama :
Poly-(ADP-Ribose) Polymerase-1 Promotes Prothrombin Gene Transcription and Produces Des-Gamma-Carboxy Prothrombin in Hepatocellular Carcinoma.,
Digestion, Vol.95, No.3, 242-251, 2017.

(要約): Although des-gamma-carboxy prothrombin (DCP) is a well-known tumor marker for hepatocellular carcinoma (HCC), the mechanism of DCP production is unclear. This study aimed to investigate the mechanism how DCP is produced in HCC cells. Levels of mRNA and DCP were analyzed by real-time polymerase chain reaction and electro-chemiluminescence immunoassay respectively. Secreted alkaline phosphatase (SEAP) expression vectors including deletion mutants of the prothrombin gene promoter were constructed for reporter gene assay. The transcription factors bound to DNA fragments were analyzed by mass spectrometry. An electrophoretic mobility shift assay (EMSA) was performed using a biotin end-labeled DNA. The prothrombin mRNA levels in all 5 DCP producing cell lines were appreciably high. However, those in 2 DCP non-producing cell lines were below detectable levels. A SEAP vector with -2985 to +27 showed a very high transcription activity in DCP-producing Huh-1 cells. However, transcription abruptly decreased when the vector with -2955 to +27 was transfected, and then remained at the similar levels with larger deletion mutants, indicating the existence of a cis-element at -2985 to -2955 (31-bp). Mass spectrometry analysis identified the protein that bound to the 31-bp DNA as poly-(ADP-ribose) polymerase-1 (PARP-1). Knockdown of the PARP-1 gene by small interfering RNA in Huh-1 cells induced marked inhibition of prothrombin gene transcription. The EMSA clearly showed that PARP-1 specifically binds to the 31-bp DNA fragment in the prothrombin gene promoter. Our data suggest that PARP-1 activates prothrombin gene transcription and that the excessive prothrombin gene transcription induces DCP production in DCP-producing HCC cells.
(徳島大学機関リポジトリ): ● Metadata: 110173
(出版サイトへのリンク): ● Publication site (DOI): 10.1159/000470837
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28384634; ● Search Scopus @ Elsevier (PMID): 28384634; ● Search Scopus @ Elsevier (DOI): 10.1159/000470837

(徳島大学機関リポジトリ: 110173, DOI: 10.1159/000470837, PubMed: 28384634) Yuri Matsumoto, Hiroshi Miyamoto, Akira Fukuya, Fumika Nakamura, Takahiro Goji, Shinji Kitamura, Tetsuo Kimura, Koichi Okamoto, Masahiro Sogabe, Naoki Muguruma, Mitsuo Shimada, Yoshimi Bando and Tetsuji Takayama :
Hemosuccus pancreaticus caused by a mucinous cystic neoplasm of the pancreas.,
Clinical Journal of Gastroenterology, Vol.10, No.2, 185-190, 2017.

(要約): Hemosuccus pancreaticus is a gastrointestinal hemorrhage through the main pancreatic duct. Here, we report a rare case of hemosuccus pancreaticus due to a mucinous cystic neoplasm of the pancreas. A 62-year-old woman who had been followed for a branch duct intraductal papillary mucinous neoplasm visited our emergency room due to severe abdominal pain and bloody discharge. Computed tomography revealed that the pancreatic cyst increased the tension of the wall and a high-density area indicative of bleeding into the cyst was observed. Endoscopy showed opening of and hemorrhaging from the papilla of Vater. The patient was diagnosed with hemosuccus pancreaticus caused by hemorrhaging into the cyst from the branch duct intraductal papillary mucinous neoplasm. Based on this diagnosis, elective distal pancreatectomy was performed. The histopathological diagnosis was a mucinous cystic neoplasm with intermediate-grade dysplasia based upon the pathological findings that fibrous ovarian-type stroma existed abundantly and the stroma cells were positive for progesterone receptor and inhibin. Hemosuccus pancreaticus caused by a mucinous cystic neoplasm is extremely rare and there has been only one case reported to date. In conclusion, it should be recognized that pancreatic cystic neoplasms including mucinous cystic neoplasms may cause hemosuccus pancreaticus.
(キーワード): Ampulla of Vater / 女性 (female) / Gastrointestinal Hemorrhage / Humans / 磁気共鳴映像法 (magnetic resonance imaging) / Middle Aged / Neoplasms, Cystic, Mucinous, and Serous / Pancreatic Cyst / Pancreatic Ducts / Pancreatic Neoplasms / Tomography, X-Ray Computed
(出版サイトへのリンク): ● Publication site (DOI): 10.1007/s12328-016-0711-2
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28054178; ● Summary page in Scopus @ Elsevier: 2-s2.0-85008158342

(DOI: 10.1007/s12328-016-0711-2, PubMed: 28054178, Elsevier: Scopus) Satoshi Teramae, Koichi Okamoto, Kumiko Tanaka, Reika Matsumoto, Shinji Kitamura, Tetsuo Kimura, Masahiro Sogabe, Hiroshi Miyamoto, Naoki Muguruma, Yoshimi Bando, Mitsuo Shimada and Tetsuji Takayama :
Duodenal cancer in a young patient with Peuts-Jeghers syndrome harboring an entire deletion of the STK11 gene.,
Clinical Journal of Gastroenterology, Vol.10, No.3, 232-239, 2017.

(出版サイトへのリンク): ● Publication site (DOI): 10.1007/s12328-017-0731-6
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28303455; ● Summary page in Scopus @ Elsevier: 2-s2.0-85015616972

(DOI: 10.1007/s12328-017-0731-6, PubMed: 28303455, Elsevier: Scopus) Yasuteru Fujino, Shunsaku Takeishi, Kensei Nishida, Koichi Okamoto, Naoki Muguruma, Tetsuo Kimura, Shinji Kitamura, Hiroshi Miyamoto, Akiko Fujimoto, Jun Higashijima, Mitsuo Shimada, Kazuhito Rokutan and Tetsuji Takayama :
Downregulation of miR-100/miR-125b is associated with lymph node metastasis in early colorectal cancer with submucosal invasion.,
Cancer Science, Vol.108, No.3, 390-397, 2017.

(要約): A majority of early colorectal cancers (CRCs) with submucosal invasion undergo surgical operation, despite a very low incidence of lymph node metastasis. Our study aimed to identify microRNAs (miRNAs) specifically responsible for lymph node metastasis in submucosal CRCs. MicroRNA microarray analysis revealed that miR-100 and miR-125b expression levels were significantly lower in CRC tissues with lymph node metastases than in those without metastases. These results were validated by quantitative real-time PCR in a larger set of clinical samples. The transfection of a miR-100 or miR-125b inhibitor into colon cancer HCT116 cells significantly increased cell invasion, migration, and MMP activity. Conversely, overexpression of miR-100 or miR-125b mimics significantly attenuated all these activities but did not affect cell growth. To identify target mRNAs, we undertook a gene expression array analysis of miR-100-silenced HCT116 cells as well as negative control cells. The Ingenuity Pathway Analysis, TargetScan software analyses, and subsequent verification of mRNA expression by real-time PCR identified mammalian target of rapamycin (mTOR) and insulin-like growth factor 1 receptor (IGF1R) as direct, and Fas and X-linked inhibitor-of-apoptosis protein (XIAP) as indirect candidate targets for miR-100 involved in lymph node metastasis. Knockdown of each gene by siRNA significantly reduced the invasiveness of HCT116 cells. These data clearly show that downregulation of miR-100 and miR-125b is closely associated with lymph node metastasis in submucosal CRC through enhancement of invasion, motility, and MMP activity. In particular, miR-100 may promote metastasis by upregulating mTOR, IGF1R, Fas, and XIAP as targets. Thus, miR-100 and miR-125b may be novel biomarkers for lymph node metastasis of early CRCs with submucosal invasion.
(キーワード): Antigens, CD95 / Cell Line, Tumor / Cell Movement / Cell Proliferation / Colorectal Neoplasms / HCT116 Cells / HT29 Cells / Humans / Lymphatic Metastasis / Matrix Metalloproteinases / MicroRNAs / RNA Interference / RNA, Small Interfering / Receptors, Somatomedin / TOR Serine-Threonine Kinases / X-Linked Inhibitor of Apoptosis Protein
(徳島大学機関リポジトリ): ● Metadata: 112375
(出版サイトへのリンク): ● Publication site (DOI): 10.1111/cas.13152
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28032929; ● Search Scopus @ Elsevier (PMID): 28032929; ● Search Scopus @ Elsevier (DOI): 10.1111/cas.13152

(徳島大学機関リポジトリ: 112375, DOI: 10.1111/cas.13152, PubMed: 28032929) Koichi Okamoto, Shinji Kitamura, Tetsuo Kimura, Tadahiko Nakagawa, Masahiro Sogabe, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama :
Clinicopathological Characteristics of Serrated Polyps as Precursors to Colorectal Cancer: Current Status and Management.,
Journal of Gastroenterology and Hepatology, Vol.32, No.2, 358-367, 2017.

(要約): Serrated polyps have long been thought to lack malignant potential in the human colorectum. However, identification of the serrated pathway to colorectal cancer based on molecular biology has improved our understanding of the pathogenesis of colorectal cancers. Accordingly, serrated polyps such as traditional serrated adenoma and sessile serrated adenoma/polyps (SSA/P) are now considered to be precursor lesions of the serrated pathway. Recently, serrated polyps were classified into three subtypes, consisting of hyperplastic polyp, SSA/P, and traditional serrated adenoma, according to the World Health Organization classification. It has been suggested that SSA/P in the proximal colon are a precursor lesion of pathogenesis of colorectal cancer and are characterized by BRAF mutation and a CpG island methylator phenotype with or without microsatellite instability. However, SSA/P is more challenging to detect by colonoscopy and is likely to account for some interval cancers, particularly in the proximal colon because it presents flat or sessile, isochroous appearance, and occasionally has a mucous cap. Furthermore, the possibility has been raised that pathologists misclassify SSA/P as hyperplastic polyp. It is important for gastroenterologists to recognize the endoscopic features of serrated polyps to facilitate their detection and removal and also to establish postpolypectomy surveillance guidelines. In this review, we discuss the recent classification of serrated polyps; the molecular characteristics of the serrated pathway; appropriate diagnostic methods using endoscopy, including a new image-enhanced endoscopic technique; and management of these lesions.
(出版サイトへのリンク): ● Publication site (DOI): 10.1111/jgh.13482
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27376251; ● Summary page in Scopus @ Elsevier: 2-s2.0-85013296238

(DOI: 10.1111/jgh.13482, PubMed: 27376251, Elsevier: Scopus) Tetsuo Kimura, Hiroshi Miyamoto, Akira Fukuya, Shinji Kitamura, Koichi Okamoto, Masako Kimura, Naoki Muguruma, Tetsuya Ikemoto, Mitsuo Shimada, Akiko Yoneda, Yoshimi Bando, Makoto Takishita and Tetsuji Takayama :
Neuroendocrine carcinoma of the pancreas with similar genetic alterations to invasive ductal adenocarcinoma.,
Clinical Journal of Gastroenterology, Vol.9, No.4, 261-265, 2016.

(要約): Neuroendocrine carcinoma (NEC) of the pancreas is very rare, and its origin is not fully elucidated. Here, we present a case of a small-size NEC of the pancreas that is genetically similar to invasive ductal adenocarcinoma (IDA). A 65-year-old man was referred to our hospital due to obstructive jaundice and found to have a 12-mm solid tumor in the pancreas head. The tumor exhibited low vascularity on enhanced computed tomography, and endoscopic retrograde pancreatographic imaging revealed an irregular obstruction in a branch duct of the pancreas. The patient was thereby diagnosed with a pancreatic ductal cancer, and stomach-preserving pancreaticoduodenectomy with regional lymph node resection was performed. Histochemical analysis of the resected tumor showed that the neoplastic cells with scanty cytoplasm and hyperchromatic nuclei strongly expressed chromogranin A and synaptophysin. The Ki-67 index was 40 % in the most proliferative tumor regions, and the tumor was diagnosed as a NEC of the pancreas. However, in the analysis of genetic alterations of the tumor tissue, the neoplastic cells showed altered KRAS, TP53, and SMAD4/DPC4, suggesting that the NEC in our case is genetically related to IDA. Our data suggest that poorly differentiated IDAs may transform into NECs.
(キーワード): Aged / Carcinoma, Neuroendocrine / Carcinoma, Pancreatic Ductal / Cholangiopancreatography, Endoscopic Retrograde / Disease Progression / Genes, p53 / Humans / Male / Mutation / Pancreatic Neoplasms / Proto-Oncogene Proteins p21(ras) / Smad4 Protein / Tomography, X-Ray Computed
(出版サイトへのリンク): ● Publication site (DOI): 10.1007/s12328-016-0655-6
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27262570; ● Search Scopus @ Elsevier (PMID): 27262570; ● Search Scopus @ Elsevier (DOI): 10.1007/s12328-016-0655-6

(DOI: 10.1007/s12328-016-0655-6, PubMed: 27262570) Toshi Takaoka, Tetsuo Kimura, Rai Shimoyama, Shunji Kawamoto, Kazuki Sakamoto, Fuminori Goda, Hiroshi Miyamoto, Yuji Negoro, Akihito Tsuji, Koji Yoshizaki, Takahiro Goji, Shinji Kitamura, Hiromi Yano, Koichi Okamoto, Masako Kimura, Toshiya Okahisa, Naoki Muguruma, Yoshiro Niitsu and Tetsuji Takayama :
Panitumumab in combination with irinotecan plus S-1 (IRIS) as second-line therapy for metastatic colorectal cancer.,
Cancer Chemotherapy and Pharmacology, Vol.78, No.2, 397-403, 2016.

(徳島大学機関リポジトリ): ● Metadata: 109985
(出版サイトへのリンク): ● Publication site (DOI): 10.1007/s00280-016-3096-5
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27342247; ● Summary page in Scopus @ Elsevier: 2-s2.0-84976254460

(徳島大学機関リポジトリ: 109985, DOI: 10.1007/s00280-016-3096-5, PubMed: 27342247, Elsevier: Scopus) Masahiro Sogabe, Toshiya Okahisa, Tetsuo Kimura, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama :
Influence of metabolic syndrome on upper gastrointestinal disease.,
Clinical Journal of Gastroenterology, Vol.9, No.4, 191-202, 2016.

(要約): A recent increase in the rate of obesity as a result of insufficient physical exercise and excess food consumption has been seen in both developed and developing countries throughout the world. Additionally, the recent increased number of obese individuals with lifestyle-related diseases associated with abnormalities in glucose metabolism, dyslipidemia, and hypertension, defined as metabolic syndrome (MS), has been problematic. Although MS has been highlighted as a risk factor for ischemic heart disease and arteriosclerotic diseases, it was also recently shown to be associated with digestive system disorders, including upper gastrointestinal diseases. Unlike high body weight and high body mass index, abdominal obesity with visceral fat accumulation is implicated in the onset of various digestive system diseases because excessive visceral fat accumulation may cause an increase in intra-abdominal pressure, inducing the release of various bioactive substances, known as adipocytokines, including tumor necrosis factor-α, interleukin-6, resistin, leptin, and adiponectin. This review article focuses on upper gastrointestinal disorders and their association with MS, including obesity, visceral fat accumulation, and the major upper gastrointestinal diseases.
(キーワード): Adenocarcinoma / Barrett Esophagus / Esophageal Neoplasms / Gastritis / Gastroesophageal Reflux / Gastrointestinal Diseases / Hernia, Hiatal / Humans / Metabolic Syndrome X / Peptic Ulcer / Stomach Neoplasms
(出版サイトへのリンク): ● Publication site (DOI): 10.1007/s12328-016-0668-1
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27372302; ● Summary page in Scopus @ Elsevier: 2-s2.0-84976486171

(DOI: 10.1007/s12328-016-0668-1, PubMed: 27372302, Elsevier: Scopus) 高山哲治, 宮本弘志, 六車直樹 :
大腸癌の予防,
日本消化器病学会雑誌, Vol.113, No.7, 1168-1175, 2016年.

(要約): 食生活を改善して大腸癌を予防する1次予防では，赤身肉，加工肉，アルコール，喫煙などの危険因子を回避(または減量)すること，野菜，線維，果物，牛乳，カルシウムなどを十分に摂取するとともに，適度な運動を行うように心がけるべきである．また，大腸癌を早期に発見する2次予防では，便潜血検査や大腸内視鏡検査を受けることが重要である．大腸内視鏡検査では，前癌病変である腺腫を摘除することも癌の予防に重要である．一方，現在種々の薬剤の発癌予防効果を調べる臨床試験が行われており，近い将来，有効な予防薬が開発されることが期待される．大腸癌の3次予防としては，異時性の大腸癌予防の観点から定期検査の受診が必要である．
(キーワード): 大腸癌 / 予防 / スクリーニング / chemoprevention
(出版サイトへのリンク): ● Publication site (DOI): 10.11405/nisshoshi.113.1168
(文献検索サイトへのリンク): ● CiNii @ 国立情報学研究所 (CRID): 1390001206403529600; ● Search Scopus @ Elsevier (DOI): 10.11405/nisshoshi.113.1168

(DOI: 10.11405/nisshoshi.113.1168, CiNii: 1390001206403529600) Yoshihiko Miyamoto, Naoki Muguruma, Tetsuo Kimura, Koichi Okamoto, Masahiro Sogabe, Hiroshi Miyamoto, Seiya Kohno, Masahiko Nakasono, Hiroshige Hayashi, Yoshimi Bando and Tetsuji Takayama :
Protein-losing enteropathy in a patient with familial adenomatous polyposis and advanced colon cancer.,
Clinical Journal of Gastroenterology, Vol.9, No.3, 134-139, 2016.

(要約): A 29-year-old female visited a hospital because of increasingly severe lower leg edema. She was diagnosed as having multiple polyps in the stomach and colon by gastroscopy and sigmoidoscopy as well as multiple liver tumors by abdominal CT. She was referred to our hospital for further examination. Total colonoscopy revealed a type 2 tumor in the transverse colon and more than 200 polyps distributed throughout the colorectum. Biopsies of the tumor and polyps showed histological characteristics of adenocarcinoma and tubulovillous adenoma, respectively. Thus, she was diagnosed as having metastatic colon cancer derived from familial adenomatous polyposis (FAP). Laboratory tests showed a marked hypoalbuminemia of 1.1 g/dl. The fecal alpha-1 anti-trypsin test showed abnormal clearance (62.1 ml/day), and scintigraphy using 99mTc-human serum albumin revealed protein loss in the whole colon. Multiple ligation probe amplification analysis of the APC gene identified a germline duplication of exons 11-13. Direct sequencing of the reverse transcription PCR products of APC mRNA revealed a deletion of 25 base pairs and a tandem duplication of exons 11-13. This case was considered to be protein-losing enteropathy resulting from numerous colonic tubulovillous adenomas and advanced colon cancer in a FAP patient with unusual mutational events in APC.
(キーワード): Adenomatous Polyposis Coli / Adult / Colonic Neoplasms / Colonoscopy / DNA Mutational Analysis / Edema / Female / Gastroscopy / Genes, APC / Humans / Leg / Liver Neoplasms / Mutation / Pedigree / Protein-Losing Enteropathies / Radionuclide Imaging / Tomography, X-Ray Computed
(出版サイトへのリンク): ● Publication site (DOI): 10.1007/s12328-016-0650-y
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27170298; ● Summary page in Scopus @ Elsevier: 2-s2.0-84966709449

(DOI: 10.1007/s12328-016-0650-y, PubMed: 27170298, Elsevier: Scopus) Miwako Kagawa, Yasuteru Fujino, Naoki Muguruma, Noriaki Murayama, Koichi Okamoto, Shinji Kitamura, Tetsuo Kimura, Kazuhiro Kishi, Hiroshi Miyamoto, Hisanori Uehara and Tetsuji Takayama :
Localized amyloidosis of the stomach mimicking a superficial gastric cancer.,
Clinical Journal of Gastroenterology, Vol.9, No.3, 109-113, 2016.

(要約): A 73-year-old man was referred to our hospital for further examination of a depressed lesion in the stomach found by cancer screening gastroscopy. A barium upper gastrointestinal series showed an area of irregular mucosa measuring 15 mm on the anterior wall of the gastric body. Esophagogastroduodenoscopy revealed a 15 mm depressed lesion on the anterior wall of the lower gastric body. We suspected an undifferentiated adenocarcinoma from the appearance and took some biopsies. However, histology of the specimens revealed amyloidal deposits in the submucosal layer without malignant findings. Congo red staining was positive for amyloidal protein and green birefringence was observed under polarized light microscopy. Congo red staining with prior potassium permanganate incubation confirmed the light chain (AL) amyloid type. There were no amyloid deposits in the colon or duodenum. Computed tomography of the chest, abdomen, and pelvis showed no remarkable findings. Thus, this case was diagnosed as a localized gastric amyloidosis characterized by AL type amyloid deposition in the mucosal or submucosal layer. As the clinical outcome of gastric AL amyloidosis seems favorable, this case is scheduled for periodic examination to recognize potential disease progression and has been stable for 2 years.
(キーワード): Aged / Amyloidosis / Biopsy / Diagnosis, Differential / Gastroscopy / Humans / Male / Stomach / Stomach Diseases / Stomach Neoplasms
(出版サイトへのリンク): ● Publication site (DOI): 10.1007/s12328-016-0651-x
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27170299; ● Summary page in Scopus @ Elsevier: 2-s2.0-84966708422

(DOI: 10.1007/s12328-016-0651-x, PubMed: 27170299, Elsevier: Scopus) Tetsu Tomonari, Shunsaku Takeishi, Tatsuya Taniguchi, Takahiro Tanaka, Hironori Tanaka, Shota Fujimoto, Tetsuo Kimura, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama :
MRP3 as a novel resistance factor for sorafenib in hepatocellular carcinoma,
Oncotarget, Vol.7, No.6, 7207-7215, 2016.

(要約): The mechanism of resistance of hepatocellular carcinoma (HCC) to sorafenib is unknown and no useful predictive biomarker for sorafenib treatment has been reported. Accordingly, we established sorafenib-resistant HCC cells and investigated the underlying mechanism of resistance to sorafenib. Sorafenib-resistant cell lines were established from the HCC cell line PLC/PRF5 by cultivation under continuous exposure to increasing concentration of sorafenib. The IC50 values of the 2 resistant clones PLC/PRF5-R1 and PLC-PRF5-R2 were 9.2±0.47 M (1.8-fold) and 25±5.1 M (4.6-fold) respectively, which were significantly higher than that of parental PLC/PRF5 cells (5.4±0.17 M) (p < 0.01 respectively), as determined by MTT assay. Western blot analysis of signal transduction-related proteins showed no significant differences in expression of AKT/pAKT, mTOR/pmTOR, or ERK/pERK between the 2 resistant clones versus parent cells, suggesting no activation of an alternative signal transduction pathway. Likewise, when expression of membrane transporter proteins was determined, there were no significant differences in expression levels of BSEP, MDR1, MRP2, BCRP, MRP4 and OCT1 between resistant clones and parent cells. However, the expression levels of MRP3 in the 2 resistant clones were significantly higher than that of parent cells. When MRP3 gene was knocked down by siRNA in PLC-PRF5-R2 cells, the sensitivity of the cells to sorafenib was restored. In the analysis of gene mutation, there was no mutation in the activation segment of Raf1 kinase in the resistant clones. Our data clearly demonstrate that the efflux transporter MRP3 plays an important role in resistance to sorafenib in HCC cells.
(徳島大学機関リポジトリ): ● Metadata: 109929
(出版サイトへのリンク): ● Publication site (DOI): 10.18632/oncotarget.6889
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26769852; ● Summary page in Scopus @ Elsevier: 2-s2.0-84981164782

(徳島大学機関リポジトリ: 109929, DOI: 10.18632/oncotarget.6889, PubMed: 26769852, Elsevier: Scopus) Jinsei Miyoshi, Hiroshi Miyamoto, Takahiro Goji, Tatsuya Taniguchi, Tetsu Tomonari, Masahiro Sogabe, Tetsuo Kimura, Shinji Kitamura, Koichi Okamoto, Yasuteru Fujino, Naoki Muguruma, Toshiya Okahisa and Tetsuji Takayama :
Serum diamine oxidase activity as a predictor of gastrointestinal toxicity and malnutrition due to anticancer drugs.,
Journal of Gastroenterology and Hepatology, Vol.30, No.11, 1582-1590, 2015.

(要約): Objective evaluation of intestinal mucosal damage due to anticancer drugs is generally difficult. Serum diamine oxidase (DAO) activity is reported to reflect the integrity and maturity of the small intestinal mucosa. Therefore, we investigated whether serum DAO activity is an indicator of gastrointestinal toxicity or nutritional status in patients receiving chemotherapy. We prospectively enrolled 20 patients with unresectable metastatic gastric cancer who received oral S-1 (80 mg/m(2) ) on days 1-14, and intravenous cisplatin (60 mg/m(2) ) and docetaxel (50 mg/m(2) ) on day 8 every 3 weeks. Serum DAO activity was measured by colorimetry. Gastrointestinal toxicity was evaluated by CTCAE v4.0. Endoscopic examination and biopsy of duodenal mucosa assessed mucosal damage. Malnutrition was evaluated by measuring serum total protein and albumin levels. Serum DAO activity decreased step-by-step significantly during anticancer drug treatment and recovered after drug holidays. In all 14 patients who experienced diarrhea, serum DAO activity significantly decreased prior to diarrhea onset. Percent decrease in DAO activity was significantly correlated with severity of diarrhea. Significant correlation was observed between percent decrease in DAO activity and percent decrease in duodenal villus height or surface area from baseline. There were also significant correlations between percent decrease in serum DAO activity at day 14 and percent decrease in serum total protein or albumin levels at day 21 from baseline. Serum DAO activity sensitively indicates gastrointestinal damage prior to symptom onset and can be a useful predictor of intestinal mucosal damage and nutritional status in patients receiving chemotherapy.
(徳島大学機関リポジトリ): ● Metadata: 109519
(出版サイトへのリンク): ● Publication site (DOI): 10.1111/jgh.13004
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25968084; ● Summary page in Scopus @ Elsevier: 2-s2.0-84943595915

(徳島大学機関リポジトリ: 109519, DOI: 10.1111/jgh.13004, PubMed: 25968084, Elsevier: Scopus) Takahiro Goji, Tetsuo Kimura, Hiroshi Miyamoto, Masanori Takehara, kaizo Kagamoto, Yasuyuki Okada, Jun Okazaki, Yoshifumi Takaoka, Yoshihiko Miyamoto, Yasuhiro Mitsui, Tatsunao Sueuchi, Kumiko Tanaka, Yasuteru Fujino, Sayo Matsumoto, Toshi Takaoka, Shinji Kitamura, Koichi Okamoto, Masako Kimura, Masahiro Sogabe, Naoki Muguruma, Toshiya Okahisa, Yasuhiro Sato, Tamotsu Sagawa, Koji Fujikawa, Yasushi Sato, Hitoshi Ikushima and Tetsuji Takayama :
A Phase I/II Study of Fixed-dose-rate Gemcitabine and S-1 with Concurrent Radiotherapy for Locally Advanced Pancreatic Cancer,
Cancer Chemotherapy and Pharmacology, Vol.76, No.3, 615-620, 2015.

(要約): This study was conducted to identify the maximum-tolerated dose (MTD) of fixed-dose-rate gemcitabine (FDR-gem) administered concurrently with S-1 and radical radiation for locally advanced pancreatic cancer (LAPC) and to provide efficacy and safety data. Patients with unrespectable pancreatic cancer confined to the pancreatic region were treated with FDR-gem (300-400 mg/m(2), 5 mg/m(2)/min) on days 1, 8, 22, and 29 and 60 mg/m(2) of S-1 orally on days 1-14, 22-35. A total radiation dose of 50.4 Gy (1.8 Gy/day, 28 fractions) was delivered concurrently. Twenty-five patients were enrolled; all were evaluable for toxicity assessment. In phase I, eight patients were treated in sequential cohorts of three to five patients per dose level. The MTD was reached at level 2, and dose-limiting toxicities were neutropenia and thrombocytopenia. The recommended doses were 300 mg/m(2) of gemcitabine and 60 mg/m(2) of S-1 daily. The overall response rate was 25% and disease control rate (partial response plus stable disease) was 92%. The progression-free survival was 11.0 months. The median overall survival and 1-year survival rates were 16.0 months and 73%, respectively. The combination of FDR-gem and S-1 with radiation is a feasible regimen that shows favorable antitumor activity with an acceptable safety profile in patients with LAPC.
(徳島大学機関リポジトリ): ● Metadata: 110046
(出版サイトへのリンク): ● Publication site (DOI): 10.1007/s00280-015-2835-3
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26220846; ● Summary page in Scopus @ Elsevier: 2-s2.0-84939568942

(徳島大学機関リポジトリ: 110046, DOI: 10.1007/s00280-015-2835-3, PubMed: 26220846, Elsevier: Scopus) Yasuhiro Mitsui, Yasushi Sato, Hiroshi Miyamoto, Yasuteru Fujino, Toshi Takaoka, Jinsei Miyoshi, Miwako Kagawa, Hiroyuki Ohnuma, Masahiro Hirakawa, Tomohiro Kubo, Takahiro Osuga, Tamotsu Sagawa, Yasuhiro Sato, Yasuo Takahashi, shinichi Katsuki, Toshinori Okuda, Rishu Takimoto, Masayoshi Kobune, Takayuki Nobuoka, Koichi Hirata, Junji Kato and Tetsuji Takayama :
Trastuzumab in combination with docetaxel/cisplatin/S-1 (DCS) for patients with HER2-positive metastatic gastric cancer: feasibility and preliminary efficacy.,
Cancer Chemotherapy and Pharmacology, Vol.76, No.2, 375-382, 2015.

(要約): We previously reported that a triplet combination of docetaxel, cisplatin, and S-1 (DCS) is active against metastatic gastric cancer with a very high response rate of 87.1 % in a phase II study. Recently, the efficacy of trastuzumab (T-mab) for the treatment of HER2-positive gastric cancer has been reported. Therefore, we investigated the feasibility and preliminary efficacy of DCS + T-mab (DCS-T) for unresectable HER2-positive metastatic gastric cancer. Patients received oral S-1 (40 mg/m(2) b.i.d.) on days 1-14, intravenous cisplatin (60 mg/m(2)), docetaxel (50 mg/m(2)), and T-mab (8 mg/kg in the first cycle and 6 mg/kg in the second cycle and thereafter) on day 8 every 3 weeks. The study included 16 patients: median age, 60 (34-76) years; males/females, 11:5; intestinal-type/diffuse-type histology, 11:5; and HER2 3+/2+(FISH+), 13:3. The completion rate until the third cycle was 87.5 % (14/16) (95 %CI 71.3-103.7 %). Adverse events of grade 3/4 severity during the first 3 cycles were: leukopenia/neutropenia, 50.0:75.0 %; febrile neutropenia, 12.5 %; diarrhea, 12.5 %; and stomatitis, 12.5 %. All of these side effects were manageable and well controlled. There were no treatment-related deaths. The overall response rate was 93.8 % (15/16), and the response rate in patients with measurable lesions was 100 % (15/15). The median cycle to response was only 1 (1-3 cycles). Non-curative factors disappeared in 56.3 % (9/16) of patients, and conversion surgery (R0 resection) was performed in all these cases. Pathological response rates in primary and metastatic lesions were 88.9 % (8/9) and 100 % (9/9), respectively. The median PFS and OS were not reached during the median follow-up time of 18.3 months ranged from 11.0 to 34.3 months. DCS-T was feasible in patients with unresectable HER2-positive metastatic gastric cancer. The observed response was very promising and warrants further investigation. UMIN000005603.
(キーワード): Adult / Aged / Antibodies, Monoclonal, Humanized / Cisplatin / Drug Combinations / Feasibility Studies / Female / Humans / Male / Middle Aged / Neoplasm Metastasis / Oxonic Acid / Receptor, Epidermal Growth Factor / Stomach Neoplasms / Taxoids / Tegafur
(徳島大学機関リポジトリ): ● Metadata: 109679
(出版サイトへのリンク): ● Publication site (DOI): 10.1007/s00280-015-2807-7
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26099968; ● Summary page in Scopus @ Elsevier: 2-s2.0-84938207398

(徳島大学機関リポジトリ: 109679, DOI: 10.1007/s00280-015-2807-7, PubMed: 26099968, Elsevier: Scopus) Naoki Muguruma, Shinji Kitamura, Tetsuo Kimura, Hiroshi Miyamoto and Tetsuji Takayama :
Endoscopic Management of Nonvariceal Upper Gastrointestinal Bleeding: State of the Art.,
Clinical Endoscopy, Vol.48, No.2, 96-101, 2015.

(要約): Nonvariceal upper gastrointestinal (GI) bleeding is one of the most common reasons for hospitalization and a major cause of morbidity and mortality worldwide. Recently developed endoscopic devices and supporting apparatuses can achieve endoscopic hemostasis with greater safety and efficiency. With these advancements in technology and technique, gastroenterologists should have no concerns regarding the management of acute upper GI bleeding, provided that they are well prepared and trained. However, when endoscopic hemostasis fails, endoscopy should not be continued. Rather, endoscopists should refer patients to radiologists and surgeons without any delay for evaluation regarding the appropriateness of emergency interventional radiology or surgery.
(徳島大学機関リポジトリ): ● Metadata: 115064
(出版サイトへのリンク): ● Publication site (DOI): 10.5946/ce.2015.48.2.96
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25844335; ● Summary page in Scopus @ Elsevier: 2-s2.0-84961291895

(徳島大学機関リポジトリ: 115064, DOI: 10.5946/ce.2015.48.2.96, PubMed: 25844335, Elsevier: Scopus) Shinji Kitamura, Yasuyuki Okada, Naoki Muguruma, Hiroshi Miyamoto, Yoshimi Bando, Rika Aoki and Tetsuji Takayama :
Epidermoid metaplasia of the esophagus with an unusual appearance on magnification.,
Endoscopy, Vol.47, No.S1, E100, 2015.

(出版サイトへのリンク): ● Publication site (DOI): 10.1055/s-0034-1391299
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25734803; ● Summary page in Scopus @ Elsevier: 2-s2.0-84930007610

(DOI: 10.1055/s-0034-1391299, PubMed: 25734803, Elsevier: Scopus) Satoshi Teramae, Hiroshi Miyamoto, Naoki Muguruma, Yasuyuki Okada, Takahiro Goji, Shinji Kitamura, Tetsuo Kimura, Masako Kimura, Yoshimi Bando and Tetsuji Takayama :
Insulin-like growth factor II-producing metastatic colon cancer with recurrent hypoglycemia.,
Clinical Journal of Gastroenterology, Vol.8, No.1, 35-40, 2015.

(要約): A 45-year-old man was referred to our hospital and found to have a tubular adenocarcinoma of the descending colon with multiple liver metastases. During hospitalization, the patient suffered recurrent hypoglycemic attacks that required intravenous 50% glucose infusion. He was diagnosed with non-islet cell tumor hypoglycemia (NICTH) because the colon cancer tissue obtained by biopsy was strongly stained for insulin-like growth factor-II (IGF-II) by immunohistochemistry. He received chemotherapy with oxaliplatin, 5-FU and leucovorin (FOLFOX) plus bevacizumab (Bmab), and showed a partial response. As the metastatic lesions decreased in size, the hypoglycemic attacks gradually disappeared. Subsequently, he received outpatient chemotherapy and maintained a high quality of life for about 10 months. Western blot analysis of IGF-II in serum at the time of admission showed a high-molecular-weight form of IGF-II, which was considered to have caused hypoglycemia. This patient presents a very rare case of colorectal cancer associated with NICTH syndrome due to production of high-molecular-weight IGF-II by cancer cells. It is important to investigate IGF-II expression in cancer tissues for establishing the diagnosis of NICTH in cases with intractable hypoglycemia complicated by advanced cancer.
(キーワード): Adenocarcinoma / Blotting, Western / Colonic Neoplasms / Humans / Hypoglycemia / Immunohistochemistry / Insulin-Like Growth Factor II / Liver Neoplasms / Male / Middle Aged / Recurrence
(出版サイトへのリンク): ● Publication site (DOI): 10.1007/s12328-015-0552-4
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25605315; ● Summary page in Scopus @ Elsevier: 2-s2.0-84925493491

(DOI: 10.1007/s12328-015-0552-4, PubMed: 25605315, Elsevier: Scopus) Atsushi Inoue, Koichi Okamoto, Yasuteru Fujino, Tadahiko Nakagawa, Naoki Muguruma, Katsutaka Sannomiya, Yasuhiro Mitsui, Toshi Takaoka, Shinji Kitamura, Hiroshi Miyamoto, Toshiya Okahisa, Takahiro Fujimori, Issei Imoto and Tetsuji Takayama :
B-RAF mutation and accumulated gene methylation in aberrant crypt foci (ACF),sessile serrated adenoma/polyp (SSA/P) and cancer in SSA/P.,
British Journal of Cancer, Vol.112, No.2, 403-412, 2015.

(要約): Sessile serrated adenomas/polyps (SSA/Ps) are a putative precursor of colon cancer with microsatellite instability (MSI). However, the developmental mechanism of SSA/P remains unknown. We performed genetic analysis and genome-wide DNA methylation analysis in aberrant crypt foci (ACF), SSA/P, and cancer in SSA/P specimens to show a close association between ACF and the SSA/P-cancer sequence. We also evaluated the prevalence and number of ACF in SSA/P patients. ACF in the right-side colon were observed in 36 patients with SSA/Ps alone, 2 with cancers in SSA/P, and 20 normal subjects and biopsied under magnifying endoscopy. B-RAF mutation and MSI were analysed by PCR-restriction fragment length polymorphism (RFLP) and PCR-SSCP, respectively, in 15 ACF, 20 SSA/P, and 2 cancer specimens. DNA methylation array analysis of seven ACF, seven SSA/P, and two cancer in SSA/P specimens was performed using the microarray-based integrated analysis of methylation by isochizomers (MIAMI) method. B-RAF mutations were frequently detected in ACF, SSA/P, and cancer in SSA/P tissues. The number of methylated genes increased significantly in the order of ACF<SSA/P<cancer. The most commonly methylated genes in SSA/P were PQLC1, HDHD3, RASL10B, FLI1, GJA3, and SLC26A2. Some of these genes were methylated in ACF, whereas all genes were methylated in cancers. Immunohistochemistry revealed their silenced expression. Microsatellite instability and MLH1 methylation were observed only in cancer. The prevalence and number of ACF were significantly higher in SSA/P patients than in normal subjects. A significant correlation was seen between the numbers of SSA/P and ACF in SSA/P patients. Our results suggest that ACF are precursor lesions of the SSA/P-cancer sequence in patients with SSA/P, where ACF arise by B-RAF mutation and methylation of some of the six identified genes and develop into SSA/Ps through accumulated methylation of these genes.
(キーワード): Aberrant Crypt Foci / Adenoma / Aged / Case-Control Studies / Colonic Neoplasms / DNA Methylation / Female / Genetic Association Studies / Genetic Predisposition to Disease / Humans / Male / Middle Aged / Mutation, Missense / Proto-Oncogene Proteins B-raf
(徳島大学機関リポジトリ): ● Metadata: 106441
(出版サイトへのリンク): ● Publication site (DOI): 10.1038/bjc.2014.545
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25314065; ● Summary page in Scopus @ Elsevier: 2-s2.0-84922337339

(徳島大学機関リポジトリ: 106441, DOI: 10.1038/bjc.2014.545, PubMed: 25314065, Elsevier: Scopus) Yasuteru Fujino, Naoki Muguruma, Shinji Kitamura, Yasuhiro Mitsui, Tetsuo Kimura, Hiroshi Miyamoto, Hisanori Uehara, Koichi Kataoka and Tetsuji Takayama :
Perineurioma in the sigmoid colon diagnosed and treated by endoscopic resection,
Clinical Journal of Gastroenterology, Vol.7, No.5, 392-396, 2014.

(要約): Perineuriomas are rare benign peripheral nerve sheath tumors in the gastrointestinal tract. We recently encountered a submucosal lesion in the sigmoid colon that was resected by endoscopic mucosal resection and was then diagnosed as perineurioma by immunohistochemistry. A 51-year-old female with a positive test for fecal occult blood was referred to our hospital for screening colonoscopy. Colonoscopy identified a submucosal lesion, approximately 15 mm in diameter, in the sigmoid colon. Endoscopic ultrasound showed a 15-mm tumor with a strong acoustic shadow. Endoscopic mucosal resection was performed in order to make a precise diagnosis as well as removal. The specimen revealed spindle cell proliferation without atypia, and immunostaining revealed that the spindle cells were positive for collagen type IV and glut-1, and the lesion was diagnosed as a colonic perineurioma with no malignancy. Gastroenterologists as well as pathologists should be aware of this type of submucosal lesion, and immunohistochemical evaluation is highly recommended when an unusual mesenchymal tumor is found.
(キーワード): perineurioma / colon / endoscopic mucosal resection
(出版サイトへのリンク): ● Publication site (DOI): 10.1007/s12328-014-0519-x
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26184017; ● Summary page in Scopus @ Elsevier: 2-s2.0-84919872298

(DOI: 10.1007/s12328-014-0519-x, PubMed: 26184017, Elsevier: Scopus) 新田佳伯, 芥川正武, 榎本崇宏, 岡久稔也, 宮本弘志, 大西芳明, 木内陽介, S. Abhijit PANDYA :
体外循環療法中に腎臓で行われる水分の再吸収効率の推定,
医工学治療, Vol.26, No.1, 24-31, 2014年. Shinji Kitamura, Naoki Muguruma, Koichi Okamoto, Fumika Nakamura, Yasuyuki Okada, Tetsuo Kimura, Hiroshi Miyamoto and Tetsuji Takayama :
Endoscopic submucosal dissection through a gastrostomy for early gastric cancer in patients with pharyngeal stenosis.,
Gastrointestinal Endoscopy, Vol.79, No.2, 206-207, 2014.

(出版サイトへのリンク): ● Publication site (DOI): 10.1016/j.gie.2013.09.018
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24129250; ● Summary page in Scopus @ Elsevier: 2-s2.0-84892564534

(DOI: 10.1016/j.gie.2013.09.018, PubMed: 24129250, Elsevier: Scopus) Yasuyuki Okada, Hiroshi Miyamoto, Takahiro Goji and Tetsuji Takayama :
Biomarkers for predicting the efficacy of anti-epidermal growth factor receptor antibody in the treatment of colorectal cancer.,
Digestion, Vol.89, No.1, 18-23, 2014.

(要約): Anti-epidermal growth factor receptor (EGFR) antibodies have been widely utilized as a standard treatment for metastatic colorectal cancer (CRC). Anti-EGFR antibodies bind competitively to EGFRs to inhibit receptor activation and subsequent signal transduction of the RAS/RAF/MEK pathway and PI3K/AKT pathway. By inhibiting EGFR-mediated signal transduction, anti-EGFR antibodies inhibit cell growth, invasion, metastasis and angiogenesis, and they induce apoptosis. The IgG1-type antibody cetuximab is also capable of inducing antibody-dependent cellular cytotoxicity. Several studies have shown that KRAS mutation is a useful biomarker for predicting the efficacy of anti-EGFR agents, and the major guidelines for the treatment of CRC recommend the use of anti-EGFR antibody only for the cancers with wild-type KRAS. Alterations of other genes, including BRAF, NRAS, PTEN and AKT, and EGFR expression/gene copy number have also been reported to be candidate biomarkers for predicting the efficacy of anti-EGFR agents. The predictive values of these biomarkers are still controversial and further investigations are required. © 2014 S. Karger AG, Basel.
(キーワード): Antibodies, Monoclonal, Humanized / Antineoplastic Agents / Colorectal Neoplasms / Forecasting / Humans / Mutation / Receptor, Epidermal Growth Factor / Tumor Markers, Biological
(出版サイトへのリンク): ● Publication site (DOI): 10.1159/000356202
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24458108; ● Summary page in Scopus @ Elsevier: 2-s2.0-84893030838

(DOI: 10.1159/000356202, PubMed: 24458108, Elsevier: Scopus) Momoko Sato, Naoki Muguruma, Nakagawa Tadahiko, Koichi Okamoto, Tetsuo Kimura, Shinji Kitamura, Hiromi Yano, Sannomiya Katsutaka, Takahiro Goji, Hiroshi Miyamoto, Toshiya Okahisa, Hiroaki Mikasa, Wada Satoshi, Iwata Masao and Tetsuji Takayama :
High antitumor activity of pladienolide B and its derivative in gastric cancer,
Cancer Science, Vol.105, No.1, 110-116, 2014.

(要約): The antitumor activity of pladienolide B, a novel splicing inhibitor, against gastric cancer is totally unknown and no predictive biomarker of pladienolide B efficacy has been reported. We investigated the antitumor activity of pladienolide B and its derivative on gastric cancer cell lines and primary cultured cancer cells from carcinomatous ascites of gastric cancer patients. The effect of pladienolide B and its derivative on six gastric cancer cell lines was investigated using a MTT assay and the mean IC50 values determined to be 1.6 ± 1.2 (range, 0.6-4.0) and 1.2 ± 1.1 (range, 0.4-3.4) nM, respectively, suggesting strong antitumor activity against gastric cancer. The mean IC50 value of pladienolide B derivative against primary cultured cells from 12 gastric cancer patients was 4.9 ± 4.7 nM, indicative of high antitumor activity. When 18 SCID mice xenografted with primary cultured cells from three patients were administered the pladienolide B derivative intraperitoneally, all tumors completely disappeared within 2 weeks after treatment. Histological examination revealed a pathological complete response for all tumors. In the xenograft tumors after treatment with pladienolide B derivative, immature mRNA were detected and apoptotic cells were observed. When the expressions of cell-cycle proteins p16 and cyclin E in biopsied gastric cancer specimens were examined using immunohisctochemistry, positivities for p16 and cyclin E were significantly and marginally higher, respectively, in the low-IC50 group compared with the high-IC50 group, suggesting the possibility that they might be useful as predictive biomarkers for pladienolide B. In conclusion, pladienolide B was very active against gastric cancer via a mechanism involving splicing impairment and apoptosis induction.
(キーワード): Aged / Aged, 80 and over / Animals / Antineoplastic Agents / Apoptosis / Cell Line, Tumor / Cyclin E / Cyclin-Dependent Kinase Inhibitor p16 / Epoxy Compounds / Female / Humans / Macrolides / Male / Mice / Mice, SCID / Middle Aged / RNA Splicing / Random Allocation / Stomach Neoplasms / Xenograft Model Antitumor Assays
(徳島大学機関リポジトリ): ● Metadata: 106055
(出版サイトへのリンク): ● Publication site (DOI): 10.1111/cas.12317
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24635824; ● Summary page in Scopus @ Elsevier: 2-s2.0-84892849884

(徳島大学機関リポジトリ: 106055, DOI: 10.1111/cas.12317, PubMed: 24635824, Elsevier: Scopus) Naoki Muguruma, Hiroshi Miyamoto, Toshiya Okahisa and Tetsuji Takayama :
Endoscopic Molecular Imaging: Status and Future Perspective.,
Clinical Endoscopy, Vol.46, No.6, 603-610, 2013.

(要約): During the last decade, researchers have made great progress in the development of new image processing technologies for gastrointestinal endoscopy. However, diagnosis using conventional endoscopy with white light optical imaging is essentially limited, and ultimately, we still rely on the histopathological diagnosis from biopsy specimens. Molecular imaging represents the most novel imaging methods in medicine, and the future of endoscopic diagnosis is likely to be impacted by a combination of biomarkers and technology. Endoscopic molecular imaging can be defined as the visualization of molecular characteristics with endoscopy. These innovations will allow us not only to locate a tumor or dysplastic lesion but also to visualize its molecular characteristics and the activity of specific molecules and biological processes that affect tumor behavior and/or its response to therapy. In the near future, these promising technologies will play a central role in endoluminal oncology.
(徳島大学機関リポジトリ): ● Metadata: 115065
(出版サイトへのリンク): ● Publication site (DOI): 10.5946/ce.2013.46.6.603
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24340252; ● Search Scopus @ Elsevier (PMID): 24340252; ● Search Scopus @ Elsevier (DOI): 10.5946/ce.2013.46.6.603

(徳島大学機関リポジトリ: 115065, DOI: 10.5946/ce.2013.46.6.603, PubMed: 24340252) Miho Tsuda, Koichi Okamoto, Naoki Muguruma, Katsutaka Sannomiya, Tadahiko Nakagawa, Hiroshi Miyamoto, Shinji Kitamura, Takahiro Goji, Tetsuo Kimura, Toshiya Okahisa, Keisuke Izumi and Tetsuji Takayama :
Suppressive effect of RAS inhibitor manumycin A on aberrant crypt foci formation in the azoxymethane-induced rat colorectal carcinogenesis model.,
Journal of Gastroenterology and Hepatology, Vol.28, No.10, 1616-1623, 2013.

(要約): The mean number of ACF in the 8-week manumycin A group (72.9 ± 20.1) was significantly lower than in the vehicle group (155.6 ± 56.7, P < 0.01), and it was significantly lower even in the 4-week manumycin A group than in the vehicle group (92.2 ± 13.0 vs 222.3 ± 83.3, P < 0.01). The positive rate for phosphorylated ERK in the manumycin A group (13.5 ± 19.2%) was significantly lower than in the vehicle group (50.2 ± 19.8%, P < 0.01). The positive rate for Ki-67 in the manumycin A group (2.2 ± 3.4%) was significantly lower than in the vehicle group (14.7 ± 8.2%, P < 0.01). There were significantly more terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling-positive cells in tissue samples from the manumycin A group versus the vehicle group (8.6 ± 9.7% vs 2.9 ± 2.0%, P < 0.05).
(徳島大学機関リポジトリ): ● Metadata: 105897
(出版サイトへのリンク): ● Publication site (DOI): 10.1111/jgh.12287
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23730936; ● Search Scopus @ Elsevier (PMID): 23730936; ● Search Scopus @ Elsevier (DOI): 10.1111/jgh.12287

(徳島大学機関リポジトリ: 105897, DOI: 10.1111/jgh.12287, PubMed: 23730936) Shinji Kitamura, Mitsugi Yasuda, Naoki Muguruma, Koichi Okamoto, Hisashi Takeuchi, Yoshimi Bando, Hiroshi Miyamoto, Toshiya Okahisa, Mitsuyasu Yano, Ryusuke Torisu and Tetsuji Takayama :
Prevalence and characteristics of nodular gastritis in Japanese elderly.,
Journal of Gastroenterology and Hepatology, Vol.28, No.7, 1154-1160, 2013.

(要約): NG was found in 62 cases (0.94%) out of 6623 patients who underwent endoscopy, with a mean age of 47.3 ± 13.3 years. Female patients were present at a significantly higher rate in the elderly group (P < 0.001). The grade of neutrophil infiltration in the greater curvature of the upper gastric body was recognized at a significantly higher rate in the elderly group (P < 0.05). PG II was present at a higher rate and PG I/II at a lower rate in the elderly group (P < 0.05). The odds ratio for the risk of gastric cancer in patients with NG was 2.1 (95% confidence interval 0.3-15.3) in the elderly group.
(キーワード): Age Factors / Aged / Aged, 80 and over / Asian Continental Ancestry Group / Gastritis / Gastroscopy / Humans / Japan / Prevalence / Risk Factors / Stomach Neoplasms
(出版サイトへのリンク): ● Publication site (DOI): 10.1111/jgh.12180
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23432631; ● Search Scopus @ Elsevier (PMID): 23432631; ● Search Scopus @ Elsevier (DOI): 10.1111/jgh.12180

(DOI: 10.1111/jgh.12180, PubMed: 23432631) Tetsuo Kimura, Naoki Muguruma, Takahiro Goji, Koichi Okamoto, Shinji Kitamura, Hiromi Yano, Hiroshi Miyamoto, Toshiya Okahisa, Naomi Sakashita and Tetsuji Takayama :
Pedunculated duodenal carcinoid successfully removed by endoscopic resection with endoloop.,
Journal of Digestive Diseases, Vol.14, No.7, 402-404, 2013.

(出版サイトへのリンク): ● Publication site (DOI): 10.1111/1751-2980.12033
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23302224; ● Summary page in Scopus @ Elsevier: 2-s2.0-84878388921

(DOI: 10.1111/1751-2980.12033, PubMed: 23302224, Elsevier: Scopus) Hirakawa Masahiro, Yasushi Sato, Ohnuma Hiroyuki, Tetsuji Takayama, Sagawa Tamotsu, Nobuoka Takayuki, Harada Keisuke, Hiroshi Miyamoto, Sato Yasuhiro, Takahashi Yasuo, Katsuki Shinichi, Hirayama Michiaki, Takahashi Minoru, Ono Michihiro, Maeda Masahiro, Takada Kohichi, Hayashi Tsuyoshi, Sato Tsutomu, Miyanishi Koji, Takimoto Rishu, Kobune Masayoshi, Hirata Koichi and Kato Junji :
A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin,and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker,
Cancer Chemotherapy and Pharmacology, Vol.71, No.3, 789-797, 2013.

(要約): The combination of docetaxel, cisplatin, and S-1 (DCS) chemotherapy is expected to be a promising regimen for advanced gastric cancer. This study was performed to evaluate the efficacy and safety of neoadjuvant DCS chemotherapy for locally advanced resectable gastric cancer. Patients with locally advanced gastric cancer received 2 courses of preoperative chemotherapy with S-1 (40 mg/m(2) b.i.d.) on days 1-14 and docetaxel (60 mg/m(2)) plus cisplatin (60 mg/m(2)) on day 8 every 3 weeks, followed by standard curative surgery within 4-8 weeks. The primary endpoint was R0 resectability. Expression of damage DNA binding protein complex subunit 2 (DDB2)/excision repair cross-complementing 1 (ERCC1) in the pretreated tumor tissues was examined by immunohistochemistry. A total of 43 patients received neoadjuvant chemotherapy. The response rate was 74.4%, and disease control ratio was 100%. Grade 4 neutropenia developed in 53.5% of patients and febrile neutropenia in 16.3%. Non-hematological grade 3/4 adverse events were anorexia (23.3%), nausea (14.0%), and diarrhea (23.3%), but these were generally transient and manageable. The proportion of R0 resections in the 43 eligible patients was 90.7%, and a pathological response was found in 65.9% of patients. There were no treatment-related deaths and no major surgical complications. The accuracy of the combination of DDB2 and ERCC1 expression for predicting chemoresistance was 82.5%. Preoperative treatment with DCS combination for locally advanced gastric cancer demonstrated a sufficient R0 resection rate and a good pathological response with manageable toxicities. The DDB2/ERCC1-high phenotype, as determined by immunohistochemistry, may be useful predictor of resistance to DCS chemotherapy.
(キーワード): Adult / Aged / Antimetabolites, Antineoplastic / Antineoplastic Agents / Antineoplastic Agents, Phytogenic / Antineoplastic Combined Chemotherapy Protocols / Biological Markers / Cisplatin / Combined Modality Therapy / DNA Repair / DNA-Binding Proteins / Drug Administration Schedule / Drug Combinations / Drug Resistance, Neoplasm / Endonucleases / Endosonography / Female / Follow-Up Studies / Humans / Kaplan-Meier Estimate / Male / Middle Aged / Neoadjuvant Therapy / Oxonic Acid / Stomach Neoplasms / Survival Analysis / Taxoids / Tegafur / Tomography, X-Ray Computed / Treatment Outcome
(出版サイトへのリンク): ● Publication site (DOI): 10.1007/s00280-013-2073-5
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23338051; ● Search Scopus @ Elsevier (PMID): 23338051; ● Search Scopus @ Elsevier (DOI): 10.1007/s00280-013-2073-5

(DOI: 10.1007/s00280-013-2073-5, PubMed: 23338051) Koichi Okamoto, Naoki Muguruma, Shinji Kitamura, Y Fujino, Takahiro Goji, Hiromi Yano, Tetsuo Kimura, Hiroshi Miyamoto, Toshiya Okahisa and Tetsuji Takayama :
A new large-diameter overtube for endoscopic submucosal dissection in the colon.,
Endoscopy, Vol.44, No.Suppl 2 UCTN, E395-6, 2012.

(キーワード): Aged / Aged, 80 and over / Colonic Diseases / Colonoscopy / Equipment Design / Female / Humans / Intestinal Mucosa / Male / Middle Aged
(出版サイトへのリンク): ● Publication site (DOI): 10.1055/s-0032-1310249
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23139039; ● Search Scopus @ Elsevier (PMID): 23139039; ● Search Scopus @ Elsevier (DOI): 10.1055/s-0032-1310249

(DOI: 10.1055/s-0032-1310249, PubMed: 23139039) Koichi Okamoto, Seisuke Okamura, Naoki Muguruma, Shinji Kitamura, Tetsuo Kimura, Yoshitaka Imoto, Hiroshi Miyamoto, Toshiya Okahisa and Tetsuji Takayama :
Endoscopic submucosal dissection for early gastric cancer using a cross-counter technique.,
Surgical Endoscopy, Vol.26, No.12, 3676-3681, 2012.

(要約): Endoscopic submucosal dissection (ESD) in early gastric cancer has rapidly come into widespread use. However, since complications such as bleeding and perforation often occur, and the procedure time is longer for ESD than endoscopic mucosal resection (EMR), development of safer and more reliable technique is required. The subjects comprised 45 patients with lesions diagnosed histologically as early gastric cancer. They were divided into three groups: cross-counter technique group (CC, n = 15), peroral traction-assisted ESD with suture material group (PT, n = 15), and no-traction group (NT, n = 15). ESD was carried out by two endoscopists who had experienced fewer than 30 cases of ESD. To compare safety and efficacy of a new traction method (CC group) for ESD in early gastric cancer with other methods (PT group and NT group), procedure time, dissected area per unit time, complete resection rate, perforation rate, and bleeding rate were evaluated. There was no significant difference among these three groups in terms of complications, complete resection rate or procedure time. The dissection area per unit time was 22.4, 15.7, and 13.5 mm(2)/min in the CC, PT, and NT groups, respectively, and there was a significant difference between the CC and NT groups (p = 0.007). The cross-counter technique shortened the treatment time for endoscopists without abundant experience in gastric ESD, and it is considered a useful method to institute in order to introduce ESD.
(キーワード): Aged / Aged, 80 and over / Early Medical Intervention / Equipment Design / Female / Gastric Mucosa / Gastroscopes / Gastroscopy / Humans / Male / Middle Aged / Stomach Neoplasms
(出版サイトへのリンク): ● Publication site (DOI): 10.1007/s00464-012-2364-7
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22692462; ● Search Scopus @ Elsevier (PMID): 22692462; ● Search Scopus @ Elsevier (DOI): 10.1007/s00464-012-2364-7

(DOI: 10.1007/s00464-012-2364-7, PubMed: 22692462) Tetsuo Kimura, Koichi Okamoto, Hiroshi Miyamoto, Masako Kimura, Shinji Kitamura, Hidetaka Takenaka, Naoki Muguruma, Toshiya Okahisa, Eriko Aoyagi, Mayumi Kajimoto, Yasushi Tsuji, Takahiro Kogawa, Akihito Tsuji and Tetsuji Takayama :
Clinical benefit of high-sensitivity KRAS mutation testing in metastatic colorectal cancer treated with anti-EGFR antibody therapy.,
Oncology, Vol.82, No.5, 298-304, 2012.

(要約): We compared high-sensitivity KRAS mutation testing with direct sequencing for predicting the efficacy of antiepidermal growth factor receptor antibodies in patients with metastatic colorectal cancer (mCRC). We analyzed the KRAS status in 61 tumors from cetuximab-treated mCRC patients by both direct sequencing and a high-sensitivity method: 2-step PCR restriction fragmentation length polymorphism (RFLP). Therapeutic effects in each mutational status were evaluated. The incidences of KRAS mutations determined by direct sequencing and 2-step PCR RFLP were 34.4 and 52.5%, respectively (p = 0.02). Patients were categorized into 3 groups [W/W, wild-type by both methods (n = 29); W/M, wild-type by direct sequencing, detected mutation by 2-step PCR RFLP (n = 11); M/M, mutant-type by both methods (n = 21)]. The response rate for cetuximab in the W/M group (0%) was the same as that in the M/M group, and was significantly lower than in the W/W group (41.4%) (p < 0.001). Progression-free survival in the W/M group (11.0 weeks) was similar to that in the M/M group (8.0 weeks), and was significantly shorter than in the W/W group (18.0 weeks) (p < 0.002). High-sensitivity KRAS mutation testing is useful for selecting true responders to cetuximab.
(キーワード): Adult / Aged / Aged, 80 and over / Antibodies, Monoclonal / Antineoplastic Agents / Colorectal Neoplasms / Female / Humans / Male / Middle Aged / Mutation / Proto-Oncogene Proteins / Receptor, Epidermal Growth Factor / Retrospective Studies / ras Proteins
(出版サイトへのリンク): ● Publication site (DOI): 10.1159/000336792
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22555244; ● Search Scopus @ Elsevier (PMID): 22555244; ● Search Scopus @ Elsevier (DOI): 10.1159/000336792

(DOI: 10.1159/000336792, PubMed: 22555244) Takeuchi Hisashi, Tetsuo Kimura, Koichi Okamoto, Aoyagi Eriko, Hiroshi Miyamoto, Masako Kaji, Hidetaka Takenaka, Seisuke Okamura, Yasushi Sato, Kato Junji, Toshiya Okahisa and Tetsuji Takayama :
A mechanism for abnormal angiogenesis in human radiation proctitis: analysis of expression profile for angiogenic factors,
Journal of Gastroenterology, Vol.47, No.1, 56-64, 2012.

(要約): Radiation proctitis is an increasingly prevalent problem, with many patients being treated with radiotherapy for pelvic cancers. However, the mechanisms by which radiation proctitis develops in humans are not well understood. In this study, the expression profiles of angiogenic factors were analyzed to clarify their role in the etiology of radiation proctitis. Rectal biopsies were taken from 8 patients with radiation proctitis and 8 normal subjects. Protein lysates of the tissues were applied to an antibody array for angiogenesis-related factors. The mRNA level of each factor was evaluated by Taqman real-time PCR. Immunohistochemistry was performed using the labeled streptavidin biotin method. Antibody array analysis revealed 2.12- to 7.31-fold higher expression levels of angiogenin, fibroblast growth factor 1 (FGF1), endoglin, matrix metalloproteinase (MMP)-8, urokinase-type plasminogen activator (uPA) and maspin in radiation proctitis tissues compared with normal rectal mucosa. The mRNA level of each factor in radiation proctitis tissue was significantly higher than in normal rectal mucosa, suggesting their transcriptional activation. Immunohistochemical staining showed strong expression of angiogenin and maspin in rectal epithelia, MMP-8 and uPA in infiltrating lymphocytes, FGF1 in fibroblasts and endoglin in endothelial cells. The expression of VEGF was not evident. Our results suggest that in radiation proctitis, MMP-8 and uPA cooperatively degrade the extracellular matrix and basement membrane to provide space for angiogenesis. Simultaneously, angiogenin and FGF1 promote endothelial cell proliferation, and endoglin induces vessel formation, culminating in angiogenesis. Inhibitors of angiogenic factors such as angiogenin and FGF1 may be effective for treating radiation proctitis.
(キーワード): Aged / Case-Control Studies / Extracellular Matrix / Female / Fibroblast Growth Factor 1 / Gene Expression Regulation / Humans / Male / Matrix Metalloproteinase 8 / Middle Aged / Neovascularization, Pathologic / Pelvic Neoplasms / Polymerase Chain Reaction / Proctitis / RNA, Messenger / Radiation Injuries / Ribonuclease, Pancreatic / Urokinase-Type Plasminogen Activator
(出版サイトへのリンク): ● Publication site (DOI): 10.1007/s00535-011-0470-2
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22081051; ● CiNii @ 国立情報学研究所 (CRID): 1573387450550673408; ● Search Scopus @ Elsevier (PMID): 22081051; ● Search Scopus @ Elsevier (DOI): 10.1007/s00535-011-0470-2

(DOI: 10.1007/s00535-011-0470-2, PubMed: 22081051, CiNii: 1573387450550673408) Hiroshi Miyamoto, Junji Takaba, Kazuhide Ohta, Tadashi Motomura, Yoichi Sugita and Yukihiko Nosé :
Preliminary studies for the development of a second generation granulocytapheresis (G-CAP) column. Part II: in vitro and ex vivo studies.,
Journal of Artificial Organs, Vol.14, No.4, 342-347, 2011.

(要約): Our previous studies concluded Egyptian cotton was the most appropriate material for making a second generation granulocytapheresis (G-CAP) column as structural dimensions of the cotton fibers are able to attract granulocytes. Unfortunately, it is considered to be blood incompatible as its fibers are of non-synthetic origins. In this study we examined the alteration of the removal rates of blood cells with different surface modifications of Egyptian cotton to enhance its blood compatibility. The surface-modified cotton fibers were compared after three kinds of combination treatments. There were no differences in the removal rates of white blood cells (WBCs) and particularly neutrophils with the use of three kinds of biolized cottons. Next, an ex vivo animal study with a healthy dog was performed with the prototype of the G-CAP column. The dog's blood pressure (BP) decreased to approximately 80% of the initial values of BP at 20 min after the start of the extracorporeal circulation. The decrease in BP gradually reverted to normal. WBCs and particularly neutrophils decreased significantly at 15 min after the start of the extracorporeal circulation and remained low during the extracorporeal circulation. The ability of this column to remove WBCs was maintained during extracorporeal circulation. Especially, neutrophils at the inlet of the column were thoroughly removed for 1 h. Based upon these results, a second generation G-CAP column could be fabricated with Egyptian cotton and applied for clinical use on the condition that the biocompatibility of the Egyptian cotton needs to be improved by the appropriate biolization method.
(キーワード): Animals / Cotton Fiber / Cytapheresis / Dogs / Female / Granulocytes
(出版サイトへのリンク): ● Publication site (DOI): 10.1007/s10047-011-0583-7
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21713519; ● Search Scopus @ Elsevier (PMID): 21713519; ● Search Scopus @ Elsevier (DOI): 10.1007/s10047-011-0583-7

(DOI: 10.1007/s10047-011-0583-7, PubMed: 21713519) Hiroshi Miyamoto, Toshiya Okahisa, Hiroshi Iwaki, Masahiro Murata, Susumu Ito, Yoshinori Nitta, Masatake Akutagawa, Yohsuke Kinouchi, Yoshiaki Ohnishi, Jun Oto and Masaji Nishimura :
Influence of leukocytapheresis therapy for ulcerative colitis on anemia and hemodynamics.,
Therapeutic Apheresis and Dialysis, Vol.11, No.1, 16-21, 2007.

(要約): In Japan, leukocytapheresis (LCAP) therapy has been carried out for ulcerative colitis as an effective therapy with a low incidence of side-effects. In the present study, we serially investigated the influence of LCAP therapy on anemia and hemodynamics in patients with ulcerative colitis using a non-invasive method with a Crit-Line monitor (CLM) (Hema Metrics Inc., Salt Lake City, UT and Boston, MA, USA). We carried out LCAP on 10 patients with ulcerative colitis using a CS-100 Cellsorba EX LCAP filter in 34 courses of LCAP. The mean hematocrit value, which was measured using the Crit-Line monitor, was 21.8 +/- 0.2% (21.0-22.4%), which showed no significant changes after each LCAP therapy. The actual erythrocyte count, hemoglobin and hematocrit values decreased by 244 000/mm3, 0.7 g/dL and 2.1%, respectively, however, the differences were insignificant. These values corresponded to 7.8, 8.0 and 7.6% of the values before LCAP, respectively. There were no significant changes in systolic blood pressure, diastolic blood pressure, or heart rate during LCAP. The results of this study suggest that one course of LCAP does not exacerbate anemia, and it does not influence hemodynamics. However, considering the exacerbation of anemia in patients with severe ulcerative colitis caused by massive melena, monitoring with a less invasive Crit-Line monitor and a vital information monitor might be useful.
(キーワード): Adult / Aged / Anemia / Colitis, Ulcerative / Erythrocyte Count / Female / Hematocrit / Humans / Leukapheresis / Male / Melena / Middle Aged
(出版サイトへのリンク): ● Publication site (DOI): 10.1111/j.1744-9987.2007.00451.x
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 17309570; ● Search Scopus @ Elsevier (PMID): 17309570; ● Search Scopus @ Elsevier (DOI): 10.1111/j.1744-9987.2007.00451.x

(DOI: 10.1111/j.1744-9987.2007.00451.x, PubMed: 17309570) Masahiko Nakasono, Mitsuyoshi Hirokawa, Naoki Muguruma, Toshiya Okahisa, Seisuke Okamura, Susumu Ito, Hiroshi Miyamoto, Satoshi Wada, Tamotsu Fukuda and Toshiaki Sano :
Colorectal xanthomas with polypoid lesion:report of 25 cases.,
APMIS, Vol.112, No.1, 3-10, 2004.

(要約): Little attention has been paid to colorectal xanthoma. To clarify the clinical and pathological features of colorectal xanthoma, we report 28 colorectal xanthomas biopsied from 25 patients. All were composed of typical xanthoma cells and showed polypoid configuration. Median age of the patients was 64 years and there were 15 men and 10 women. Diabetes mellitus, constipation, and hyperlipidemia were found in two, one, and seven patients, respectively. Seventeen (60.7%) of the 28 polyps were located in the sigmoid colon and the remaining 11 in the rectum. Twenty-three polyps (82.1%) were sessile. Twelve (60.0%) of twenty polyps that were recorded were reddish in color. Only two polyps revealed a yellowish tone. Microscopically, foamy cells were present in the lamina propria, but the submucosa did not contain foamy cells. Immunohistochemically, the foamy cells invariably expressed extensive positivity for CD68. The colonic glands showed a deformity in the case with moderate to intense density of the foamy cells. The surface epithelium showed a hyperplastic change in 22 (78.6%) xanthomas. The colonic glands in four xanthomas were also associated with hyperplastic changes. The basement membrane of the surface epithelium was often thickened. Cell debris and proliferation of the capillaries were observed just below the surface epithelium in 19 (67.9%) and 22 (78.6%) xanthomas, respectively. Previous mucosal minute injury was suggested as the pathogenesis of colorectal xanthomas. Colorectal xanthomas were not identical to gastric and esophageal xanthoma, endoscopically or microscopically. We prefer the term "xanthomatous polyp" rather than xanthoma in the colorectal region. They may be regarded as a novel type of colorectal non-neoplastic polyp.
(キーワード): Adult / Aged / Aged, 80 and over / Biopsy / Colonic Diseases / Female / Humans / Immunohistochemistry / Male / Middle Aged / Rectal Diseases / Retrospective Studies / Xanthomatosis
(出版サイトへのリンク): ● Publication site (DOI): 10.1111/j.1600-0463.2004.apm1120102.x
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 14961968; ● Search Scopus @ Elsevier (PMID): 14961968; ● Search Scopus @ Elsevier (DOI): 10.1111/j.1600-0463.2004.apm1120102.x

(DOI: 10.1111/j.1600-0463.2004.apm1120102.x, PubMed: 14961968) 岡久稔也, 宮本弘志, 居和城宏, 伊東進, 大西芳明, 黒田泰弘, 芥川正武, 新田佳伯, 木内陽介 :
高速フーリエ解析を用いた圧波形解析によるフィルタの目詰まり評価,
ICUとCCU, Vol.28, No.suppl-1, S128-S130, 2004年.

(文献検索サイトへのリンク): ● CiNii @ 国立情報学研究所 (CRID): 1521980704997023232

(CiNii: 1521980704997023232)

MISC

研究者総覧に該当データはありませんでした。

総説・解説

Yasushi Sato, Koichi Okamoto, Yoshifumi Kida, Yasuhiro Mitsui, Yutaka Kawano, Masahiro Sogabe, Hiroshi Miyamoto and Tetsuji Takayama :
Overview of Chemotherapy for Gastric Cancer.,
Journal of Clinical Medicine, Vol.12, No.4, 1336, Feb. 2023.

(要約): Gastric cancer (GC) is one of the most clinically challenging cancers worldwide. Over the past few years, new molecular-targeted agents and immunotherapy have markedly improved GC prognosis. Human epidermal growth factor receptor 2 (HER2) expression is a key biomarker in first-line chemotherapy for unresectable advanced GC. Further, the addition of trastuzumab to cytotoxic chemotherapy has extended the overall survival of patients with HER2-positive advanced GC. In HER2-negative GC, the combination of nivolumab, an immune checkpoint inhibitor, and a cytotoxic agent has been demonstrated to prolong the overall survival of GC patients. Ramucirumab and trifluridine/tipiracil, which are second- and third-line treatments for GC, and trastuzumab deruxtecan, an antibody-drug conjugate for HER2-positive GC, have been introduced in clinics. New promising molecular-targeted agents are also being developed, and combination therapy comprising immunotherapy and molecular-targeted agents is expected. As the number of available drugs increases, it is important to understand the target biomarkers and drug characteristics and select the optimal therapy for each patient. For resectable disease, differences in the extent of standard lymphadenectomy between Eastern and Western countries have led to different standard treatments: perioperative (neoadjuvant) and adjuvant therapy. This review aimed to summarize recent advances in chemotherapy for advanced GC.
(徳島大学機関リポジトリ): ● Metadata: 118894
(出版サイトへのリンク): ● Publication site (DOI): 10.3390/jcm12041336
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36835872; ● Search Scopus @ Elsevier (PMID): 36835872; ● Search Scopus @ Elsevier (DOI): 10.3390/jcm12041336

(徳島大学機関リポジトリ: 118894, DOI: 10.3390/jcm12041336, PubMed: 36835872) Yasushi Sato, Koichi Okamoto, Tomoyuki Kawaguchi, Fumika Nakamura, Hiroshi Miyamoto and Tetsuji Takayama :
Treatment Response Predictors of Neoadjuvant Therapy for Locally Advanced Gastric Cancer: Current Status and Future Perspectives.,
Biomedicines, Vol.10, No.7, 1614, Jul. 2022.

(要約): Neoadjuvant chemotherapy (NAC) for locally advanced gastric cancer (LAGC) has been recognized as an effective therapeutic option because it is expected to improve the curative resection rate by reducing the tumor size and preventing recurrence of micrometastases. However, for patients resistant to NAC, not only will operation timing be delayed, but they will also suffer from side effects. Thus, it is crucial to develop a comprehensive strategy and select patients sensitive to NAC. However, the therapeutic effect of NAC is unpredictable due to tumor heterogeneity and a lack of predictive biomarkers for guiding the choice of optimal preoperative treatment in clinical practice. This article summarizes the related research progress on predictive biomarkers of NAC for gastric cancer. Among the many investigated biomarkers, metabolic enzymes for cytotoxic agents, nucleotide excision repair, and microsatellite instability, have shown promising results and should be assessed in prospective clinical trials. Noninvasive liquid biopsy detection, including miRNA and exosome detection, is also a promising strategy.
(徳島大学機関リポジトリ): ● Metadata: 117415
(出版サイトへのリンク): ● Publication site (DOI): 10.3390/biomedicines10071614
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35884916; ● Search Scopus @ Elsevier (PMID): 35884916; ● Search Scopus @ Elsevier (DOI): 10.3390/biomedicines10071614

(徳島大学機関リポジトリ: 117415, DOI: 10.3390/biomedicines10071614, PubMed: 35884916) 佐藤康史, 宮本弘志, 佐川保, 高山哲治 :
COVID-19とがん治療,
腫瘍内科, Vol.27, No.4, 468-473, 2021年4月.

(キーワード): 患者管理院内感染(予防,合併症) 抗腫瘍剤(治療的利用) 疾病の発生死亡率 *腫瘍(薬物療法,合併症) 大腸腫瘍(薬物療法,合併症) 感染予防管理外来診療腫瘍医 *COVID-19(予防,合併症) ヒト
(文献検索サイトへのリンク): ● CiNii @ 国立情報学研究所 (CRID): 1522543656005111296

(CiNii: 1522543656005111296) 宮本弘志, 三好人正, 竹中英喬, 木村哲夫, 竹内尚, 岡久稔也, 佐藤康史, 加藤淳二, 高山哲治 :
【StageIV胃癌治療への挑戦】StageIV胃癌に対するDCS療法の意義,
消化器外科, Vol.34, No.5, 575-581, 2011年5月.

(キーワード): *Cisplatin(治療的利用,毒性・副作用) *胃腫瘍(薬物療法) 腫瘍多剤併用療法生存分析第I相試験第II相試験治療成績 *Docetaxel(治療的利用,毒性・副作用) *TS-1(治療的利用,毒性・副作用) ヒト

講演・発表

Yoshifumi Kida, Toshiya Okahisa, Yasushi Sato, Masahiro Bando, shota fujimoto, Tadahiko Nakagawa, Tomoyuki Kawaguchi, Fumika Nakamura, Koichi Okamoto, Hiroshi Miyamoto, Masahiro Sogabe, Koichi Tsuneyama and Tetsuji Takayama :
Thepapeutic strategy of Ulcerative Colitis targeting Urokinase-type Plasminogen Activator.,
DDW2023, May 2023. Tomoyuki Kawaguchi, Koichi Okamoto, shota fujimoto, Masahiro Bando, hironori wada, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama :
Lansoprazole as an effective chemopreventive agent for serrated-neoplasia pathway; A comprehensive analysis using connectivity map.,
DDW2023, May 2023. Yasushi Sato, Kazuyoshi Noda, Yasuyuki Okada, Kensei Nishida, Yutaka Kawano, Toshihito Tanahashi, Masanori Takehara, Yasuteru Fujino, Koichi Okamoto, Hiroshi Miyamoto and Tetsuji Takayama :
Exosomal miR-199a-3p secreted from cancer-associated adipocytes promote pancreatic cancer progression.,
DDW2023, Chicago, May 2023. Tetsuji Takayama, Yoshifumi Kida, Toshiya Okahisa, Yasushi Sato, Masahiro Bando, shota Fujimoto, Tomoyuki Kawaguchi, Fumika Nakamura, Koichi Okamoto, Hiroshi Miyamoto, Koichi Tsuneyama and Masahiro Sogabe :
The relevance of urokinase-type plasminogen activator in pathogenesis of ulcerative colitis.,
WCOG2022 (World Congress of Gastroenterology), Dubai, Dec. 2022. Toshiya Okahisa, Masahiro Sogabe, Ryosuke Ogata, Takatoshi Komatsu, Yoshiaki Ohnishi, Hiroyuki Ueda, Tomoyuki Kawaguchi, Akira Fukuya, Yoshifumi Kida, Tetsu Tomonari, Hiroshi Miyamoto and Tetsuji Takayama :
Concentration Ratio Self-regulation Function of Ascites Filtration and Concentration Equipment for Cell-free and Concentrated Ascites Reinfusion Therapy,
ASAIO 67th Annual Conference, Chicago, Jun. 2022. Yasushi Sato, Kumiko Tanaka, Ishikawa Hideki, Satoshi Teramae, Fumika Nakamura, Yasuhiro Mitsui, Kagemoto Kaizo, Hiroshi Miyamoto, Koichi Okamoto, Naoki Muguruma, Ohmiya Naoki, Mutoh Michihiro and Tetsuji Takayama :
Small- intestinal involvement in familial adenomatous polyposis: characteristics and genotype- phenotype correlation from a Japanese cohort study,
DDW, May 2020. Yasushi Sato, Tetsu Tomonari, Hironori Tanaka, Takahiro Tanaka, Hirao Akihiro, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma, Kagiwada Harumi, Kitazawa Masashi, Fukui Kazuhiko, Horimoto Katsuhisa and Tetsuji Takayama :
Potential use of lenvatinib for patients with unresectable hepatocellular carcinoma beyond progression of sorafenib treatment: A real-world evidence and in vitro assessment with protein phosphorylation array,
ASCO Gastrointestinal Cancers Symposium(ASCO-GI 2020), San Francisco, Jan. 2020.

(出版サイトへのリンク): ● Publication site (DOI): 10.1200/JCO.2020.38.4_suppl.485
(文献検索サイトへのリンク): ● Search Scopus @ Elsevier (DOI): 10.1200/JCO.2020.38.4_suppl.485

(DOI: 10.1200/JCO.2020.38.4_suppl.485) Hiroshi Miyamoto, Jun Okazaki and Tetsuji Takayama :
The relationship between poor prognosis in pancreatic cancer with miR-296-5p/BOK signaling axis according to a genome-wide microRNA array analysis using micro-tissues by EUS-FNA.,
JDDW2019(第27回日本消化器関連学会週間), Kobe, Nov. 2019. Naoki Muguruma, Daisaku Fujimot, Tomoyuki Kawaguchi, Kaizoh Kagemoto, Satoshi Teramae, Yoshifumi Kida, Hironori Wada, Fumika Nakamura, Yasuteru Fujino, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Toshihito Tanahashi, Hiroshi Miyamoto, Yasushi Sato and Tetsuji Takayama :
Linked Color Imaging Improves Detection Rate of Sessile Serrated Adenoma/Polyp in the Colon: A Prospective Randomized Controlled Trial.,
UEG Week 2019, Barcelona, Oct. 2019. Yasushi Sato, Tadahiko Nakagawa, Toshihito Tanahashi, Shinji Kitamura, Hiroshi Miyamoto, Koichi Okamoto, Naoki Muguruma and Tetsuji Takayama :
JMJD2A is a novel epigenetic factor of chemotherapeutic susceptibility in gastric cancer.,
The ESMO Congress 2019, Barcelona, Sep. 2019.

(出版サイトへのリンク): ● Publication site (DOI): 10.1093/annonc/mdz239.077
(文献検索サイトへのリンク): ● Search Scopus @ Elsevier (DOI): 10.1093/annonc/mdz239.077

(DOI: 10.1093/annonc/mdz239.077) Hironori Tanaka, Tetsu Tomonari, Takahiro Tanaka, Akihiro Hirao, Fumika Nakamura, Kumiko Tanaka, Koichi Okamoto, Yasushi Sato, Masahiro Sogabe, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama :
Therapeutic efficacy of chemoradiotherapy with Miriplatin for hepatocellular carcinoma.,
digestive disease week2019, San Diego, May 2019. Jinsei Miyoshi, Noriaki Murayama, Kumiko Tanaka, Takahiro Tanaka, Fumika Nakamura, Yasuteru Fujino, Keiichiro Matsumura, Miwako Kagawa, Tetsu Tomonari, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama :
Development of a Novel Mirna-Based Signature to Predict Invasion and Metastasis in Rectal Neuroendocrine Tumors.,
digestive disease week2019, Vol.156, No.6, 133, San Diego, May 2019.

(出版サイトへのリンク): ● Publication site (DOI): 10.1016/S0016-5085(19)37123-9
(文献検索サイトへのリンク): ● Search Scopus @ Elsevier (DOI): 10.1016/S0016-5085(19)37123-9

(DOI: 10.1016/S0016-5085(19)37123-9) Jun Okazaki, Toshihito Tanahasi, Yasushi Sato, Jinsei Miyoshi, Tadahiko Nakagawa, Tetsuo Kimura, Hiroshi Miyamoto, Yasuteru Fujino, Fumika Nakamura, Masanori Takehara, Masahiro Bando, Shinji Kitamura, Koichi Okamoto, Naoki Muguruma, Masahiro Sogabe and Tetsuji Takayama :
Interaction Between Pancreatic Cancer Cells and Adipocytes Promote Pancreatic Cancer Progression Through Overexpression of Saa1.,
digestive disease week2019, San Diego, May 2019. Tetsuji Takayama, Toshihito Tanahashi, Koichi Okamoto, Shota Fujimoto, Tadahiko Nakagawa, Kaizoh Kagemoto, Yasuyuki Okada, Fumika Nakamura, Yasuteru Fujino, Shinji Kitamura, Hiroshi Miyamoto, Yasushi Sato and Naoki Muguruma :
S100P as a novel hypomethylation target in Sessile Serrated Adenoma(SSA/P)-cancer sequence: A genome-wide DNA methylation array analysis.,
UEG Week2018, Wien, Oct. 2018. Jinsei Miyoshi, Noriaki Murayama, Tadahiko Nakagawa, Tetsu Tomonari, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama :
Mir-144-3P/451A as a Novel Biomarker for Predicting Recurrence and Metastasis in Rectal Neuroendocrine Tumors Through Targeting Pten/P19.,
Digestive Disease Week 2018, Washington, D.C., Jun. 2018. Fumika Nakamura, Koichi Okamoto, Kumiko Tanaka, Yasuteru Fujino, Jinsei Miyoshi, Shinji Kitamura, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama :
Clinicopathological Analyses of Colorectal Polyps and Cancers in Serrated Polyposis Syndrome.,
DIgestive Disease Week2018, Washington, D.C., Jun. 2018. Yasushi Sato, Tamotsu Sagawa, Yasuo Takahashi, Hiroyuki Ohnuma, Kyoko Hamaguchi, Masahiro Hirakawa, Koshi Fujikawa, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama :
A dose-escalation study of docetaxel, oxaliplatin and S-1 (DOS) as a first-line therapy for patients with unresectable metastatic gastric cancer.,
2018 Gastrointestinal Cancers Symposium, San Francisco, Jan. 2018. Yasushi Sato, Hiroyuki Ohnuma, Koichi Okamoto, Hiroshi Miyamoto, Masahiro Hirakawa, Naoki Uemura, Shohei Kikuchi, Tamotsu Sagawa, Koji Fujikawa, Yasuo Takahashi, Toshinori Okuda, Shinya Minami, Minoru Takahashi, Tetsuro Okamoto, Junji Kato and Tetsuji Takayama :
Phase II study of modified docetaxel, cisplatin and S-1 (mDCS) combination chemotherapy in patients with unresectable metastatic gastric cancer,
ESMO 2017 Congress, Madrid, Spain, Madrid, Sep. 2017. Daisaku Fujimoto, Kaizo Kagemoto, Yasuyuki Okada, Hironori Tanaka, Satoshi Teramae, Akihiro Hirao, Fumika Nakamura, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama :
Usefulness of Linked Color Imaging System in Endoscopic Diagnosis of Sessile Serrated Adenoma/Polyp: A Novel Image Enhanced Technique.,
Digestive Disease Week2017, Chicago, May 2017. Kaizo Kagemoto, Koichi Okamoto, Tohshi Takaoka, Yasuyuki Okada, Kumiko Tanaka, Akihiro Hirao, Shinji Kitamura, Tetsuo Kimura, Hiroshi Miyamoto, Naoki Muguruma, Toshiya Okahisa, Koichi Tsuneyama and Tetsuji Takayama :
Detection of Aberrant Crypt Foci Using Image-Enhanced Endoscopy.,
Digestive Disease Week2017, Chicago, May 2017. Naoki Muguruma, Koichi Okamoto, Shota Fujimoto, Tadahiko Nakagawa, Katsutaka Sannomiya, Yasuhiro Mitsui, Tetsuo Kimura, Hiroshi Miyamoto, Mitsuo Shimada, Yoko Horino, Shinya Matsumoto, Kenjiro Hanaoka and Tetsuji Takayama :
Optical Molecular Imaging of Aberrant Crypt Foci in the Human Colon by Glutathione S-Transferase-Activated Fluorogenic Probe.,
Digestive Disease Week2017, Chicago, May 2017. Masanori Takehara, Naoki Muguruma, Koichi Okamoto, Kazuyoshi Noda, Kaizo Kagemoto, Yuri Matsumoto, Tadahiko Nakagawa, Shunsaku Takeishi, Jun Okazaki, Daisaku Fujimoto, Shinji Kitamura, Tetsuo Kimura, Hiroshi Miyamoto and Tetsuji Takayama :
Endoscopic Resection is safe and effective for rectal carcinoid tumors.,
The First World Congress of Gastrointestinal Endoscopy,, Hyderabad, Feb. 2017. Tomoyuki Kawaguchi, Naoki Muguruma, Koichi Okamoto, Kumiko Tanaka, Satoshi Teramae, Yasuhiro Mitsui, Yoshifumi Takaoka, Tatsunao Sueuchi, Takahiro Goji, Shinji Kitamura, Masako Kimura, Tetsuo Kimura, Hiroshi Miyamoto and Tetsuji Takayama :
Assessment of small bowel capsule endoscopy and APC gene mutation in familial adenomatous polyposis.,
The First World Congress of Gastrointestinal Endoscopy, Hyderabad, Feb. 2017. Tatsuya Taniguchi, Hironori Tanaka, Takahiro Tanaka, Tetsu Tomonari, Kazuhiro Kishi, Hiroshi Miyamoto, Naoki Muguruma, Masahiro Sogabe, Tadahiko Nakagawa and Tetsuji Takayama :
Des-g-carboxy Prothrombin (DCP) Is Produced by Overexpression of Prothrombin Gene in Hepatocellular Carcinoma,
Digestive Disease Week2016, San Diego, May 2016. Tetsu Tomonari, Shunsaku Takeishi, Tatsuya Taniguchi, Takahiro Tanaka, Hironori Tanaka, Tetsuo Kimura, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama :
MRP3 As a Novel Resistance Factor for Sorafenib in Hepatocellular Carcinoma,
Digestive Disease Week2016, San Diego, May 2016. Naoki Muguruma, Yoshihiko Miyamoto, Shota Fujimoto, Tadahiko Nakagawa, Shinji Kitamura, Tetsuo Kimura, Koichi Okamoto, Hiroshi Miyamoto, Kazuki Horikawa and Tetsuji Takayama :
Endoscopic molecular imaging of colorectal cancer targeting epidermal growth factor receptor.,
APDW2015, Taipei, Dec. 2015. Tatsuya Taniguchi, Tetsu Tomonari, Hironori Tanaka, Takahiro Tanaka, Kazuhiro Kishi, Hiroshi Miyamoto, Naoki Muguruma, Masahiro Sogabe, Toshiya Okahisa, Tadahiko Nakagawa and Tetsuji Takayama :
Des-G-Carboxy Prothrombin (DCP) Is Induced by PARP-1 in Hepatocellular Carcinoma,
Digestive Disease Week 2015, Washington, D.C., May 2015. Kaizo Kagemoto, Atsushi Inoue, Koichi Okamoto, Yasuyuki Okada, Jun Okazaki, Yoshifumi Takaoka, Yoshihiko Miyamoto, Yasuhiro Mitsui, Jinsei Miyoshi, Kumiko Tanaka, Yasuteru Fujino, Shinji Kitamura, Tetsuo Kimura, Masahiro Sogabe, Hiroshi Miyamoto, Naoki Muguruma, Toshiya Okahisa and Tetsuji Takayama :
Proximal Aberrant Crypt Foci As Precursor Lesions of SSA/P-Cancer Sequence.,
Digestive Disease Week 2015, Washington, D.C., May 2015. Rai Shimoyama, Tetsuo Kimura, Toshi Takaoka, Kazuki Sakamoto, Shunji Kawamoto, Koji Yoshizaki, Yuji Negoro, Fuminori Goda, Akihito Tsuji, Tsuyoshi Nakayama, Hiroshi Miyamoto, Tetsuji Takayama and Yoshihiro Niitsu :
A phase II trial of panitumumab with irinotecan and S-1 (IRIS) as second-line treatment in patients with wild-type KRAS metastatic colorectal cancer.,
2015 Gastrointestinal Cancers Symposium, San Francisco, Jan. 2015. Naoki Muguruma, Miyamoto Yoshihiko, Fujimoto Shota, Okada Yasuyuki, Shinji Kitamura, Tetsuo Kimura, Koichi Okamoto, Hiroshi Miyamoto and Tetsuji Takayama :
Optical Molecular Imaging and Assessment of Therapeutic Response of Colorectal Cancer Targeting Epidermal Growth Factor Receptor,
World Congress of Molecular Imaging 2014, Sep. 2014. Kagawa Miwako, Toshiya Okahisa, Takaoka yoshifumi, Yasuteru Fujino, Jinsei Miyoshi, Takaoka Toshi, Tetsu Tomonari, Shinji Kitamura, Okada Yasuyuki, Kagemoto Kaizo, Takehara Masanori, Kumiko Tanaka, Matsumoto Sayo, Teramae Tomofumi, Hiroshi Miyamoto, Naoki Muguruma, Tetsuji Takayama and Takaoka Toshi :
Angiogenesis-Related Factors At the Residual Inflammation in Patients With Ulcerative Colitis in Clinical Remission Stage,
Digestive Disease Week2014, Chicago, May 2014. Yasushi Sato, Tetsuji Takayama, Hiroyuki Ohnuma, Masahiro Hirakawa, Takahiro Osuga, Hiroshi Miyamoto, Tamotsu Sagawa, Yasuhiro Sato, Yasuo Takahashi, Shinichi Katsuki, Kohichi Takada, Tokunori Okuda, Tsuyoshi Hayashi, Tsutomu Sato, Koji Miyanishi, Rishu Takimoto, Masayoshi Kobune, Takayuki Nobuoka, Koichi Hirata and Junji Kato :
Trastuzumab (T-mab) in combination with docetaxel/cisplatin/S-1 (DCS) for patients with HER2-positive metastatic gastric cancer: Feasibility and preliminary efficacy.,
2014 Gastrointestinal Cancers Symposium, San Francisco, Jan. 2014. Akina Nakanishi, Toshiya Okahisa, Emi Umezu, Tadahiko Nakagawa, Miwako Kagawa, Toshi Takaoka, Takahiro Goji, Hiromi Yano, Shinji Kitamura, Takahiro Goji, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama :
Expression of Thymidline EMT via ERK 1/2 Signal Patway in Ulcerative Colitis,
DDW2013,Orland, Orange County Convention Center, Orlando, May 2013. Yasuteru Fujino, Koichi Okamoto, Naoki Muguruma, Jun Okazaki, Yasuyuki Okada, Hironori Tanaka, Jinsei Miyoshi, Toshi Takaoka, Shinji Kitamura, Hiroshi Miyamoto, Toshiya Okahisa and Tetsuji Takayama :
Usefulness of a new sphincterotome for the endoscopic submucosal dissection of colorectal neoplasms,
DDW2013, Orlando, May 2013. Atsushi Inoue, Koichi Okamoto, Yasuteru Fujino, Jinsei Miyoshi, Takahiro Tanaka, Tetsuo Kimura, Masako Kaji, Hiroshi Miyamoto, Toshiya Okahisa, Seisuke Okamura and Tetsuji Takayama :
Aberrant Crypt Foci in Patients With Sessile Serrated Adenomas,
Digestive Disease Week2011, Chicago, May 2011. Hiroshi Miyamoto, Takaba Junji and Nose Yukihiko :
Cryoreactive albumin removal apheresis (CRARA) therapy for the prevention of diabetic complication,
The 56th Annual Conference of the American Society for Artificial Internal Organs, May 2010. Yoshinori Nitta, Masatake Akutagawa, Takahiro Emoto, Toshiya Okahisa, Hiroshi Miyamoto, Yoshiaki Ohnishi, Shunya Nakane, Ryuji Kaji, Masaji Nishimura and Yohsuke Kinouchi :
The possibility of the classification about Ht values using the AR model,
Proceedings of 2009 World Congress on Medical Physics and Biomedical Engineering, Vol.25, No.7, 525-528, Munich, Sep. 2009. Yoshinori Nitta, Masatake Akutagawa, Takahiro Emoto, Toshiya Okahisa, Hiroshi Miyamoto, Yoshiaki Ohnishi, Masaji Nishimura, Shunya Nakane, Ryuji Kaji and Yohsuke Kinouchi :
Investigation of a Classification about Time Series Signal Using SOM,
The 13th International Conference on Biomedical Engineering, 598-601, Singapore, Dec. 2008. Yoshinori Nitta, Masatake Akutagawa, Toshiya Okahisa, Hiroshi Miyamoto, Yoshiaki Ohnishi, Shunya Nakane, Ryuji Kaji, Abhijit S. Pandya and Yohsuke Kinouchi :
Analysis of hematocrit value during the plasma exchange,
Proceedings of the Intenational Symposium on Biological and Physiological Engineering /The 22nd SICE Symposium on Biological and Physiological Engineering, 278-279, Harbin, Jan. 2008. Yoshinori Nitta, Masatake Akutagawa, Hiroshi Miyamoto, Toshiya Okahisa, Yoshiaki Ohnishi, Masaji Nishimura, Shunya Nakane, Ryuji Kaji and Yohsuke Kinouchi :
Possibility of predicting Ht values during a plasma exchange therapy using back propagation neural network,
Proceedings of 2006 World Congress on Medical Physics and Biomedical Engineering, Seoul, Korea, August 27-September 1, 2006, Vol.1, 1041-1044, Seoul, Aug. 2006.

(キーワード): Guillain-Barre Syndrome / plasma exchange / hematocrit / Crit-Line Monitor / ニューラルネットワーク (neural network)

Okita Yoshio, Toshiya Okahisa, Sogabe Masahiro, Suzuki Masaharu, Hiroshi Miyamoto, Iwaki Hiroshi, Murata Masahiro and Susumu Ito :
Trypsin removal by continuous hemodiafiltration.,
ASAIO J., Vol.52, No.2, 77A, Chicago, Jun. 2006. Yoshinori Nitta, Masatake Akutagawa, Toshiya Okahisa, Hiroshi Miyamoto, Yoshiaki Onishi, Kazuo Yoshizaki, Masaji Nishimura and Yohsuke Kinouchi :
Short term prediction of Ht value using BPNN during LCAP,
Proceedings of the 27th Annual Conference of the IEEE-EMBS, Vol.7, 4560-4563, Shanghai, Sep. 2005.

(文献検索サイトへのリンク): ● Summary page in Scopus @ Elsevier: 2-s2.0-33846897208

(Elsevier: Scopus) Toshiya Okahisa, Hiroshi Miyamoto, Susumu Ito, Yoshiaki Ohnishi and Tamura Masahiro :
Development of new double-bag type bicarbonate substitution fluid set to prevent the non mixture use.,
ASAIO J., Vol.51, No.2, 61A, Washington, D.C., Jun. 2005. Toshiya Okahisa, Okubo Hisashi, Oda Takeshi, Motomura Tadashi, Glueck Julia, Nosé Yukihiko, Hiroshi Miyamoto, Susumu Ito, Yoshiaki Ohnishi and Tamura Masahiro :
New double-bag type bicarbonate substitution fluid set resolve the problem of non mixture use.,
Ther Apher Dial., Vol.9, No.A11, A11, Warnemuende, May 2005. Toshiya Okahisa, Hiroshi Iwaki, Hiroshi Miyamoto, Susumu Ito, Yoshiaki Ohnishi and Masahiro Tamura :
A double-bag system filled with pre-measured bicarbonate substitution fluid reduces preparation time regardless of experience.,
Blood Purif., Vol.24, 266, California, Mar. 2005. Yoshinori Nitta, Toshiya Okahisa, Masatake Akutagawa, Hiroshi Miyamoto, Ohnishi Yoshiaki, Yohsuke Kinouchi, Masaji Nishimura and Susumu Ito :
Application of BPNN to prediction of hematocrit values during LCAP,
Proceedings of Biomedical Engineering Conference, 125-129, Hong Kong, Sep. 2004. Toshiya Okahisa, Hiroshi Iwaki, Hiroshi Miyamoto, Masahiro Sogabe, Susumu Ito, Yoshiaki Ohnishi, Jun Oto, Yasuhiro Kuroda, Shuzo Oshita, Yoshinori Nitta, Yohsuke Kinouchi and Masatake Akutagawa :
Monitoring filter clogging by analyzing the conductive condition of the roller pump flow pressure wave,
Proceedings of 4th World Congress of the International Society for Apheresis, A9, Nashville, TN, USA, Oct. 2003. Hiroshi Miyamoto, Toshiya Okahisa, Hiroshi Iwaki, Masaharu Suzuki, Susumu Ito, Yoshiaki Ohnishi, Jun Oto, Yasuhiro Kuroda, Shuzo Oshita, Yoshinori Nitta, Yohsuke Kinouchi and Masatake Akutagawa :
Variation of the hematocrit value during leukocytapheresis therapy,
Proceedings of 4th World Congress of the International Society for Apheresis, A5, Nashville, TN, USA, Oct. 2003. 宮本弘志, 上田浩之, 三宅孝典, 髙橋拓, 横山怜子, 岡田泰行, 曽我部正弘, 佐藤康史, 高山哲治 :
膵癌における相同組換え修復欠損とプラチナ製剤を含む化学療法の関連.,
JDDW2024, 2024年11月. Hiroshi Miyamoto, Ayuka Mineda, Sawaka Yukishige, Soichiroh Sasa, Kei Daizumoto, Tomoya Fukawa, Yasuyuki Okada, Yasuhiro Mitsui, Koichi Okamoto, Yasushi Sato, Hiroyuki Morino and Tetsuji Takayama :
Management of patients with presumed germline pathogenic variant from comprehensive genomic profiling tests.,
日本人類遺伝学会第69回大会, Oct. 2024. 今井芳枝, 井上寛章, 宮本容子, 吉田友紀子, 森野豊之, 湊沙希, 笹聡一郎, 行重佐和香, 宮本弘志 :
BRCA2 variant of uncertain significanceと診断された乳癌症例の血縁者に対するサーベイランスの一考,
第31回日本がん予防学会総会, 2024年9月. 川口智之, 岡本耕一, 藤本将太, 上田浩之, 和田浩典, 宮本弘志, 佐藤康史, 六車直樹, 高山哲治 :
オルガノイド培養を用いたSessile serrated lesion の動物モデルの樹立とLansoprazole の⼤腸癌予防効果の検討.,
第31回日本がん予防学会総会(日本がん予防学会学術大会2024徳島), 2024年9月. 喜田慶史, 岡久稔也, 佐藤康史, 藤本将太, 川口智之, 中村文香, 岡本耕一, 宮本弘志, 曽我部正弘, 高山哲治 :
<シンポジウム>潰瘍性大腸炎におけるウロキナーゼ型プラスミノーゲンアクチベーター(uPA)の発現解析と治療標的としての意義.,
第110回日本消化器病学会総会, 2024年5月. 福家慧, 佐藤康史, 岡田泰行, 岡本耕一, 河野豊, 宮本弘志, 高山哲治, 影本開三, 喜田慶史 :
UBR4 は EGFR の内在化を制御することで，大腸癌患者における抗 EGFR 抗体の新規バイオマーカーとなる.,
第21回日本臨床腫瘍学会学術集会, 2024年2月. 藤本将太, 樫原孝典, 三宅孝典, 岡本耕一, 河野豊, 宮本弘志, 曽我部正弘, 佐藤康史, 高山哲治 :
抗c-KIT抗体フラグメントと近赤外蛍光内視鏡を用いた水分子イメージングおよび光治療によるGISTの新規診断治療法の開発.,
第20回日本消化管学会総会学術集会, 2024年2月. 岡田泰行, 宮本弘志, 高山哲治 :
膵腫瘍に対するがん遺伝子パネル検査を念頭に置いたEUS-FNAの至適な方法についての検討.,
JDDW2023, 2023年11月. 横山怜子, 佐藤康史, 中村文香, 川口智之, 影本開三, 喜田慶史, 三井康裕, 藤野泰輝, 岡本耕一, 河野豊, 宮本弘志, 高山哲治 :
直腸悪性黒色腫に対する免疫チェックポイント阻害剤の効果予測因子としての irAE の意義.,
第 61 回日本癌治療学会学術集会, 2023年10月. 川口智之, 岡本耕一, 藤本将太, 上田浩之, 和田浩典, 宮本弘志, 佐藤康史, 六車直樹, 高山哲治 :
Connectivity Mapによる大腸癌予防薬の網羅的解析とSessile serrated lesionのオルガノイドを用いた抑制効果の検討.,
がん予防学術大会2023金沢, 2023年9月. 友成哲, 田中宏典, 谷口達哉, 河野豊, 宮本弘志, 高山哲治 :
悪性肝腫瘍に対するEmprint Ablation Systemの治療成績.,
日本超音波医学会第96回学術集会, 2023年5月. 平田圭市郎, 上田浩之, 三宅孝典, 樫原孝典, 岡田泰行, 田中宏典, 和田浩典, 藤野泰輝, 友成哲, 谷口達哉, 岡本耕一, 宮本弘志, 川中崇, 生島仁史, 坂東良美, 佐藤康史, 高山哲治 :
切除不能・再発膵神経内分泌腫瘍(pancreatic neruoendocrine neoplasm:P-NEN)に対する集学的治療による治療成績の向上.,
第109回日本消化器病学会総会, 2023年4月. 川口智之, 岡本耕一, 藤本将太, 上田浩之, 和田浩典, 宮本弘志, 佐藤康史, 六車直樹, 高山哲治 :
前癌病変Sessile serrated lesionのオルガノイドを用いたLansoprazoleの抑制効果およびその機序の検討.,
第40回サイトプロテクション研究会, 2023年3月. akinari kasai, Jinsei Miyoshi, Akihiro Haga, Takashi Kawanaka and Hiroshi Miyamoto :
CT画像に基づいたAI機械学習モデルによる食道扁平上皮癌に対する化学放射線療法の効果予測.,
第20回日本臨床腫瘍学会学術集会, Mar. 2023. 影本開三, 中村文香, 岡本耕一, 吉本貴則, 川口智之, 横山怜子, 喜田慶史, 三井康裕, 北村晋志, 宮本弘志, 佐藤康史, 高山哲治 :
鋸歯状ポリポーシス症候群における大腸腫瘍の病理像と発癌機序についての解析.,
第60回癌治療学会学術集会, 2022年10月. Yasuyuki Okada, Yasuhiro Mitsui, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama :
LAMC2 is a novel predictive biomarker for gemcitabine-based therapy in pancreatic ductal adenocarcinoma.,
第19回日本臨床腫瘍学会学術集会, Feb. 2022. 川口智之, 岡本耕一, 板東正浩, 上田浩之, 和田浩典, 宮本弘志, 佐藤康史, 六車直樹, 高山哲治 :
前癌病変Sessile serrated lesionのオルガノイドを用いた大腸癌予防薬の開発∼Connectivity Mapを用いた網羅的な分析∼,
第18回日本消化管学会学術集会, 2022年2月. 村山典聡, 岡本耕一, 三好人正, 川口智之, 北村晋志, 馬貝貝, 宮本弘志, 六車直樹, 佐藤康史, 高山哲治 :
miR-144-3p/miR-451aは，PTEN/p19を介して直腸カルチノイド(NET-G1)の浸潤に関与する.,
第59回日本癌治療学会学術集会, 2021年10月. 田中宏典, 友成哲, 影本開三, 岡田泰行, 和田浩典, 中村文香, 北村晋志, 岡本耕一, 宮本弘志, 佐藤康史, 六車直樹, 高山哲治 :
免疫チェックポイント阻害薬投与中の肝障害.,
第59回日本癌治療学会学術集会, 2021年10月. 矢野庄悟, 中村文香, 佐藤康史, 福家慧, 藤野泰輝, 北村晋志, 岡本耕一, 宮本弘志, 六車直樹, 高山哲治 :
消化管悪性腫瘍における免疫チェックポイント阻害薬の効果と免疫関連副作用の関連性について.,
第17回日本消化管学会総会学術集会, 2021年2月. 中村文香, 岡本耕一, 影本開三, 喜田慶史, 田中久美子, 北村晋志, 佐藤康史, 宮本弘志, 六車直樹, 高山哲治 :
Serrated polyposis syndrome に合併した大腸癌の臨床病理学的特徴ならびに発癌機序の検討.,
第17回日本消化管学会総会学術集会, 2021年2月. 芳川明奈, 三好人正, 笠井昭成, 松本れいか, 宮城愛, 宮本弘志, 佐藤康史, 六車直樹, 北研二, 高山哲治 :
AI-based ESCC miRNA diagnosis model: retro-prospective multinational cohort study.,
第74回日本食道学会学術集会, 2020年12月. 中川忠彦, 竹内彩郁薫, 山田青季, 井形直紀, 板東直紀, 緒方良輔, 佐藤翔平, 友成哲, 宮本弘志, 六車直樹, 高山哲治, 曽我部正弘, 岡久稔也 :
胸腹水の循環式濾過濃縮処理時の物理刺激によるサイトカイン濃度の上昇.,
第58回日本人工臓器学会大会, 2020年11月. 竹内彩郁薫, 山田青季, 多田理香, 井形直紀, 佐藤翔平, 緒方良輔, 坂東直紀, 大西芳明, 大野将樹, 獅々堀正幹, 泓田正雄, 寺田賢治, 北村晋志, 宮本弘志, 高山哲治, 曽我部正弘, 岡久稔也 :
腹水濾過器洗浄液量の最適化を行うための模擬腹水を用いた評価系の構築.,
第58回日本人工臓器学会大会, 2020年11月. 佐藤康史, 棚橋俊仁, 中川忠彦, 北村晋志, 宮本弘志, 岡本耕一, 六車直樹, 高山哲治 :
JMJD2Aヒストン脱メチル化酵素はCCDC8と協調し胃癌に対する化学療法感受性を制御する.,
第58回日本癌治療学会学術集会, 2020年10月. 横山怜子, 中村文香, 佐藤康史, 岸和弘, 和田浩典, 友成哲, 北村晋志, 岡本耕一, 宮本弘志, 六車直樹, 岡久稔也, 高山哲治 :
胃癌におけるICI治療の効果予測因子としてのirAEの意義とその後治療への影響.,
第58回日本癌治療学会学術集会, 2020年10月. 川口智之, 藤本将太, 板東正浩, 上田浩之, 和田浩典, 岡本耕一, 宮本弘志, 佐藤康史, 六車直樹, 高山哲治 :
Connectivity Map とsessile serrated lesion オルガノイドを用いた網羅的な大腸癌予防薬の検索.,
がん予防学術大会2020米子, 2020年9月. 藤井祥平, 中村文香, 佐藤康史, 岸和弘, 吉田守美子, 三井康裕, 藤野泰輝, 北村晋志, 岡本耕一, 宮本弘志, 六車直樹, 高山哲治 :
<第23回若手奨励賞>胃癌における免疫チェックポイント阻害薬の効果と免疫関連副作用(irAE)との関連性についての検討.,
四国医学雑誌, Vol.76, No.3-4, 173-178, 2020年8月.

(要約): Recently, immune checkpoint inhibitors(ICI)have been approved for use in advanced gastric cancer(AGC)based on the positive results of ATTRACTION‐2 trial in Japan. There has been accumulating evidence that the development of immune-related adverse events(irAE)may be associated with a response to ICI therapy, particularly in lung cancer, although little is known about these correlations in gastrointestinal cancer. To investigate the efficacy and irAE of ICI treatment and their correlation in AGC, we retrospectively examined 29 patients with AGC who received nivolumab therapy in our departments. Among them, 15 patients(52%)developed irAEs including 4 patients(14%)for grade 3 irAEs ; liver dysfunction(n＝2), type 1 diabetes mellitus(n＝2) and adrenal insufficiency(n＝1). The median overall survival was12．0months in the irAE group and 3．25 months in the non-irAE group(p＝0．164), which suggested the relationship between the effects and irAEs in ICI treatment of AGC. Further research is required to understand the implications of irAE characteristics on ICI response in GCA patients.
(キーワード): Immune-checkpoint inhibitors / Gastric cancer / Immune-related adverse events / Nivolumab
(文献検索サイトへのリンク): ● CiNii @ 国立情報学研究所 (CRID): 1050004953486029824

(CiNii: 1050004953486029824) 樫原孝典, 宮本佳彦, 藤本将太, 和田浩典, 川口智之, 喜田慶史, 中村文香, 田中久美子, 北村晋志, 岡本耕一, 宮本弘志, 佐藤康史, 六車直樹, 高山哲治 :
大腸腫瘍に発現するepidermal growth factor receptor in colorectal tumors.,
第16回日本消化管学会総会学術集会, 2020年2月. 中村文香, 岡本耕一, 影本開三, 田中久美子, 藤野泰輝, 北村晋志, 宮本弘志, 佐藤康史, 六車直樹, 高山哲治 :
Serrated polyposis syndrome の臨床病理学的特徴ならびに発癌機序の検討.,
第16回日本消化管学会総会学術集会, 2020年2月. 川口智之, 武原正典, 影本開三, 寺前智史, 中村文香, 田中貴大, 北村晋志, 岡本耕一, 宮本弘志, 佐藤康史, 六車直樹, 高山哲治 :
胸腺を含む5臓器にわたって10個の同時性多発重複癌を呈したLynch症候群の一例 .,
第57回日本癌治療学会学術集会, 2019年10月. 武原正典, 佐藤康史, 川口智之, 野田和克, 福家慧, 北村晋志, 岡本耕一, 宮本弘志, 六車直樹, 高山哲治 :
癌関連脂肪細胞は膵癌のSAA1発現を誘導し，転移・浸潤を促進する.,
第57回日本癌治療学会学術集会, 2019年10月. Hironori Tanaka, Koichi Okamoto, 岡田泰行, 宮本佳彦, Yasuhiro Mitsui, Fumika Nakamura, Jinsei Miyoshi, Yasuteru Fujino, Takahiro Tanaka, Tetsu Tomonari, Shinji Kitamura, Hiroshi Miyamoto, Naoki Muguruma, Yasushi Sato and Tetsuji Takayama :
Therapeutic efficacy of miriplatin in combination with radiotherapy for advanced hepatocellular carcinoma.,
第17回日本臨床腫瘍学会学術集会, Jul. 2019. 三好人正, 村山典聡, 寺前智史, 宮本佳彦, 田中宏典, 岡田泰行, 三井康裕, 藤野泰輝, 田中貴大, 田中久美子, 松村圭一郎, 香川美和子, 友成哲, 北村晋志, 岡本耕一, 宮本弘志, 佐藤康史, 六車直樹, 高山哲治 :
直腸NETのmicroRNA網羅的発現解析を用いた転移機序の解明と新規転移予測バイオマーカーの探索.,
第17回日本臨床腫瘍学会学術集会, 2019年7月. 藤本将太, 六車直樹, 岡本耕一, 佐藤康史, 宮本佳彦, 北村晋志, 宮本弘志, 高山哲治 :
近赤外蛍光標識c-KIT抗体を用いた消化管間質腫瘍(GIST)に対する新たな内視鏡診断治療法(Theranostics)の開発.,
第15回日本消化管学会総会学術集会, 2019年2月. 藤本将太, 六車直樹, 岡本耕一, 佐藤康史, 宮本佳彦, 中尾允泰, 北村晋志, 宮本弘志, 佐野茂樹, 石田竜弘, 常山幸一, 高山哲治 :
Theranostics理論に基づく消化管間質腫瘍(GIST)の新規診断治療法の開発.,
第26回日本消化器関連学会週間(第96回日本消化器内視鏡学会総会), 2018年11月. 水谷太郎, 西岡潤司, 井形直紀, 岩佐一秀, 本多哲也, 川口智之, 三井康裕, 三好人正, 末内辰尚, 岡本耕一, 宮本弘志, 六車直樹, 高山哲治, 曽我部正弘, 岡久稔也 :
携帯型小型腸音図システムの試作による腸蠕動音測定時間の最適化.,
第56回日本人工臓器学会大会, 2018年11月. 本多哲也, 岩佐一秀, 井形直紀, 水谷太郎, 西岡潤司, 野田和克, 宮城愛, 山本加奈子, 新居徹, 津保友香, 福家慧, 武原正典, 寺前智史, 藤野泰輝, 宮本弘志, 六車直樹, 高山哲治, 曽我部正弘, 岡久稔也 :
潰瘍性大腸炎における内視鏡画像解析による腫瘍の診断.,
第56回日本人工臓器学会大会, 2018年11月. 和田浩典, 北村晋志, 中村文香, 福家慧, 武原正典, 岡田泰行, 三井康裕, 三好人正, 藤野泰輝, 田中久美子, 岡本耕一, 宮本弘志, 佐藤康史, 六車直樹, 高山哲治 :
CRT後咽頭狭窄を伴う表在型食道癌に対して細径内視鏡を用いたPDTが有効であった一例.,
第56回日本癌治療学会学術集会, 2018年10月. 寺前智史, 田中久美子, 三橋威志, 三井康裕, 中村文香, 藤野泰輝, 三好人正, 北村晋志, 岡本耕一, 宮本弘志, 佐藤康史, 六車直樹, 高山哲治 :
新規APC遺伝子変異(C.1626+1G>A)を認めた家族性大腸腺腫症の一例.,
第6回日本家族性大腸腺腫症研究会学術集会, 2018年9月. 武原正典, 佐藤康史, 津保友香, 福家慧, 岡田泰行, 宮本佳彦, 三井康裕, 藤野泰輝, 中村文香, 北村晋志, 岡本耕一, 宮本弘志, 六車直樹, 高山哲治 :
膵癌と脂肪細胞の相互作用はSAA1の発現を誘導することにより膵癌の浸潤を促進させる.,
第16回日本臨床腫瘍学会学術集会, 2018年7月. 津保友香, 三井康裕, 福家慧, 武原正典, 岡田泰行, 三好人正, 藤野泰輝, 中村文香, 田中久美子, 北村晋志, 岡本耕一, 宮本弘志, 佐藤康史, 六車直樹, 高山哲治 :
切除不能進行神経内分泌癌に対するIrinotecan+Cisplatin併用療法の後方視的検討.,
第16回日本臨床腫瘍学会学術集会, 2018年7月. 福家慧, 佐藤康史, 佐川保, 高橋康雄, 大沼啓之, 濱口京子, 平川昌宏, 藤川幸司, 藤野泰輝, 三井康裕, 岡田泰行, 北村晋志, 岡本耕一, 宮本弘志, 六車直樹, 高山哲治 :
切除不能進行胃癌に対するdocetaxel/ oxaliplatin/S-1(DOS)療法の第I相試験.,
第16回日本臨床腫瘍学会学術集会, 2018年7月. 友成哲, 新居徹, 津保友香, 宮本佳彦, 田中宏典, 田中貴大, 岡本耕一, 宮本弘志, 曽我部正弘, 佐藤康史, 六車直樹, 高山哲治 :
集学的治療奏功例を含む進行肝癌に対するRegorafenibの初期治療成績.,
第54回日本肝癌研究会, 2018年6月. 六車直樹, 岡本耕一, 藤本将太, 宮本佳彦, 北村晋志, 宮本弘志, 島田光生, 高山哲治 :
分子解析に基づく大腸前癌病変 Aberrant crypt foci の新規イメージング技術開発.,
第 13 回日本分子イメージング学会総会・学術集会, 2018年5月. Hiroyuki Ohnuma, Teppei Matsuno, Chisa Fujita, Masahiro Hirakawa, Koji Miyanishi, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Tetsuji Takayama and Junji Kato :
[WS4-5] Efficacy of DCS±T/DOS combination chemotherapy for gastric cancer with peritoneal metastasis,
Workshop 4 Treatment of gastric cancer patients with peritoneal dissemination 90th Annual Meeting of the Japanese Gastric Cancer Association, Mar. 2018. 中村文香, 岡本耕一, 影本開三, 村山典聡, 田中久美子, 藤野泰輝, 北村晋志, 三宮勝隆, 佐藤康史, 宮本弘志, 六車直樹, 高山哲治 :
Serrated polyposis syndromeにおける遺伝性及び発癌機序の検討.,
第14回日本消化管学会総会学術集会, 2018年2月. 藤野泰輝, 岡本耕一, 六車直樹, 三井康裕, 北村晋志, 藤本大策, 曽我部正弘, 宮本弘志, 佐藤康史, 高山哲治 :
microRNA arrayを用いた大腸粘膜下層浸潤癌リンパ節転移に関わるバイオマーカーの同定及び機能解析,
第14回日本消化管学会総会学術集会, 2018年2月. 岡田泰行, 木村哲夫, 岡本耕一, 中村文香, 藤野泰輝, 田中久美子, 三好人正, 三井康裕, 北村晋志, 宮本弘志, 佐藤康史, 六車直樹, 高山哲治 :
抗EGFR抗体薬治療におけるEarly tumor shrinkage(ETS)とEGFR内在化の関連について,
第88回大腸癌研究会, 2018年1月. 藤野泰輝, 野田和克, 村山典聡, 田中久美子, 北村晋志, 岡本耕一, 宮本弘志, 佐藤康史, 六車直樹, 岡久稔也, 高山哲治, 久保宜明, 坂東良美, 岡村誠介 :
胃巨大ポリープから出血をきたしたCowden病の一例.,
第4回消化管ポリポーシス研究会(日本消化器病学会関連研究会), 2018年1月. 藤本将太, 六車直樹, 岡本耕一, 佐藤康史, 宮本佳彦, 北村晋志, 宮本弘志, 高山哲治 :
Gastrointestinal stromal tumorに対するC-KITを標的とした新規近赤外蛍光イメージング診断と光抗体療法の開発.,
第3回G-PLUS, 2017年12月. 藤野泰輝, 池田敬洋, 友成哲, 三井康裕, 香川美和子, 佐藤桃子, 仁木美也子, 北村晋志, 木村哲夫, 岡本耕一, 宮本弘志, 佐藤康史, 六車直樹, 高山哲治 :
Ipilimumab にて完全奏功が得られた転移性直腸悪性黒色腫の1例.,
第 55 回日本癌治療学会学術集会,, 2017年10月. 高岡慶史, 影本開三, 三井康裕, 田中久美子, 中村文香, 藤野泰輝, 北村晋志, 木村哲夫, 岡本耕一, 木村雅子, 仁木美也子, 宮本弘志, 六車直樹, 石川正志, 高山哲治 :
免疫チェックポイント阻害薬で加療した直腸肛門部悪性黒色腫の4例.,
第55回日本癌治療学会学術集会, 2017年10月. 岡田泰行, 福家慧, 郷司敬洋, 岡本耕一, 宮本弘志, 六車直樹, 岡久稔也, 辻靖, 高山哲治 :
大腸癌における抗 EGFR 抗体薬による EGFR の lysosome への誘導と治療効果との関連について.,
第15回日本臨床腫瘍学会学術集会, 2017年7月. 藤野泰輝, 田中久美子, 中村文香, 北村晋志, 木村哲夫, 岡本耕一, 宮本弘志, 佐藤康史, 六車直樹, 高山哲治 :
大腸粘膜下層浸潤癌リンパ節転移に関わるmicroRNAの網羅的解析.,
第87回大腸癌研究会, 2017年7月. 影本開三, 岡本耕一, 岡田泰行, 高岡慶史, 三井康裕, 藤本大策, 北村晋志, 木村哲夫, 宮本弘志, 佐藤康史, 六車直樹, 高山哲治 :
画像強調内視鏡(IEE)によるヒト Aberrant crypt foci (ACF)の観察∼従来のメチレンブルー散布法と比較して∼.,
がん予防学術大会2017, 2017年6月. 藤本大策, 岡田怜子, 福家慧, 影本開三, 三井康裕, 郷司敬洋, 北村晋志, 木村哲夫, 岡本耕一, 宮本弘志, 六車直樹, 高山哲治 :
大腸サーベイランスにおけるSSA/P検出率の上昇を目指して―LCIの有用性の検討―,
第13回日本消化管学会総会学術集会, 2017年2月. 村山典聡, 寺前智史, 三井康裕, 藤野泰輝, 田中久美子, 木村哲夫, 北村晋志, 岡本耕一, 宮本弘志, 六車直樹, 高山哲治 :
Serrated polyposis syndromeにおけるポリープ，大腸癌の性状と発癌機序の検討.,
第13回日本消化管学会総会学術集会, 2017年2月. 宇山真由, 曽我部正弘, 岡久稔也, 平田光里, 中川忠彦, 村山典聡, 武原正典, 松本友里, 岡崎潤, 高岡慶史, 藤野泰輝, 香川美和子, 田中貴大, 友成哲, 谷口達哉, 郷司敬洋, 木村哲夫, 宮本弘志, 六車直樹, 高山哲治 :
胸腹水濾過濃縮再静注法の施行状況と今後の課題,
第37会日本アフェレシス学会学術大会, 2016年11月. 玉井瑠人, 笠井嘉人, 田中大基, 谷直也, 平田光里, 中川忠彦, 友成哲, 谷口達哉, 岡本耕一, 宮本弘志, 高山哲治, 榎本崇宏, 芥川正武, 下畑隆明, 上番増喬, 馬渡一諭, 髙橋章, 宇山真由, 曽我部正弘, 岡久稔也 :
胸腹水濾過濃縮再静注法のクロスフロー方式の腹水濾過時の物理的刺激が腹水に及ぼす影響に関する実験的検討.,
第54回日本人工臓器学会大会, 2016年11月. 笠井嘉人, 玉井瑠人, 谷直也, 田中大基, 末内辰尚, 高岡慶史, 香川美和子, 中川忠彦, 北村晋志, 木村哲夫, 岡本耕一, 宮本弘志, 六車直樹, 高山哲治, 宇山真由, 曽我部正弘, 岡久稔也 :
携帯型腸蠕動音収集解析システムの試作開発.,
第54回日本人工臓器学会大会, 2016年11月. 岡田泰行, 木村哲夫, 郷司敬洋, 北村晋志, 宮本弘志, 六車直樹, 辻靖, 高山哲治 :
大腸癌における抗EGFR抗体薬のEGFR内在化誘導と治療効果の検討.,
第54回日本癌治療学会学術集会, 2016年10月. 松本早代, 岡本耕一, 六車直樹, 中川忠彦, 関崚太, 武原正典, 影本開三, 高岡慶史, 岡崎潤, 藤本大策, 木村哲夫, 北村晋志, 宮本弘志, 岡久稔也, 高山哲治 :
10mm以下の直腸カルチノイド(NET-G1)に対する内視鏡的治療の有用性の検討.,
第54回日本癌治療学会学術集会, 2016年10月. 中川忠彦, 木村哲夫, 岡本耕一, 曽我部正弘, 宮本弘志, 坂東良美, 六車直樹, 岡久稔也, 高山哲治 :
ヒストン脱メチル化酵素JMJD2Aは切除不能進行胃癌における新しい治療効果予測因子である.,
第75回日本癌学会学術総会, 2016年10月. 髙岡遠, 木村哲夫, 下山ライ, 川元俊二, 坂本和喜, 合田文則, 宮本弘志, 新津洋司郎, 高山哲治 :
切除不能大腸癌に対する二次化学療法としてのIRIS+panitumumab療法の有効性 -多施設共同第二相試験の結果報告-.,
第14回日本臨床腫瘍学会学術集会, 2016年7月. 六車直樹, 岡本耕一, 藤本将太, 藤野泰輝, 中川忠彦, 北村晋志, 木村哲夫, 島田光生, 宮本弘志, 高山哲治 :
分子解析に基づいたAberrant crypt fociの新規イメージング技術開発,
がん予防学術大会2016, 2016年7月. 寺前智史, 田中久美子, 六車直樹, 高岡慶史, 岡崎潤, 村山典聡, 末内辰尚, 三井康裕, 藤本大策, 郷司敬洋, 北村晋志, 木村哲夫, 岡本耕一, 宮本弘志, 江副康正, 石川秀樹, 竹内洋司, 高山哲治 :
家族性大腸腺腫症における小腸病変についての検討,
第85回大腸癌研究会, 2016年7月. 寺前智史, 岡本耕一, 六車直樹, 田中久美子, 藤野泰輝, 香川美和子, 北村晋志, 木村哲夫, 宮本弘志, 島田光生, 高山哲治 :
若年で原発性十二指腸癌を合併したSTK11全欠失型Peutz–Jeghers症候群の1例,
第22回日本家族性腫瘍学会学術集会, 2016年6月. 北村晋志, 竹内尚, 影本開三, 岡田泰行, 木村哲夫, 岡本耕一, 宮本弘志, 六車直樹, 高山哲治 :
経鼻内視鏡検診における送水装置(AF-WP1)の有効性の検討,
第91回日本消化器内視鏡学会総会, 2016年5月. 松本早代, 岡本耕一, 六車直樹, 野口拓樹, 中川忠彦, 武原正典, 影本開三, 宮本佳彦, 高岡慶史, 岡崎潤, 岡田泰行, 藤野泰輝, 田中久美子, 香川美和子, 木村哲夫, 北村晋志, 宮本弘志, 岡久稔也, 高山哲治 :
10mm以下の直腸カルチノイド(NET-G1)に対する内視鏡的治療の有用性の検討,
第12回日本消化管学会総会学術集会, 2016年2月. 六車直樹, 岡本耕一, 藤本将太, 藤野泰輝, 中川忠彦, 北村晋志, 木村哲夫, 宮本弘志, 島田光生, 高山哲治 :
GST 活性型新規蛍光プローブによる大腸前癌病変 ACF の in vivo 分子イメージング,
第1回G-PLUS, 2015年12月. 武原正典, 宮本弘志, 岡田泰行, 三井康裕, 藤野泰輝, 田中久美子, 木村哲夫, 北村晋志, 岡本耕一, 仁木美也子, 木村雅子, 六車直樹, 岡久稔也, 坂東良美, 高山哲治 :
化学療法により長期生存が得られた脾臓原発血管肉腫の一例,
第53回日本癌治療学会学術集会, 2015年10月. 中川忠彦, 曽我部正弘, 岡崎潤, 松本早代, 北村晋志, 岡本耕一, 宮本弘志, 六車直樹, 高山哲治, 榎本崇宏, 芥川正武, 岡久稔也 :
腹水濾過濃縮再静注法の濾過工程の物理刺激が腹水中サイトカイン濃度に及ぼす影響第2報:培養癌細胞を用いた検討,
第36回日本アフェレシス学会学術総会, 2015年10月. 影本開三, 末内辰尚, 三井康裕, 田中久美子, 香川美和子, 北村晋志, 木村哲夫, 岡本耕一, 木村雅子, 仁木美也子, 宮本弘志, 六車直樹, 石川正志, 高山哲治 :
Nivolumabにて加療した直腸肛門部悪性黒色腫の2例,
第53回日本癌治療学会学術集会, 2015年10月. 岡田泰行, 谷口達哉, 田中貴大, 木村哲夫, 岡本耕一, 宮本弘志, 高山哲治 :
大腸癌の抗 EGFR 抗体薬療法における EGFR 内在化の効果予測因子としての検討.,
第74回日本癌学会学術総会, 2015年10月. 中川忠彦, 北村晋志, 岡田泰行, 谷口達哉, 田中貴大, 木村哲夫, 岡本耕一, 宮本弘志, 六車直樹, 岡久稔也, 高山哲治 :
ヒストン脱メチル化酵素 JMJD2A は切除不能胃癌に対する化学療法の新しい治療効果予測因子である,
第74回日本癌学会学術総会, 2015年10月. 田中久美子, 六車直樹, 岡崎潤, 岡田泰行, 高岡慶史, 田中宏典, 宮本佳彦, 松本早代, 田中貴大, 藤野泰輝, 香川美和子, 友成哲, 谷口達哉, 北村晋志, 木村哲夫, 岡本耕一, 宮本弘志, 岡久稔也, 石川秀樹, 高山哲治 :
家族性大腸腺腫症における小腸病変の検討 -形態学的，病理組織学的解析を含めて-,
第23回消化器関連学会週間(第57回日本消化器病学会大会), 2015年10月. 岡田泰行, 藤野泰輝, 北村晋志, 木村哲夫, 木村雅子, 宮本弘志, 岸和弘, 六車直樹, 辻靖, 高山哲治 :
大腸癌に対する抗EGFR抗体薬の効果予測因子の解析.,
第13回日本臨床腫瘍学会学術集会, 2015年7月. Jun Okazaki, Tetsuo Kimura, Hiroshi Miyamoto, Yasuhiro Mitsui, Yasuteru Fujino, Shinji Kitamura, Masako Kimura, Koichi Okamoto, Naoki Muguruma and Tetsuji Takayama :
S-1/oxaliplatin/irinotecan (SOXIRI) for advanced unresectable pancreatic cancer : A dose-finding study,
第13回日本臨床腫瘍学会学術集会, Jul. 2015. 三井康裕, 六車直樹, 田中久美子, 高岡慶史, 藤野泰輝, 岡本耕一, 北村晋志, 木村哲夫, 宮本弘志, 高山哲治 :
異なる胃病変を呈する家族性大腸腺腫症(FAP)の1家系,
第21回日本家族性腫瘍学会学術集会, 2015年6月. 岡崎潤, 福家慧, 影本開三, 高岡慶史, 宮本佳彦, 岡田泰行, 松本早代, 三井康裕, 末内辰尚, 田中久美子, 藤野泰輝, 高岡遠, 北村晋志, 宮本弘志, 六車直樹, 岡久稔也, 高山哲治 :
EUS-FNAで確定診断し得た小型退形成性膵管癌の1例.,
第89回日本消化器内視鏡学会総会, 2015年5月. 木村哲夫, 武原正典, 岡崎潤, 高岡慶史, 岡田泰行, 宮本佳彦, 松本早代, 三井康裕, 末内辰尚, 田中久美子, 藤野泰輝, 髙岡遠, 北村晋志, 木村雅子, 宮本弘志, 六車直樹, 池本哲也, 島田光生, 高山哲治 :
非典型的な画像所見を呈する膵神経内分泌腫瘍(膵NET)の治療方針,
第101回日本消化器病学会総会, 2015年4月. 高岡慶史, 岡久稔也, 岡崎潤, 岡田泰行, 松本早代, 末内辰尚, 三井康裕, 藤野泰輝, 田中久美子, 藤本大策, 木村哲夫, 北村晋志, 宮本弘志, 六車直樹, 河野正樹, 難波和樹, 赤田茂甫規, 榎本崇宏, 高山哲治 :
過敏性腸症候群の客観的診断と病態評価のための腸音図システムの開発,
第101回日本消化器病学会総会, 2015年4月. 藤野泰輝, 松本早代, 佐藤勝哉, 藤本大策, 田中久美子, 末内辰尚, 三井康裕, 木村哲夫, 北村晋志, 宮本弘志, 六車直樹, 岡久稔也, 高山哲治 :
Serrated polyposis syndromeの前癌病変としての意義―病理所見，発癌，遺伝子異常の解析―,
第101回日本消化器病学会総会, 2015年4月. 藤本大策, 佐藤勝哉, 松本早代, 藤野泰輝, 末内辰尚, 三井康裕, 岡田泰行, 岡崎潤, 宮本佳彦, 高岡慶史, 田中宏典, 北村晋志, 木村哲夫, 宮本弘志, 岡久稔也, 武石俊作, 六車直樹, 高山哲治 :
Serrated polyposisの前癌病変としての意義,
第11回日本消化管学会総会学術集会, 2015年2月. 北村晋志, 岡田泰行, 福家慧, 岡崎潤, 高岡慶史, 宮本佳彦, 末内辰尚, 松本早代, 三井康裕, 田中久美子, 藤野泰輝, 藤本大策, 木村哲夫, 宮本弘志, 六車直樹, 高山哲治 :
ヨード染色後に病変の大部分が消失した表在型食道癌の一例,
第11回日本消化管学会総会学術集会, 2015年2月. 宮本佳彦, 六車直樹, 北村晋志, 影本開三, 岡田泰行, 岡崎潤, 松本早代, 末内辰尚, 三井康裕, 田中久美子, 藤野泰輝, 木村哲夫, 宮本弘志, 高山哲治 :
大腸癌におけるEpidermal Growth Factor Receptor(EFGR)をターゲットとした分子イメージングと薬効評価,
第88回日本消化器内視鏡学会総会, 2014年10月. 中川忠彦, 田中宏典, 岡崎潤, 田中久美子, 田中貴大, 髙岡遠, 友成哲, 谷口達哉, 宮本弘志, 高山哲治, 曽我部正弘, 榎本崇宏, 芥川正武, 柴田啓志, 矢野充保, 岸史子, 大喜田義雄, 山路諭, 田中善二, 岡久稔也 :
腹水濾過濃縮再静注法の濾過工程の物理刺激が腹水中サイトカイン濃度に及ぼす影響,
第35回日本アフェレシス学会学術大会, 2014年9月. 谷口達哉, 影本開三, 田中宏典, 田中貴大, 友成哲, 三宮勝隆, 宮本弘志, 六車直樹, 高山哲治 :
肝細胞癌におけるPIVKA-Ⅱの発現機序の解明―PARP1の役割―,
第73回日本癌学会学術総会, 2014年9月. Tetsuo Kimura, Takahiro Goji, Jinsei Miyoshi, Yasuteru Fujino, Shinji Kitamura, Momoko Sato, Masako Kimura, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama :
The prospective study of S-1+gemcitabine and concurrent radiotherapy for unresectable locally advanced pancreatic cancer,
第12回日本臨床腫瘍学会学術集会, Jul. 2014. 北村晋志, 六車直樹, 松本友里, 松本早代, 岡崎潤, 髙岡遠, 村山典聡, 香川美和子, 藤野泰輝, 三好人正, 中村文香, 大塚加奈子, 宮本弘志, 岡久稔也, 高山哲治 :
内視鏡切除された直腸カルチノイド(NET-G1)の臨床経過に関する検討,
第87回日本消化器内視鏡学会総会, 2014年5月. 宮本佳彦, 六車直樹, 北村晋志, 松本友里, 松本早代, 中村文香, 髙岡遠, 藤野泰輝, 三好人正, 田中久美子, 郷司敬洋, 矢野弘美, 香川美和子, 宮本弘志, 岡久稔也, 高山哲治 :
大腸癌に対する内視鏡分子イメージング技術の開発,
第87回日本消化器内視鏡学会総会, 2014年5月. 北村晋志, 六車直樹, 松本友里, 松本早代, 岡崎潤, 髙岡遠, 香川美和子, 藤野泰輝, 三好人正, 中村文香, 田中久美子, 宮本弘志, 岡久稔也, 高山哲治 :
バレット食道癌における欧米と日本のマネジメントの相違に関する検討,
第87回日本消化器内視鏡学会総会, 2014年5月. 六車直樹, 田中久美子, 高岡慶史, 松本早代, 藤野泰輝, 北村晋志, 岡本耕一, 宮本弘志, 高山哲治 :
家族性大腸腺腫症における胃小腸病変に関する検討,
第100回日本消化器病学会総会附置研究会消化管ポリポーシス研究会, 2014年4月. 岡田泰行, 宮本弘志, 高山哲治 :
大腸癌におけるEGFR 発現の意義と抗EGFR 抗体薬に対する感受性の検討,
第100回日本消化器病学会総会, 2014年4月. 田中宏典, 谷口達哉, 高山哲治, 田中貴大, 友成哲, 原田利枝, 佐藤桃子, 三宮勝隆, 宮本弘志, 六車直樹, 岡久稔也 :
高度進行肝細胞癌に対するミリプラチンを用いた放射線併用動注化学療法の有用性,
第100回日本消化器病学会総会, 2014年4月. 藤野泰輝, 大塚加奈子, 田中久美子, 中村文香, 三好人正, 香川美和子, 郷司敬洋, 髙岡遠, 矢野弘美, 北村晋志, 宮本弘志, 六車直樹, 岡久稔也, 高山哲治 :
Sessile serrated adenoma/polyp(SSA/P)の前病変としてのAberrant crypt foci(ACF)の解析,
第10回日本消化管学会総会学術集会, 2014年2月. 松本早代, 六車直樹, 松本友里, 岡崎潤, 田中久美子, 中村文香, 藤野泰輝, 三好人正, 香川美和子, 郷司敬洋, 髙岡遠, 村山典聡, 矢野弘美, 北村晋志, 宮本弘志, 岡久稔也, 高山哲治 :
内視鏡治療された直腸カルチノイド(NET-G1)の臨床経過に関する検討,
第80回大腸癌研究会, 2014年1月. 高岡遠, 藤野泰輝, 平尾章博, 宮本佳彦, 岡田泰行, 三井康裕, 田中貴大, 高場梓, 香川美和子, 友成哲, 津田美穂, 谷口達哉, 郷司敬洋, 矢野弘美, 北村晋志, 岡本耕一, 宮本弘志, 六車直樹, 岡久稔也, 高山哲治 :
SSA/PのLASSEREO Blue LASER Imaging併用拡大内視鏡診断,
第21回日本消化器関連学会週間JDDW2013,第86回日本消化器内視鏡学会総会, 2013年10月. 六車直樹, 宮本佳彦, 藤野泰輝, 高岡遠, 北村晋志, 岡本耕一, 宮本弘志, 岡久稔也, 高山哲治 :
大腸癌における分子イメージング,
第21回日本消化器関連学会週間JDDW2013,第86回日本消化器内視鏡学会総会, 2013年10月. 香川美和子, 岡久稔也, 中川忠彦, 高場梓, 郷司敬洋, 矢野弘美, 北村晋志, 岡本耕一, 宮本弘志, 六車直樹, 高山哲治 :
Thymidine Phosphorylaseを標的とした潰瘍性大腸炎治療薬の開発,
第21回日本消化器関連学会週間JDDW2013,第55回消化器病学会大会, 2013年10月. 藤野泰輝, 六車直樹, 岡本耕一, 北村晋志, 矢野弘美, 高岡遠, 岡崎潤, 郷司敬洋, 宮本弘志, 岡久稔也, 島田光生, 高山哲治 :
多発性小腸重積を生じたPeutz-Jeghers syndromeの1例,
第19回日本家族性腫瘍学会学術集会, 2013年7月. 三好人正, 宮本弘志, 三井康裕, 郷司敬洋, 矢野弘美, 北村晋志, 岡本耕一, 六車直樹, 岡久稔也, 高山哲治 :
DAO活性による抗癌剤投与時の消化管粘膜障害と栄養の関連,
第110回日本内科学会総会・講演会, 2013年4月. 宮本弘志 :
化学療法における癌患者のQOL改善を目指して―血清DAOを用いた消化管傷害の予測―,
第99回日本消化器病学会総会, 2013年3月. 岡田泰行, 宮本弘志, 宮本弘志, 木村哲夫, 六車直樹, 高山哲治 :
大腸癌細胞におけるEGFR数及び各種遺伝子変異とcetuximabの有効性に関する検討,
第9回日本消化管学会総会学術集会, 2013年1月. 高岡遠, 岡久稔也, 香川美和子, 岡田泰行, 宮本佳彦, 田中貴大, 津田美穂, 友成哲, 郷司敬洋, 矢野弘美, 北村晋志, 岡本耕一, 宮本弘志, 六車直樹, 高山哲治, 榎本崇宏 :
腸蠕動音測定による簡便かつ非侵襲的腸運動機能評価法の確立,
第9回日本消化管学会総会学術集会, 2013年1月. 三井康裕, 藤野泰輝, 三好人正, 郷司敬洋, 竹中英喬, 北村晋志, 木村哲夫, 矢野弘美, 木村雅子, 仁木美也子, 宮本弘志, 岡久稔也, 高山哲治 :
Docetaxe投与により過敏反応を呈した切除不能進行胃癌4症例の検討,
第10回臨床腫瘍学会学術集会,大阪,2012.7.26-28, 2012年7月. 末内辰尚, 岡村誠介, 井本佳孝, 有田加奈子, 竹内尚, 岡本耕一, 宮本弘志, 六車直樹, 藤本浩史, 廣瀬隆則, 高山哲治 :
胃perineuriomaの1例,
第83回日本消化器内視鏡学会総会, 2012年5月. 三好人正, 宮本弘志, 高山哲治 :
抗癌剤による消化管粘膜障害と血清DAO活性によるその評価,
第98回日本消化器病学会総会, 2012年4月. 北村晋志, 岡村誠介, 木村哲夫, 木村哲夫, 宮本弘志, 六車直樹, 岡久稔也, 高山哲治 :
シュミレーターを用いたESDトレーニングシステムの試み,
第8回日本消化管学会総会学術集会, 2012年2月. 三好人正, 宮本弘志, 松本早代, 藤野泰輝, 郷司敬洋, 矢野弘美, 北村晋志, 木村哲夫, 岡本耕一, 六車直樹, 岡久稔也, 岡村誠介, 山口想太郎, 中屋豊, 高山哲治 :
消化管癌化学療法における血清Diamine Oxidase(DAO)活性と栄養障害に関する検討,
第8回日本消化管学会総会学術集会, 2012年2月. 郷司敬洋, 木村哲夫, 松本早代, 藤野泰輝, 三好人正, 北村晋志, 矢野弘美, 岡本耕一, 宮本弘志, 仁木美也子, 六車直樹, 岡久稔也, 岡村誠介, 高山哲治 :
CPT11+CDDP療法を施行した胃原発神経内分泌癌(NEC)の4例,
第49回日本癌治療学会学術集会, 2011年10月. 北村晋志, 青柳えり子, 郷司敬洋, 木村哲夫, 矢野弘美, 宮本弘志, 六車直樹, 岡久稔也, 岡村誠介, 高山哲治 :
DNAマイクロアレイを用いたdocetaxel+cisplatin+S-1併用化学療法の治療効果予測,
第49回日本癌治療学会学術集会, 2011年10月. 北村晋志, 青柳えりこ, 木村哲夫, 岡本耕一, 木村雅子, 矢野弘美, 宮本弘志, 六車直樹, 岡久稔也, 仁木美也子, 高山哲治 :
進行胃癌に対するdocetaxel+cisplatin+S-1併用化学療法の効果予測因子の開発,
第9回日本臨床腫瘍学会学術集会, 2011年7月. 北村晋志, 宮本弘志, 高山哲治 :
DNAマイクロアレイを用いた切除不能進行胃癌に対するS-1+docetaxel+cisplatin 3剤併用化学療法の治療効果予測,
第97回日本消化器病学会総会,東京, 2011年5月. 岡久稔也, 木村哲夫, 岡本耕一, 宮本弘志, 岡村誠介, 高山哲治, 神野涼太, 芥川正武, 榎本崇宏, 小中信典 :
炎症性腸疾患に対するアフェレシスを支える次世代内視鏡画像解析システムの開発,
第31回アフェレシス学会学術大会, 2010年11月. Yoshinori Nitta, Masatake Akutagawa, Takahiro Emoto, Toshiya Okahisa, Hiroshi Miyamoto, Shinsuke Konaka, Yoshiaki Ohnishi and Yohsuke Kinouchi :
Modeling and simulation about Ht value during LCAP,
第49回日本生体医工学会大会抄録集, No.48, 288, Jun. 2010. 新田佳伯, 芥川正武, 榎本崇宏, 岡久稔也, 宮本弘志, 大西芳明, 西村匡司, 木内陽介 :
LCAP施行中における現在と1分後のHt値の解析,
医療の質·安全学会誌, Vol.9, 163, 2009年11月. 新田佳伯, 芥川正武, 榎本崇宏, 岡久稔也, 宮本弘志, 大西芳明, 西村匡司, 木内陽介 :
LCAP施行時におけるHt値の解析,
電気関係学会四国支部連合大会講演論文集, 222, 2009年9月. 新田佳伯, 芥川正武, 榎本崇宏, 岡久稔也, 宮本弘志, 大西芳明, 中根俊也, 梶龍兒, 西村匡司, 木内陽介 :
SOMを使用した血液浄化療法中における患者体内の水分移動の評価,
第31回日本生体医工学会中四国支部大会講演抄録, 32, 2008年10月. 新田佳伯, 芥川正武, 岡久稔也, 宮本弘志, 大西芳明, 西村匡司, 中根俊成, 梶龍兒, 木内陽介 :
自己組織化を用いたHt 波形のパターン分類の検討,
電気関係学会四国支部連合大会講演論文集, 257, 2008年9月. 嘉村友一, 芥川正武, 岡久稔也, 宮本弘志, 大西芳明, 西村匡司, 中根俊成, 梶龍兒, 木内陽介 :
血漿交換療法時におけるヘマトクリット値の固有値解析,
電気関係学会四国支部連合大会講演論文集, 256, 2008年9月. 新田佳伯, 芥川正武, 岡久稔也, 宮本弘志, 大西芳明, 西村匡司, 中根俊成, 梶龍兒, 木内陽介 :
ニューラルネットワークを用いたHt値の予測と信号解析,
システム・情報部門学術講演会2007講演論文集, 141-146, 2007年11月. 嘉村友一, 芥川正武, 岡久稔也, 宮本弘志, 大西芳明, 西村匡司, 中根俊成, 梶龍兒, 木内陽介 :
血漿交換療法時におけるヘマトクリット値の解析,
電気関係学会四国支部連合大会講演論文集, 226, 2007年9月. 新田佳伯, 芥川正武, 岡久稔也, 宮本弘志, 大西芳明, 西村匡司, 中根俊成, 梶龍兒, 木内陽介 :
血液浄化療法時における1分後のHt値の解析,
電気関係学会四国支部連合大会講演論文集, 225, 2007年9月. 岡村誠介, 六車直樹, 宮本弘志, 木村哲夫, 井本佳孝, 友兼毅, 梶雅子, 伊東進 :

第71回日本消化器内視鏡学会総会, 2006年10月. 岡村誠介, 木村哲夫, 板垣達三, 井本佳孝, 梶雅子, 宮本弘志, 六車直樹, 伊東進, 西岡将規, 島田光生 :
輪状潰瘍瘢痕によるイレウス症状を呈した小腸結核の一例,
第85回日本消化器病学会四国支部例会, 2006年6月. 岡村誠介, 六車直樹, 宮本弘志, 木村哲夫, 井本佳孝, 友兼毅, 梶雅子, 伊東進 :
把持鉗子を用いたマルチベンディング2CHスコープによるESD, --- -2チャンネル法EMRからESDへの安全な導入- ---,
第85回日本消化器病学会四国支部例会, 2006年6月. 岡村誠介, 宮本弘志, 六車直樹 :
よりスムーズなERCPを目指して, --- -知っておきたい基本手技- ---,
第71回日本消化器内視鏡学会総会, 2006年5月. 新田佳伯, 芥川正武, 宮本弘志, 岡久稔也, 大西芳明, 大藤純, 伊東進, 西村匡司, 木内陽介 :
人工ニューラルネットワークを用いたCHF施行時におけるHt値の予測,
日本集中治療医学会雑誌, Vol.13, 306, 2006年3月. 新田佳伯, 芥川正武, 岡久稔也, 宮本弘志, 大西芳明, 西村匡司, 木内陽介 :
移動平均型ニューラルネットワークを用いたCHF施行時におけるHt値の予測,
日本生体医工学会中四国支部大会, 2005年10月. 新田佳伯, 芥川正武, 岡久稔也, 宮本弘志, 大西芳明, 西村匡司, 木内陽介 :
血液浄化時におけるHt値予測精度向上, --- BPNN構造の検討 ---,
電気関係学会四国支部連合大会講演論文集, 224, 2005年9月. 村上昭継, 岡久稔也, 宮本弘志, 伊東進, 大西芳明, 大藤純, 西村匡司, 新田佳伯, 芥川正武, 木内陽介 :
高速フーリエ変換を用いた血液浄化フィルタの目詰まり評価システムの開発,
第32回日本集中治療医学会学術集会プログラム・抄録集, Vol.12, 312, 2005年2月. 新田佳伯, 木内陽介, 芥川正武, 岡久稔也, 宮本弘志, 居和城宏, 大西芳明, 大藤純, 西村匡司 :
白血球除去療法施行中のヘマトクリット値の予測, --- 人工ニューラルネットワークの最適化と予測時点の延長 ---,
第32回日本集中治療医学会学術集会プログラム・抄録集, Vol.12, 309, 2005年2月.

研究会・報告書

新田佳伯, 芥川正武, 岡久稔也, 宮本弘志, 大西芳明, 西村匡司, 木内陽介 :
ニューラルネットワークを用いた変動するHt値の近未来予測, --- 1分後，3分後，5分後 ---,
電子情報通信学会技術研究報告, Vol.105, No.222, 41-44, 2005年7月. 新田佳伯, 岡久稔也, 芥川正武, 宮本弘志, 大西芳明, 木内陽介, 西村匡司, 伊東進 :
BPNNを用いた血液浄化施行時のヘマトクリット値の予測,
電子情報通信学会技術研究報告, Vol.104, No.179, 37-40, 2004年7月. Hiroshi Miyamoto, Toshiya Okahisa, Hiroshi Iwaki, Masaharu Suzuki, Susumu Ito, Yoshiaki Ohnishi, Jun Oto, Yasuhiro Kuroda, Shuzo Oshita, Yoshinori Nitta, Yohsuke Kinouchi and Masatake Akutagawa :
Variation of the hematocrit value during leukocytapheresis therapy.,
Ther Apher&Dial(Therapeutic Apheresis and Dialysis), Vol.7, No.5, A5, Oct. 2003. Toshiya Okahisa, Hiroshi Iwaki, Hiroshi Miyamoto, Masahiro Sogabe, Susumu Ito, Yoshiaki Ohnishi, Jun Oto, Yasuhiro Kuroda, Shuzo Oshita, Yoshinori Nitta, Yohsuke Kinouchi and Masatake Akutagawa :
Monitoring filter clogging by analyzing the conductive condition of the roller pump flow pressure wave.,
Ther Apher&Dial(Therapeutic Apheresis and Dialysis), Vol.7, No.5, A9, Oct. 2003. 伊賀彰子, 野村昌弘, 和田哲, 宮本弘志, 久次米佐映, 六車直樹, 岡久稔也, 柴田啓志, 岡村誠介, 本田浩仁, 清水一郎, 伊東進 :
消化器内視鏡下総胆管処置中の循環動態の検討,
第63回日本消化器内視鏡学会総会, 2002年4月.

(要約): 内視鏡下総胆管処置中は自律神経活動のアンバランスとQT dispersionの増大がみられ，この自律神経活動が引き金となり偶発症へ進展する可能性が示唆された．

伊賀彰子, 野村昌弘, 久次米佐映, 宮本弘志, 和田哲, 本田浩仁, 清水一郎, 伊東進 :
糖尿病におけるニザチジンの胃運動促進作用の検討:胃電図および心電図による評価,
日本消化器病学会大会, 2001年10月.

(要約): ニザチジンは，自律神経に影響をおよぼさない胃運動亢進作用があり，自律神経障害を有する糖尿病症例には使用しやすい有用な薬剤であると思われた．

岡村誠介, 木村哲夫, 矢野弘美, 井本佳孝, 梶雅子, 青木利佳, 佐藤康紀, 宮本弘志, 六車直樹, 伊東進, 山下理子, 佐野壽昭, 池本哲也, 藤井正彦, 三宅秀則 :
膵管内発育を主とし特異な形態を呈した膵腺房細胞癌の1例,
消化器画像, Vol.9, No.1, 41-46, 2007年1月. 岡村誠介, 佐野壽昭, 木村哲夫, 矢野弘美, 井本佳孝, 梶雅子, 青木利佳, 佐藤康紀, 宮本弘志, 六車直樹, 伊東進, 梅本淳, 下田忠和, 春藤譲治 :
嚢胞変性により特異な形態を呈した胃GISTの1例,
胃と腸, Vol.41, No.5, 844-850, 東京, 2006年.

特許

研究者総覧に該当データはありませんでした。

作品

宮本弘志 :
大腸がんの最新の診断・治療,
四国医学雑誌, Vol.72, No.1,2, 5-8, 2016年4月.

(要約): Colorectal cancer has the third mortality in 2013 and the second morbidity in 2011 of all cancers in Japan. Therefore, it is very important to know the newest information about colorectal cancer. The latest endoscopy has been equipped with not also magnifying function but image enhancing function, such as narrow band imaging and blue laser imaging. These functions enable us to know distinguish benign from malignancy of colorectal polyps without a biopsy. As a therapeutic progress, endoscopic submucosal dissection for the early colorectal cancer has been spread due to approval by the Japanese health insurance system in 2012. Drug therapy for the colorectal cancer has progressed due to the new drug and regimen. Above all, the molecular target drug has improved the prognosis of stage IV colorectal cancer with or without other chemotherapy.The molecular target drugs for colorectal cancer are currently anti VEGF antibody(bevacizumab)and anti EGFR antibody(cetuximab, panitumumab)in clinical use. Moreover, regorafenib and TAS-102 showed efficacy for the colorectal cancer and have been in clinical use. As a result, overall survival rate of stage IV colorectal cancer has reached more than30months in case of use up all these drugs.
(キーワード): colorectal cancer / endoscopic submucosal dissection / diagnosis / treatment / molecular target drug
(徳島大学機関リポジトリ): ● Metadata: 110372
(文献検索サイトへのリンク): ● CiNii @ 国立情報学研究所 (CRID): 1050845762395241344

(徳島大学機関リポジトリ: 110372, CiNii: 1050845762395241344)

補助金・競争的資金

AIを用いた切除可能膵癌に対する化学療法最適化を予測するためのmiRNAモデルの開発 (研究課題/領域番号: 23K07396 )
膵癌における肝転移の分子機序の解明と新規血清バイオマーカーの確立 (研究課題/領域番号: 16K09408 )
潰瘍性大腸炎におけるdysplasiaの高感度分子イメージング法の開発 (研究課題/領域番号: 25461034 )
大腸発癌におけるACF-SSA/P-cancer sequenceの証明 (研究課題/領域番号: 24590942 )
研究者番号（90398024）による検索

その他: 研究者総覧に該当データはありませんでした。

研究者総覧で最新データを確認する

2024年11月22日更新

専門分野・研究分野: ライフサイエンス (Life sciences) [消化器内科学 (Gastroenterology)]
所属学会・所属協会: 日本内科学会
日本消化器病学会
日本消化器内視鏡学会
日本臨床腫瘍学会
日本癌治療学会
日本アフェレーシス学会
委員歴・役員歴: 日本内科学会 (四国支部評議員 [2014年6月〜2016年])
日本消化器病学会 (学会評議員 [2014年1月〜2015年1月], 四国支部評議員 [2014年1月〜2015年12月], 支部幹事 [2014年1月〜2015年12月])
日本消化器内視鏡学会 (学術評議員 [2013年5月〜2018年5月], 四国支部常任評議員 [2014年3月〜2016年2月])
日本臨床腫瘍学会 ( [2012年〜2013年], [2012年7月〜2014年2月])
日本癌治療学会 ( [2012年〜2013年], [2012年7月〜2014年2月])
日本アフェレーシス学会 ( [2012年〜2013年], [2012年7月〜2014年2月])
受賞: 研究者総覧に該当データはありませんでした。
活動: 研究者総覧に該当データはありませんでした。

リサーチマップで最新データを確認するＪグローバルで最新データを確認する

2024年11月17日更新

2024年11月16日更新

Ｊグローバル

Jグローバル最終確認日: 2024/11/16 01:28
氏名（漢字）: 宮本弘志
氏名（フリガナ）: ミヤモトヒロシ
氏名（英字）: Miyamoto Hiroshi
所属機関: 徳島大学講師

リサーチマップ

researchmap最終確認日: 2024/11/17 02:08
氏名（漢字）: 宮本弘志
氏名（フリガナ）: ミヤモトヒロシ
氏名（英字）: Miyamoto Hiroshi
プロフィール: リサーチマップAPIで取得できませんでした。
登録日時: 2006/2/10 00:00
更新日時: 2024/7/17 18:03
アバター画像URI: リサーチマップAPIで取得できませんでした。
ハンドル: リサーチマップAPIで取得できませんでした。
eメール: リサーチマップAPIで取得できませんでした。
eメール（その他）: リサーチマップAPIで取得できませんでした。
携帯メール: リサーチマップAPIで取得できませんでした。
性別: リサーチマップAPIで取得できませんでした。
没年月日: リサーチマップAPIで取得できませんでした。
所属ID: 0344003000
所属: 徳島大学
部署: 徳島大学病院消化器内科
職名: 講師
学位: 医学博士
学位授与機関: 徳島大学
URL: リサーチマップAPIで取得できませんでした。
科研費研究者番号: リサーチマップAPIで取得できませんでした。
Google Analytics ID: リサーチマップAPIで取得できませんでした。
ORCID ID: リサーチマップAPIで取得できませんでした。
その他の所属ID: リサーチマップAPIで取得できませんでした。
その他の所属名: リサーチマップAPIで取得できませんでした。
その他の所属部署: リサーチマップAPIで取得できませんでした。
その他の所属職名: リサーチマップAPIで取得できませんでした。
最近のエントリー: リサーチマップAPIで取得できませんでした。
Read会員ID: リサーチマップAPIで取得できませんでした。
経歴
受賞: リサーチマップAPIで取得できませんでした。
Misc
論文
講演・口頭発表等
書籍等出版物
研究キーワード: リサーチマップAPIで取得できませんでした。
研究分野
所属学協会
担当経験のある科目
その他: リサーチマップAPIで取得できませんでした。
Works
特許
学歴
委員歴
社会貢献活動: リサーチマップAPIで取得できませんでした。

ＫＡＫＥＮで最新データを確認する

2024年11月16日更新

研究者番号: 90398024

所属（現在）: 2024/4/1 : 徳島大学, 大学院医歯薬学研究部(医学域), 准教授

所属（過去の研究課題 情報に基づく）*注記: 2023/4/1 : 徳島大学, 大学院医歯薬学研究部(医学域), 准教授
2018/4/1 : 徳島大学, 病院, 講師
2017/4/1 : 徳島大学, 大学病院, 講師
2016/4/1 : 徳島大学, 病院, 講師
2015/4/1 : 徳島大学病院, 講師
2012/4/1 : 徳島大学, 大学病院, 助教

審査区分/研究分野

研究代表者

生物系 / 医歯薬学 / 内科系臨床医学 / 消化器内科学
小区分53010:消化器内科学関連

研究代表者以外

生物系 / 医歯薬学 / 内科系臨床医学 / 消化器内科学

キーワード

研究代表者

膵癌 / マイクロRNA / 超音波内視鏡下穿刺吸引術 / 肝転移 / 癌 / AI / miRNA / 術前化学療法 / 予測効果

研究代表者以外

ACF / SSA/P / DNAメチル化アレイ / 大腸癌 / EGFR / 分子イメージング / 潰瘍性大腸炎

研究課題研究成果共同研究者

「研究課題をさがす」で表示
テキスト（CSV）で出力

テキスト（CSV）で出力

注目研究はありません。

研究者を探す

宮本 弘志

Ｊグローバル

リサーチマップ

研究代表者

研究代表者以外

研究代表者

研究代表者以外

宮本弘志